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Introduction and outline of the thesis
Introduction 9
1thE gENus Aspergillus, ClINICal syNdromEs aNd CausatIVE agENts oF INVasIVE PulmoNary asPErgIllosIs
Aspergillus species (Figure 1 and 2) are ubiquitous fungi that are found all over the world. 
Aspergillus species are important in many commercial biological processes such as the 
production of citric acid, glucose oxidase and catalase (1, 2). Fungal spores of Aspergillus 
species are present in the open air and inside buildings. Concentrations inside build-
ings are relatively low, but can reach 104-107 per cubic meter in areas where compost is 
shredded (3). Humans and animals inhale fungal spores every day. Usually this remains 
without consequences when the immune system functions properly and the cells of 
the innate immune system among which macrophages attack and phagocytize the 
fungal spores. Epithelial cells and alveolar macrophages form the first barrier. Polymor-
phonuclear neutrophils are the second line of host defense to clear the fungal spores 
Figure 1. Macroscopy of A. fumigatus. Photo by Loes van Damme-Rietvelt.
a B
Figure 2. Microscopy of A. fumigatus. Photos by Loes van Damme-Rietvelt. A A. fumigatus in tissue, mag-
nification ×40. Grocott staining. B A. fumigatus in vitro with conidiophore, magnification ×40. Lactophenol 
blue staining.
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from the lungs (4, 5). As a result of this well-functioning innate immune response after 
inhalation of fungal spores, no disease develops (6).
In case of an overactive immune system, allergic airway disease can develop: allergic 
bronchopulmonary aspergillosis (ABPA)(7). This syndrome is characterized by immune-
mediated airway damage, triggered by Aspergillus species after sensitization. ABPA is 
mainly found in asthma patients and in patients with cystic fibrosis. Patients with ABPA 
experience a worsening of their underlying asthma or a decrease in lung function (8).
On the other side of the spectrum of clinical disease, Aspergillus species may also 
cause invasive fungal infections. In these cases the immune response is not adequate 
or even absent and individuals are at risk for opportunistic invasive fungal infections 
(IFIs), including invasive pulmonary aspergillosis (IPA) (9). IPA is found exclusively in im-
munocompromised patients.
Over the past decades, the incidence of fungal infections has risen. In 2010 an inci-
dence of over 178 cases per million population per year was reported (10, 11), however 
this might be an underestimation. From the several hundreds of Aspergillus species 
known, relatively few cause disease in humans. Aspergillus terreus, Aspergillus niger, 
Aspergillus flavus and Aspergillus lentulus are among the pathogenic species, though 
Aspergillus fumigatus is found most frequently as causative agent of IPA (7).
PathogENEsIs oF INVasIVE PulmoNary asPErgIllosIs
After inhalation of fungal conidia by a healthy person, several lines of defense protect 
the individual from becoming ill. Due to their small size of 2-3 μm, conidia reach the 
alveoli, where alveolar macrophages phagocytize the conidia. Conidia that have 
escaped the macrophages are attacked and destroyed by neutrophils and monocytes 
through the release of oxidants and degranulation (12). In an immunocompromised 
patient however, lines of defense are missing and disease develops. Conidia germinate 
into hyphae and an invasive type of fungal growth develops that disregards natural 
tissue barriers including the vasculature. Studies in neutropenic animal models show 
that a neutrophilic infiltrate is formed, followed by inflammation and a mononuclear cell 
infiltrate, ultimately leading to disseminated infection with hemorrhagic necrosis (7, 13).
dIagNosINg INVasIVE PulmoNary asPErgIllosIs
Diagnosing fungal infections is usually not easy especially at the early stages of the 
infection. The first step in diagnosing an IFI is recognition of the patients at risk for the 
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1infection, which is a heterogeneous group of patients. Not only patients with prolonged neutropenia are at risk, but also patients with advanced HIV-infection, with transplanta-
tions or with inherited immune deficiencies, as well as other critically-ill patients at in-
tensive care units are prone to develop IFIs (9, 14, 15). The symptoms of fungal infections 
are non-specific signs of airway infection, like fever, dyspnea and coughing, which are 
not displayed by all patients due to impairment of the immune system (7, 15-18). When 
a patient is suspected of having an IFI, diagnostics are used to confirm the diagnosis. 
Patient material from normally sterile sites (blood, sputum, broncho-alveolar lavage 
fluid or lung biopsy) is sent for histopathological and microbiological evaluation in order 
to find the causative agent of the infection. Traditional diagnostic methods include mi-
crobiological techniques such as culture-based direct light microscopy, galactomannan 
assay (detecting the Aspergillus antigen galactomannan) and histopathology of biopsies 
(19). Traditional methods have several limitations. The sensitivity of cultures is relatively 
low (9, 15, 20) and a positive culture of e.g. sputum does not discriminate between colo-
nization and infection. Also, identification to the species level can be difficult. Further-
more, diagnostic tests might be falsely negative in patients already receiving antifungal 
therapy. In some patients, at bronchoscopy the infected tissue in the lung might not 
be reached, resulting in falsely negative direct smears or needle biopsy. In other words, 
negative cultures do not exclude the possibility of invasive pulmonary aspergillosis (9, 
15).
In the last years, molecular techniques have increasingly become available. These 
newer mostly PCR-based techniques offer several advantages compared to traditional 
methods, such as the ease of use, simplicity, short turnaround time and correct species 
identification (19, 20).
In addition to microbiological methods, imaging methods can also be helpful in the 
diagnostic route towards diagnosing an IFI. Radiologic investigations including chest 
X-ray and high resolution computed tomography (HR-CT) could show characteristic 
findings for invasive aspergillosis, such as the halo sign or air crescent sign (17, 21, 22). 
Based on clinical findings, histopathological and microbiological evaluation and radio-
logical findings, patients can be classified as either proven, probable or possible cases 
of IPA according to the criteria defined by the European Organization for Research and 
the Treatment of Cancer-Mycoses Study Group (EORTC-MSG)(23). In brief, the criteria of 
“proven aspergillosis” are met when fungal material is cultured or observed microscopi-
cally in normally sterile material from direct biopsy or needle aspiration, in a patient 
with clinical signs of infection. A patient is classified as “probable aspergillosis” when a 
host factor (e.g. prolonged neutropenia), a radiological sign of fungal disease (e.g. halo 
sign, air-crescent sign) and a mycological factor (e.g. positive galactomannan index, 
positive culture) are present. Patients lacking a mycological factor are classified as “pos-
sible” aspergillosis, according to the definitions (23). This classification allows clinicians 
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to assess the risk of a patient to have aspergillosis. Early diagnosis of fungal infections is 
important, since treatment outcomes improve and healthcare costs are reduced when 
early and adequate therapy is started (9, 14, 24).
trEatmENt oF INVasIVE PulmoNary asPErgIllosIs
When a patient with IPA is diagnosed, the next challenge is treatment of the infection. 
Currently, IPA is mostly treated with voriconazole, based on data obtained in a random-
ized controlled trial that included 277 individuals with proven or probable aspergillosis 
(25). After publication of this study in 2002, no other randomized clinical trials with 
this high a number of patients have been published. Before this study was published, 
amphotericin B was the drug of choice for decades. Amphotericin B is a relatively old 
agent, belonging to the polyenes. It has a small therapeutic range due to a well-known 
dose-limiting nephrotoxicity (9). It binds to ergosterol in the fungal cell membrane and 
by forming pores, the permeability of the cell wall is increased, resulting in loss of essen-
tial nutrients and finally cell death. Amphotericin B was the first choice antifungal agent 
for a long time, but newer agents with lower toxic side effects have moved this agent 
downwards in the order of choice. The azoles, to which itraconazole, voriconazole and 
posaconazole belong, target 14-α demethylase and block the formation of ergosterol 
from its precursor lanosterol. Without ergosterol the fungal cell membrane and cell wall 
are not stable, resulting in cracks in the cell wall, ultimately leading to cell death. Azoles 
show less toxicity and voriconazole has become first choice in the treatment of aspergil-
losis (9, 14). The newest group of antifungal agents is the group of the echinocandins, to 
which caspofungin belongs, currently in use as salvage therapy.
CasPoFuNgIN, a dIFFErENt aNtIFuNgal agENt
Echinocandins have a different target than the polyenes and the azoles and act by the 
inhibition of synthesis of β-glucan, a major component of the fungal cell wall (Figure 3A 
and B)(26). In general, echinocandins are well tolerated and only few side effects were 
reported so far. Caspofungin is one of the echinocandins that is approved by the Food 
and Drug Administration for use in humans with IPA, though only as salvage therapy 
when patients are refractory or intolerant to other therapies (9, 14, 26). However, studies 
show that treatment with caspofungin in IPA is effective in terms of reduced mortality 
and cost effectiveness (27, 28).
The antifungal activity of caspofungin is different compared to that of other agents. 
When tested in vitro, low concentrations of caspofungin cause morphological altera-
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tions in the growth of A. fumigatus, resulting in aberrant morphology with short highly 
branched hyphae, visible by the naked eye (29). Complete macroscopic growth inhibi-
tion of Aspergillus species is only observed at high concentrations of caspofungin (29, 
30). Based on these in vitro results, one would not expect good clinical outcomes after 
caspofungin therapy. However when patients are treated with relatively low doses of 
caspofungin, a clinical response is seen. Since the drug itself was not able to inhibit the 
growth of A. fumigatus but only to alter it, it seems that there is a discrepancy between 
the in vitro results of susceptibility testing and the in vivo results of treatment with 
caspofungin. Already years ago, it was shown that human sera, human monocytes and 
monocyte-derived macrophages enhanced the antifungal activity of caspofungin (26, 
31, 32). However, the exact mechanisms behind the clinical response with caspofungin 
therapy are not well understood and various hypotheses are available.
β-1,3 glucan 
β-1,6 glucan 
mannoproteins 
β-1,3 glucan 
synthase 
ergosterol 
chitin 
cell membrane (fosfolipid bilayer) 
β-1,3 glucan synthase 
caspofungin 
B
a
Figure 3. Fungal cell wall (schematic) with its components.
A. Normal fungal cell wall
B. Target and mechanism of action of caspofungin. Caspofungin targets β-1,3 glucan synthase, inhibiting 
the synthesis of β-1,3 and β-1,6 glucan. This results in a weaker cell wall with less β-glucan.
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The studies summarized in this thesis aim to answer the following research question:
how can the discrepancy be explained between the favorable clinical response to 
treatment with caspofungin, while the in vitro antifungal activity of this agent is 
poor?
To answer this research question, more insight is needed in the mode of action of caspo-
fungin, why it alters A. fumigatus growth and the resulting effects on the immune system 
of the host. We therefore divided this question into several narrower questions and we 
also investigate new diagnostic and therapeutic strategies for IPA:
• How does caspofungin alter the composition of the fungal cell wall? Is chitin con-
tents upregulated as a result of β-glucan depletion?
• Does altered cell wall composition result in altered immune response of the host? 
Is cytokine and chemokine response differentially activated after treatment with 
caspofungin?
• Are chitinases upregulated in IPA as a result of exposure to chitin of the fungal cell 
wall? Does treatment with caspofungin alter the chitinase response?
• Do genetic polymorphisms, resulting in absent chitinase activity, increase the risk for 
IPA or for other fungal infections?
• Can newer diagnostic methods successfully identify A. fumigatus and distinguish it 
from morphologically identical species such as Aspergillus lentulus?
• Do new agents such as branched histidine and lysin rich peptides have antifungal 
activity against A. fumigatus or yeasts?
EFFECts oF CasPoFuNgIN oN thE FuNgal CEll wall
Chitin and β-glucan are the two main components of the fungal cell wall that are 
responsible for maintaining its functional strength. As described above, caspofungin in-
hibits β-1,3-glucan synthase (26, 33, 34), causing a significant inhibition of the synthesis 
of β-1,3-glucan and β-1,6-glucan. This inhibition results in morphological alterations in 
the growth in several fungal species (26, 35, 36). In order to understand the biological 
processes behind this altered morphology, the cell wall components of Candida spe-
cies were analyzed, which showed paradoxical growth at concentrations higher than 
the MIC of caspofungin (36-38). In several previous publications it was reported that 
inhibition of the synthesis of β-glucan resulted in upregulation of the chitin synthesis 
(35-37, 39-46). When Candida species were exposed to a combination of a glucan syn-
thase inhibitor and a chitin synthase inhibitor, synergy was noted and fungal growth 
was significantly decreased (39, 47). In Aspergillus species morphological changes were 
also observed after treatment with caspofungin, and β-glucan synthesis inhibitors and 
chitin synthase inhibitors were previously shown to act synergistically (30, 39, 43, 44, 
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146-50). We hypothesized that in filamentous fungi such as A. fumigatus, similar changes in cell wall composition could be found as in Candida species. Several studies showed 
that in A. fumigatus the β–glucan content is decreased after exposure to caspofungin 
(26, 44, 46, 48). A compensatory increase in chitin was reported in A. fumigatus as well 
(40, 48). To confirm this finding and to determine if in A. fumigatus inhibition of β -glucan 
synthesis results in an altered chitin synthesis, we investigated the synergy between 
inhibitors of the β-glucan and chitin synthesis pathways in Chapter 2. We combined the 
β-glucan synthesis inhibitor caspofungin with the chitin synthesis inhibitor nikkomycin 
Z and studied the morphology and the metabolic activity of A. fumigatus after exposure 
to several combinations of these agents.
EFFECts oF aN altErEd FuNgal CEll wall ComPosItIoN oN thE host 
ImmuNE systEm
Since it was already demonstrated that caspofungin alters the cell wall composition 
of fungal species, potential effect of this altered cell wall composition on the immune 
response of the host, needs further investigation. Chitin and β-glucan are molecules on 
the outer surface of the fungal cell wall and belong to the so-called pathogen-associated 
molecular patterns (PAMPs), molecules that can be recognized by specific receptors 
of the host’s immune system, pattern recognition receptors (PRRs), including Toll-like 
receptors (TLRs) (12, 51-53). A. fumigatus hyphae are known to be recognized by TLR4 
(12). β-glucan is recognized by dectin-1 (53-56) whereas no specific PRR has yet been 
identified that recognizes chitin (53, 54, 57).
If A. fumigatus’ cell wall composition is indeed changed by exposure to caspofungin 
and the level of cell wall chitin is upregulated, this could result in an altered interaction 
with certain host PRRs and, subsequently, in an altered host immune response. When 
PAMPs are changed, different PRRs and molecular pathways are activated and signaling 
cascades are changed (51). This could lead to an increased or decreased production of 
certain cytokines and chemokines, ultimately influencing the clearance of the fungus. 
Since it is currently not known which cytokines and chemokines are involved in this 
process, we investigated the effects of treatment with caspofungin on the levels of 
pro- and anti-inflammatory cytokines during experimental IPA. We measured levels of 
24 cytokines and chemokines in rats with IPA that were either left untreated or that were 
treated with caspofungin in Chapter 3.
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ChItINasEs, sPECIFIC ENzymEs oF thE host ImmuNE systEm, rEaCtINg 
oN ChItIN
In addition to being recognized as a PAMP, chitin itself is also recognized and cleaved by 
chitinases, enzymes produced by the host that specifically cleave chitin. Chitinases were 
first discovered in chitin-containing insects, where they are involved in remodeling their 
chitin skeleton. Also plants and later mammals were shown to produce these enzymes 
as defense mechanism against chitin-containing pathogens (58-60). Chitinases are 
categorized as endochitinase or exochitinase, based upon the site where the hydrolytic 
activity takes place (Figure 4) (61, 62). Two chitinases have been discovered in humans so 
far: chitotriosidase, which is an endochitinase and is found in lungs and lacrimal glands 
of mammals (63-67) and acidic mammalian chitinase (AMCase), which is an exochitinase 
and is found mainly in the gastro-intestinal tract (59). Chitinases are associated with 
allergic diseases (68, 69), however their role in infectious diseases by chitin-containing 
fungi was not investigated extensively.
Overdijk et al reported increased levels of chitinases in guinea pigs suffering from 
systemic A.  fumigatus infections (70, 71). As described in the previous paragraph, we 
expected the chitin contents of the fungal cell wall to be increased after treatment 
with caspofungin, resulting in an increased chitinase activity in the host (compared 
to untreated rats with IPA). This might be responsible for the good clinical response to 
treatment with caspofungin. In order to investigate the effects of caspofungin therapy 
on the levels of chitinases, we measured chitotriosidase and AMCase levels in our IPA rat 
model with IPA in Chapter 4.
Chitin molecule 
endochitinase exochitinase 
Figure 4. Chitin, chitinases and their sites of action.
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1gENEtIC dIFFErENCEs IN gENEs ENCodINg For ChItINasEs
Previous studies in different geographic regions show that impaired (or decreased) 
chitinase activity in humans is quite common. Polymorphisms in both chitotriosidase 
and AMCase have been described, resulting in either increased or decreased enzyme 
activity (58, 72-75). If indeed chitinase activity plays a role in the defense against fungal 
infections, the question arises if fungal infections occur more often in individuals with 
impaired chitinase activity. In other words, we hypothesized that a polymorphism in 
the genes for chitinases, resulting in impaired chitinase activity, increases the risk for 
IPA. In addition, increased chitinase activity might also limit the risk for IPA. To test this 
hypothesis, we investigated whether chitinase impairing polymorphisms are found 
more often in patients with IPA, compared to patients without IPA. Chapter 5 describes 
the prevalence of four different polymorphisms resulting in increased or decreased 
chitotriosidase or AMCase activity among patients at risk for IPA.
In case the prevalence of these polymorphisms is different in IPA patients compared 
to patients without IPA, one would hypothesize that this would also be true for infec-
tions caused by other fungi. In patients infected with other fungi containing chitin and 
β-glucan in their cell wall, increased chitinase production by the host could also be 
induced. In Chapter 6 we investigated whether the same polymorphisms in the genes 
for chitinases play a role in the incidence of the tropical disease mycetoma caused by 
Madurella mycetomatis in Sudanese patients.
NoVEl dIagNostIC aNd thEraPEutIC oPtIoNs For FuNgal INFECtIoNs
As described above, the diagnosis and treatment of fungal infections remain a challenge 
to clinicians. Next to better understanding of the predictive value of in vitro antifungal 
susceptibility testing for clinical treatment outcome, further improvement of the di-
agnostic methods and novel therapeutic approaches are of high importance. The last 
two chapters of this thesis cover novel diagnostic and therapeutic options for fungal 
infections.
In Chapter 7 we investigated novel diagnostic techniques to correctly identify Asper-
gillus fumigatus and to distinguish this species from Aspergillus lentulus. To distinguish 
between these two species of Aspergilli which are morphologically very similar (76) is 
important as their susceptibility to antifungal agents is different (77-79). Rapid and cor-
rect identification of the causative agent of fungal infections is important in order to 
enable appropriate treatment at an early stage, leading to better clinical outcomes and 
to limitation of costs of hospitalization (80).
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To identify several Aspergillus species including A. lentulus and A. fumigatus, we com-
pared two relatively new techniques, being Raman spectroscopy and matrix-associated 
laser desorption/ionization time-of-flight mass spectroscopy (MALDI-TOF MS). Both 
techniques identify pathogens based upon their biophysical properties. In addition to 
correct identification of A. fumigatus and A. lentulus, the time frame in which both fungal 
species can be identified by these two methods is also discussed.
Apart from new diagnostic options, in Chapter 8 we also investigated new therapeutic 
strategies, which is important to achieve limitations of costs and toxic side effects of the 
antifungal drugs currently in use. We investigated a group of agents called branched 
histidine and lysine-rich peptides (BHKPs). BHKPs were originally developed for gene 
delivery (81). These peptides were found to have antimicrobial activity and are thought 
to act in a similar way as histatin-5 (82). Antifungal activity of BHKPs against Candida 
species has been detected, but the antifungal activity against Aspergillus species is 
unknown (82).
Chapter 9 is the summarizing discussion of the main findings presented and discussed 
in this thesis. It focused on a better understanding of the mechanism of action of caspo-
fungin in IPA, and the role played by host-derived chitinases during these interactions. 
Furthermore, the results obtained with new antifungal agents are discussed, as well as 
findings obtained with improved diagnostic methods.
The knowledge gained leads to improved diagnosis and treatment of IPA with either 
combination therapy of caspofungin, or with newer antifungal agents that target differ-
ent components of the fungal cell wall. We hope that our results will contribute to novel 
strategies, resulting in a better clinical outcome.
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aBstraCt
Chitin and β-glucan are major cell wall components of Aspergillus species. We inves-
tigated the antifungal activity of chitin synthesis inhibitors nikkomycin Z, polyoxin D, 
flufenoxuron, lufenuron and teflubenzuron, alone and combined with the β-glucan 
synthesis inhibitor caspofungin. Only nikkomycin Z and caspofungin were found to act 
synergistically. The nikkomycin Z-induced chitin decrease corresponded with a β-glucan 
increase, while with the caspofungin-induced β-glucan decrease, an increase in chitin 
was found. This could explain the synergistic activity of this combination of drugs.
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INtroduCtIoN
Chitin and β-glucan, major constituents of the fungal cell wall and not found in humans, 
are interesting targets for new antifungal strategies. Inhibitors of chitin synthesis have 
been classified as either peptidyl nucleosides or acylureas. The peptidyl nucleosides, 
such as nikkomycins and polyoxins, function as substrate analogues and inhibit chitin 
synthase at its catalytic site (1). The exact mechanism of the acylurea compounds such 
as teflubenzuron, lufenuron and flufenoxuron is unknown (2).
β-Glucan synthesis is inhibited by the echinocandins, such as caspofungin, which are 
cyclic lipopeptide compounds inhibiting the enzyme 1,3-β-D-glucan synthase. Lack of 
chitin and β-glucan in the cell wall leads to osmotic lysis of the fungal cell (1). Therefore, 
combining a chitin and β-glucan inhibitor may enhance fungal killing.
This study reports the in vitro susceptibility of Aspergillus fumigatus to different classes 
of chitin synthesis inhibitors used alone and combined to caspofungin, a β-glucan 
synthesis inhibitor.
matErIals & mEthods
Minimal inhibitory concentrations (MICs) of caspofungin (Merck and Co, Rahway, NJ, 
USA), and for nikkomycin Z, flufenoxuron, lufenuron, teflubenzuron (all from Sigma-
Aldrich, Zwijndrecht, the Netherlands) and polyoxin D (Kaken Pharmaceutical Co., 
Tokyo, Japan) were determined for 10 A. fumigatus strains, including A. fumigatus ATCC 
204305. For caspofungin, the minimal effective concentration (MEC) of caspofungin was 
also determined. Nikkomycin Z and polyoxin D were dissolved in water and all other 
agents were dissolved in dimethyl sulfoxide (DMSO). MICs and MECs were determined 
in triplicate in RPMI 1640 medium, according to the CLSI broth microdilution method (3).
Synergy between the antifungal agents was investigated by a checkerboard antifungal 
susceptibility assay. The fractional inhibitory concentration index (FICI) was calculated 
using method 1 according to Bonapace et al (4) with the following formula:
FICI = [(MICA in combination)/MICA] + [(MICB in combination)/MICB]
Drug interactions were classified as synergistic (FICI ≤ 0.5), indifferent (0.5 < FICI < 4), or 
antagonistic (FICI ≥ 4). For each isolate, FICIs were determined in triplicate.
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To assess antifungal activity with respect to fungal metabolic activity, the colorimetric 
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt hy-
droxide (XTT) assay was used (5). Morphology was studied using light microscopy. 
Concentrations of chitin and β-glucan were determined as previously published (6-9).
rEsults
Caspofungin was the only agent that inhibited growth of A.  fumigatus (median MICs 
and median MEC for 10 strains are shown in Table 1). These MICs were in agreement 
with previously described MICs for A. fumigatus (3). None of the chitin synthesis inhibi-
tors inhibited growth of A. fumigatus (Table 1). Microscopic evaluation revealed some 
morphological alterations after exposure to nikkomycin Z at ≥8 mg/L: some cells were 
rounded and swollen (Figure 1), though most cells appeared normal.
table 1. Minimal inhibitory concentrations (MICs) for several groups of antifungal agents. FICIs were calcu-
lated in order to assess synergy (see text for calculation method)
Class and antifungal agent MIC and MEC
(μg/ml) (range)*
FICI in combination
with caspofungin#
β-glucan synthesis inhibitors
Echinocandins
 Caspofungin 128 (128 ->128)
0.25 (0.06 – 0.5)*
Chitin synthesis inhibitors
Peptidyl nucleosides
 Nikkomycin Z >64 (>64) 0.15
 Polyoxin D >64 (>64) 2.0
Acylureas
 Flufenoxuron >16 (>16) 2.0
 Lufenuron >16 (>16) 2.0
 Teflubenzuron >16 (>16) 2.0
* Minimal effective concentration (MEC; indicated by the asterisk) was determined for caspofungin only.
# Median fractional inhibitory concentration index (FICI) of caspofungin in combination with various chitin 
synthesis inhibitors for 10 A. fumigatus strains.
Nikkomycin Z combined with caspofungin resulted in synergy (median FICI of 0.15 for 
10 strains), which was not observed with other chitin synthesis inhibitors (median FICI 
of 2.00; Table 1). Synergy between caspofungin and nikkomycin Z is in agreement with 
previously published data (1).
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Figure 1. Cells of A. fumigatus (original magnification, ×400). Scale bar 25 μm.
A. A.  fumigatus not exposed to any antifungal agent. Elongated hyphae are noted; no swollen cells are 
present.
B. A. fumigatus exposed to 8 mg/L nikkomycin Z. Elongated hyphae are still seen, but some of the hyphae 
appear to be swollen and rounded.
C. A. fumigatus exposed to 0.125 mg/L caspofungin. Hyphae are shortened, stubby and broad based.
D. A. fumigatus exposed to 4 mg/L caspofungin. Hyphae are further shortened, stubby and broad based. 
This morphology is more evident than with 0.125 mg/L caspofungin.
E. A. fumigatus exposed to 0.125 mg/L caspofungin and 8 mg/L nikkomycin Z. Cell morphology is disrupted, 
and many cells are swollen and rounded, though normal hyphae are still seen.
F. A. fumigatus exposed to 4 mg/L caspofungin and 8 mg/L nikkomycin Z. Cell morphology is completely 
disturbed and no normal hyphae are seen.
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Figure 2. Concentrations of the cell wall components β-glucan and chitin in A. fumigatus ATCC 204305 after 
exposure to caspofungin and nikkomycin Z at various concentrations.
A. Glucosamine concentrations represent chitin concentrations. Means from three independent experi-
ments are shown. Bars represent standard deviations. β-Glucan and chitin concentrations were corrected 
to the number of viable cells with the XTT assay by the following formula: (amount of β-glucan or chitin 
measured) × (number of viable cells in the growth control/number of vibale cells in the well tested).
B. Fungal response in cell wall components. Concentrations of β-glucan and chitin after expoure to 0.125 
μg/ml of caspofungin combined with 2 μg/ml nikkomycin Z, each agent alone, and the growth control. This 
graph shows that combining caspofungin and nikkomycin Z causes a drastic decrease in β-glucan content, 
resulting in a compensatory increase in chitin content.
C. Shift in cell wall components β-glucan and chitin after exposure to caspofungin and nikkomycin Z at 
two concentrations (schematic representation). Both components are standardized to 50% in the drug-free 
control.
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Antifungal activity with respect to fungal metabolic activity was tested using the 
colorimetric XTT assay (5). Exposure to none of the agents alone led to >80% decreased 
metabolic activity of the fungal cells, except for caspofungin at 128 mg/L. Similar results 
were described by Antachopoulos et al (10). However, combining caspofungin and nik-
komycin Z mostly affected the decrease in fungal metabolic activity. For example, 0.125 
mg/L caspofungin alone resulted in an 8% decrease in metabolic activity, whereas 0.125 
mg/L caspofungin combined with 2 mg/L nikkomycin Z resulted in a 56% decrease in 
metabolic activity (data not shown). The morphology of fungal cells exposed to the 
drugs in combination was also studied (Figure 1). This figure shows that when A. fumiga-
tus was exposed to 8 mg/L nikkomycin Z, elongated hyphae were still present but some 
of the cells became rounded (Figure 1B). Exposure to caspofungin caused short, stubby 
branched hyphae (Figure 1C and D). When both agents were combined, the rounded 
cells became more prevalent (Figure 1E). At a concentration of 4 mg/L caspofungin 
combined with 8 mg/L nikkomycin Z, the cell morphology was completely disturbed 
and no hyphae were identified anymore (Figure 1F).
To elucidate the observed synergy between caspofungin and nikkomycin Z, 5 × 104 
conidia/ml were exposed to these drugs for 48 hours and the changes in cell wall com-
ponents chitin and β-glucan were determined. At caspofungin concentrations of 4 mg/L 
and greater, a decrease in β-glucan content was observed (Figure 2A). Additionally, with 
caspofungin concentrations of 32 mg/L and greater, chitin concentrations were elevated 
(Figure 2B). With nikkomycin Z, the opposite was observed: β-glucan concentrations 
increased when a concentration of 0.5 mg/L or greater was used, while chitin concentra-
tions decreased when a concentration of 16 mg/L or greater was used. This observation 
is in agreement with Fortwendel et al, who reported that exposure to nikkomycin Z in 
concentrations up to 16 mg/L did not influence chitin concentrations (11). The combina-
tion of nikkomycin Z and caspofungin caused instability of the fungal cell wall. Figure 
2C shows that β-glucan concentrations were strongly decreased after exposure to 
0.125 mg/L caspofungin combined with 2 mg/L nikkomycin Z. As a consequence, chitin 
concentrations were increased in order to survive. This effect was also found for other 
combinations (data not shown).
dIsCussIoN
Exposure to a single drug, either caspofungin or nikkomycin Z, causes a reshuffling of 
cell wall components chitin and β-glucan (schematically shown in Figure 2D). Inhibi-
tion of chitin synthesis in A. fumigatus resulted in increased synthesis of β-glucan and 
vice versa. This would explain the synergy between both agents as well as the altered 
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morphology after exposure to caspofungin and nikkomycin Z. This alteration in cell wall 
components is not unique for A. fumigatus. Stevens et al showed that Candida albicans 
reacts to caspofungin concentrations above the MIC by compensatory increases of 
the chitin contents of the cell wall, resulting in survival (12). Furthermore, Walker et al 
reviewed several studies that investigated the enhancement of echinocandins activity 
when combined to nikkomycin Z in yeasts and fungi (13).
Nikkomycin Z was the only chitin synthesis inhibitor that inhibited A. fumigatus growth 
when combined to caspofungin. Since polyoxin D is also a peptidyl nucleoside, we 
expected to find the same synergy. However, polyoxin D, either alone or combined with 
caspofungin, did not inhibit growth of A. fumigatus. Polyoxin D is capable of inhibiting 
growth of Saccharomyces cerevisiae (14, 15), C. albicans and Cryptococcus neoformans 
(16). Archer showed that polyoxin D does inhibit A. fumigatus chitin synthase (17). How-
ever, in the present study, the inhibition of chitin synthase by polyoxin D, even when 
combined with caspofungin, was not sufficient to result in fungal growth arrest.
In summary, we have shown that the inhibition of the synthesis of a single cell wall com-
ponent (either β-glucan or chitin) results in a subsequent increase in synthesis of the 
other cell wall component. The observed synergy between caspofungin and nikkomycin 
Z is probably the result of an inability of the fungus to compensate for the altered ratio 
of chitin to β-glucan. Indeed, Luque et al showed that the β-glucan synthesis inhibitor 
micafungin combined to the chitin synthase inhibitor nikkomycin Z improved survival 
in mice with systemic aspergillosis (18). Additional studies are needed to investigate the 
in vivo potential of nikkomycin Z and caspofungin as a new antifungal combination for 
the treatment of aspergillosis.
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aBstraCt
Caspofungin is effective against invasive pulmonary aspergillosis (IPA) in immunocom-
promised hosts. In vitro however, caspofungin has no detectable fungicidal or fungi-
static activity on hyphal growth in Aspergillus fumigatus, although aberrant growth is 
observed. We hypothesized that the in vivo beneficial effects of caspofungin may be the 
result of a caspofungin-induced change in immune response, thus improving patients’ 
outcomes.
To investigate our hypothesis, we determined levels of cytokines and chemokines in 
an experimental model of lethal IPA in neutropenic rats. Neutropenic rats were infected 
intratracheally with A. fumigatus conidia. Levels of 24 pro- and anti-inflammatory cyto-
kines and chemokines were measured at several intervals in different body compart-
ments to determine the effects of caspofungin treatment on host immune response 
relative to survival.
IPA induced changes in the level of many cytokines, the response in the infected lungs 
being different from that in the blood compartment. In lungs, IL-6, IP-10, KC (equivalent 
of human IL-8) and MCP-1 increased at least 100-fold or more. In serum, GM-CSF, IL-
12p70, IL-10 and KC likewise increased. Life-saving treatment with caspofungin (achiev-
ing 100% rat survival) resulted in a similar immune response, though the cytokine 
response in the lungs, especially of MCP-1, was attenuated.
In conclusion, in an experimental rat model of lethal IPA in neutropenic rats, life-saving 
caspofungin treatment was associated with attenuation of the hosts’ proinflammatory 
response in the lung, however, levels of cytokines were similar in caspofungin-treated 
rats as in rats left untreated.
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INtroduCtIoN
Over the last decades, the incidence of Aspergillus species infections is increasing (1). 
In immunocompromised patients, invasive pulmonary aspergillosis (IPA) remains a 
cause of severe mortality and morbidity. Currently the first choice therapy consists of 
voriconazole.
Caspofungin, belonging to the class of echinocandins, is used as salvage therapy for 
invasive aspergillosis (2). Caspofungin inhibits the β-glucan synthesis and, therefore, 
has a direct effect on the composition of the Aspergillus cell wall. In vitro exposure to 
caspofungin results in an aberrant hyphal growth of Aspergillus fumigatus, but not in 
growth inhibition or death of the fungus, which is commonly observed for other an-
tifungal agents. In contrast, in vivo, in our model of IPA in transiently neutropenic rats, 
which has a fatal course if left untreated, the human equivalent dosage of caspofungin 
resulted in 100% rat survival (3). Therefore the question arises what causes this excellent 
therapeutic outcome, as caspofungin itself has no apparent activity on the viability of 
the fungal mycelium.
When A. fumigatus is exposed to caspofungin, β-glucan synthesis is inhibited and the 
chitin component of the cell wall is upregulated in vitro (4). Both chitin and β-glucan 
function as pathogen-associated molecular patterns (PAMPs), which are recognized by 
pattern recognition receptors (PRRs) of the hosts’ immune system. Since caspofungin 
alters the fungal cell wall composition, the type and amount of PAMPs are also changed 
(5). The alteration of fungal PAMPs is known to result in an altered immune response (6) 
and thus we hypothesized that an altered cytokine response was responsible for the 
beneficial clinical response to caspofungin in Aspergillus infections.
No studies were published with respect to the cytokine profile of neutropenic patients 
with IPA. We studied the levels of 24 pro- and anti-inflammatory cytokines and che-
mokines in our IPA model in neutropenic rats treated with caspofungin versus rats left 
untreated.
matErIals & mEthods
Experimental animal model
The model of invasive pulmonary aspergillosis (IPA) in neutropenic rats was previously 
described in detail (3, 7). Some minor changes have led to the following experimental 
design. Female strain RP/AEur/RijHsd albino rats were used in all experiments. Animals 
18-25 weeks of age, body weight 200-250 g with specified pathogen-free status were 
used. Transient neutropenia was induced by intraperitoneally (i.p.) administration of 
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cyclophosphamide (Endoxan, Baxter, Utrecht, The Netherlands) in doses of 75, 60, 50 
and 40 mg/kg at day 5 and day 1 before fungal inoculation, and at day 3 and day 7 
after fungal inoculation, respectively. This protocol resulted in substantially decreased 
leukocyte and granulocyte counts (7). To prevent bacterial superinfections, rats were 
given ciprofloxacin (500 mg/L) and colistin (100 mg/L) in their drinking water ad libitum. 
Furthermore, rats were given teicoplanin intramuscularly in doses of 30 mg/kg on days 
5 and 1 before fungal inoculation, and 15 mg/kg on days 1, 3, 6, 8 and 10 after fungal 
inoculation.
A clinical A. fumigatus isolate was used for infection. This strain was originally isolated 
from a hemato-oncological patient with IPA. Left-sided pulmonary infection was estab-
lished by intubation of the left main bronchus, while the rats were under general anes-
thesia. A cannula was passed through the tube and the left lung was inoculated with 20 
μl phosphate buffered saline containing 6 ×104 conidia of A. fumigatus. Sham-infected 
animals were inoculated with 20 μl saline. Caspofungin–treated rats received saline-
diluted caspofungin (Merck & Company, Rahway, NJ, USA) i.p. once daily in a dose of 4 
mg/kg/day, starting at 24h after initiation of the infection. Untreated animals received 
saline i.p. Regarding the experimental set-up, the experiment consisted of 4 groups of 
rats: A) infected, untreated rats; B) infected, caspofungin-treated rats; C) sham-infected, 
untreated rats and D) sham-infected, caspofungin-treated rats.
Blood samples were taken from the tail vein on day 1, 3 or 6 after initiation of infec-
tion and serum was isolated and stored at −80°C within 2 hours after sampling. Next, 
rats were sacrificed by CO2 exposure. Lungs were dissected at the same time points and 
were either stored at −80°C until further processing, or fixated in formalin to be used for 
immunohistochemistry. Tissue coupes were stained with Grocott methenamine-silver. 
On each time point, all groups consisted of 5 rats, except the group of infected rats left 
untreated on day 6, which consisted of 4 rats as 1 out of 5 rats died. Infected organs and 
blood from rats found dead were always cultured to exclude bacterial superinfections.
The animal experimental protocols adhered to the rules laid down in the Dutch Animal 
Experimentation Act and the EU Animal Directive 2010/63/EU. The Institutional Animal 
Care and Used Committee of the Erasmus University Medical Centre Rotterdam ap-
proved the present protocols.
determination of cytokine levels
Lungs were homogenized and cytokine levels were determined in both lung ho-
mogenate and serum using a bead-based flow cytometry technique (xMap; Luminex 
Corporation, Austin, TX, USA). The rat soluble cytokine receptor multiplex panel that 
was used (BioLegend custom Rat LEGENDPlex 24) contained bead-labelled cytokine 
Cytokines in rats with aspergillosis 39
3
receptors against pro- inflammatory cytokines (granulocyte-colony stimulating factor 
[G-CSF], granulocyte macrophage-stimulating factor [GM-CSF], interferon [IFN-γ], inter-
leukin [IL]-1α, IL-1β, IL-2, IL-6, IL-12p70, IL-17a, IL-18, IL-21, IL-22, tumour necrosis factor 
[TNF-α] and thymic stromal lymphopoietin [TSLP]), anti-inflammatory cytokines (IL-4, 
IL-5, IL-10 and IL-13), chemokines (interferon-gamma induced protein [IP]-10, keratino-
cyt chemoattractant [KC, the murine functional homologue of human IL-8], monocyte 
chemoattractant protein [MCP]-1, macrophage inflammatory protein [MIP-1α] and 
regulated on activation, normal T-cell expressed and secreted (8)) and the regulatory 
vascular endothelial growth factor (VEGF). Assays were performed according to the 
manufacturer’s instructions and samples were measured in duplicate. Cytokine levels 
were converted from median fluorescence intensity (MFI) to pg/mL using MILLIPLEX 
Analyst software (Millipore) and duplicates were averaged.
The immune response in untreated rats is defined by the absolute difference between 
infected, untreated rats (group A) and sham-infected, untreated rats (group C), which 
is called ΔUNTREATED. The immune response in caspofungin-treated rats is defined by the 
absolute difference between infected, caspofungin-treated rats (group B) and sham-
infected, caspofungin-treated rats (group D), which is called ΔTREATED. At each time point 
and for each cytokine or chemokine, ΔUNTREATED was compared with ΔTREATED and the differ-
ence was assessed for statistical significance. In short:
ΔUNTREATED = (cytokine level in infected, untreated rats) – (cytokine level in sham-
infected, untreated rats)
ΔTREATED = (cytokine level in infected, treated rats) – (cytokine level in sham-infected, 
treated rats)
ΔUNTREATED and ΔTREATED were compared and tested for significance.
statistics
Absolute cytokine levels of infected rats were compared with cytokine levels of sham-
infected rats using Mann-Whitney U-test (GraphPad Prism Software, San Diego, USA). 
The relative increase or decrease in cytokine level was expressed as an x-fold increase. 
Median cytokine levels of infected animals were divided by median cytokine levels of 
sham-infected animals on the same time point, resulting in an x-fold increase of the 
cytokine level.
The cytokine response in caspofungin-treated rats was compared with the cyto-
kine response in sham-treated rats as follows. Absolute differences in cytokine levels 
(Δ-cytokine) were calculated between individual infected and sham-infected rats. At 
each time point, Δ-cytokines were compared between caspofungin-treated rats and 
sham-treated rats, using Mann-Whitney U-test. A p-value of <0.05 was considered 
significant.
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rEsults
Rats infected with A. fumigatus conidia developed invasive pulmonary aspergillosis (IPA), 
as shown in Figure 1. All untreated rats died within 7 days and all caspofungin-treated 
rats survived, as we previously described elsewhere (3). To investigate the cytokine ki-
netics during this infection, pro- and anti-inflammatory cytokine levels were determined 
in both serum and in homogenized lung, in order to compare cytokine responses at the 
site of infection with the cytokine levels simultaneously present in the blood compart-
ment.
Pulmonary cytokine levels
IPA caused pulmonary insufficiency and ultimately death in all rats. No pulmonary dis-
comfort or death was observed in sham-infected rats.
The pulmonary cytokine levels of the infected rats differed considerably from those 
of sham-infected rats. In infected rats, levels of pro-inflammatory IFN-γ, IL-1α, IL-6, IL-18, 
IL-21, IL-22 and TNF-α and chemokines IP-10, KC, MCP-1, MIP-1α and RANTES increased 
during the course of infection (Supplementary Table S1). An exception was TSLP, which 
decreased during infection, although not statistically significant. The changes observed 
in the levels of other cytokines measured in lung homogenates were statistically not 
significant (data not shown). For the 12 cytokines and chemokines that changed signifi-
cantly during the infection, we calculated the relative changes. For IL-6, IP-10, KC and 
MCP-1 the relative change was most remarkable, since levels of these proteins increased 
over 100 fold (Figure 2A), with maximum levels reached on day 6 after infection (Figure 
3). The median level of IL-6 being 0.14 pg/mL before infection remained unchanged 
at day 1 after infection and from there increased to 95 and 569 pg/mL on day 3 and 
day 6 after infection, respectively (Figure 3A). In infected rats, the median level of IP-10 
increased from 4.3 pg/mL before infection up to 5.5, 44 and 150 pg/mL on day 1, day 3 
Figure 1. Grocott staining of Aspergillus fumigatus infected lungs. Fungal hyphae are stained black. Mag-
nification ×400.
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and day 6 after infection, respectively, whereas in sham-infected rats, median level of 
IP-10 decreased to 0.33 pg/mL on day 6 after infection (Figure 3B). The median level of 
KC in infected rats increased from 107 pg/mL before infection to 119, 550 and 8796 pg/
mL on day 1, day 3 and day 6 after infection, respectively, whereas in sham-infected rats 
KC decreased to 5 pg/mL on day 6 after infection (Figure 3C). The median level of MCP-1 
increased from 63.4 pg/mL before infection to 351, 818 and 18849 pg/mL on day 1, day 
3 and day 6 after infection, respectively (Figure 3D).
serum cytokine levels
The lung is the primary site of IPA. Cytokines produced in the lung do not always spill 
over into the systemic circulation (9). Therefore, it cannot be assumed that during IPA 
the same cytokine profi les develop in the blood compartment as in the lung. Therefore, 
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Figure 2. Relative changes in cytokines and chemokines during IPA.
A. Pulmonary cytokines in the lung
B. Systemic cytokines in serum.
Median cytokine levels in infected rats were divided by median cytokine levels of sham-infected rats, re-
sulting in a fold-increase (y-axis). Levels of cytokines in infected, untreated rats (group A) were compared 
with those in sham-infected, untreated rats (group C). Levels of cytokines in infected, caspofungin-treated 
rats (group B) were compared with those in sham-infected, caspofungin-treated rats (group D). White bars: 
infected rats on day 1, before caspofungin treatment was started. Black striped bars: infected rats on day 3. 
Black bars: infected caspofungin-treated rats on day 3. Grey striped bars: infected rats on day 6. Grey bars: 
infected caspofungin-treated rats on day 6. Pulmonary IL-6, IP-10, KC and MCP-1 all show a relative increase 
of 100× or more at any time during IPA. In contrast, systemic GM-CSF, IL-12p70, IL-10 and KC show a relative 
increase of 100× or more during IPA. Each sample was measured in duplicate and duplicates were aver-
aged. N=5 for each group, except infected rats left untreated on day 6 (n=4).
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we also determined cytokine levels in serum samples at the same time points. During 
infection, 11 out of 24 cytokines and chemokines showed changes. Serum levels of 
pro-infl ammatory GM-CSF, IL-12p70, IL-18 and TSLP, anti-infl ammatory IL-5 and IL-10, 
chemokines IP-10, KC, MCP-1, RANTES and of regulatory VEGF varied signifi cantly during 
the course of infection (Supplementary Table S2). All of these cytokines increased during 
infection but some cytokine levels decreased after an initial increase. For all 11 cytokines 
that changed signifi cantly during the course of infection, we calculated relative changes 
(Figure 2B). Levels of GM-CSF, IL-10, IL-12p70 and KC increased over 100-fold within 24 
hours of infection. The median level of GM-CSF increased from 0.44 pg/mL before infec-
tion to 45.2 on day 1 after infection and then decreased to 16.6 pg/mL on day 3 after 
infection (Figure 4A). On day 6, GM-CSF level returned to levels from prior infection (0.44 
pg/mL, Figure 4A). Apparently, GM-CSF is increased in the early stage of the infection 
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Figure 3. Absolute levels of pulmonary IL-6 (panel A), IP-10 (panel B), KC (panel C) and MCP-1 (panel D) 
during IPA. Rats were sham-infected or infected with A. fumigatus and were left untreated. Median levels of 
cytokines are shown. Each sample was measured in duplicate and duplicates were averaged. N=5 for each 
group, except infected rats left untreated on day 6 (n=4).
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only. IL-10 showed a similar pattern. The median level of IL-10 increased from 0.39 pg/mL 
before infection to 25.6 pg/mL on day 1 after infection and subsequently decreased to 
24.2 and 3.9 pg/mL on day 3 and day 6 after infection, respectively (Figure 4C). Median 
levels of IL-12p70 also increased early in the infection but did not return to levels from 
prior to infection. The median level of IL-12p70 increased from 0.18 pg/mL before infec-
tion to 43.9 pg/mL on day 1 after infection and then decreased to 34.2 pg/mL on day 3 
and day 6 after infection, respectively (Figure 4B). The median level of KC increased from 
0.47 pg/mL prior to infection to 127, 66.7 and 138.5 pg/mL on day 1, day 3 and day 6 
after infection, respectively (Figure 4D).
Pulmonary versus systemic cytokine kinetics
During IPA cytokine kinetics in the lungs were not similar to the cytokine kinetics in 
serum. We found that pro-infl ammatory IL-18 and chemokines IP-10, KC, MCP-1 and 
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Figure 4. Absolute levels of systemic GM-CSF (panel A), IL-12p70 (panel B), IL-10 (panel C) and KC (panel D) 
during IPA. Rats were sham-infected or infected with A. fumigatus and were left untreated. Median levels of 
cytokines are shown. Each sample was measured in duplicate and duplicates were averaged. N=5 for each 
group, except infected rats left untreated on day 6 (n=4).
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RANTES were significantly increased in both serum and in the lung, however followed 
a different pattern during infection in each compartment. For example levels of KC in 
serum show a stronger increase during infection than in the lungs, whereas levels of 
MCP-1 in serum showed a milder increase during infection than in the lungs (Figure 
2A,B).
The remaining cytokines and chemokines were increased in either lung or in serum. 
Pro-inflammatory IFN-γ, IL-1α, IL-6, IL-21, IL-22, TNF-α and chemokine MIP-1α were 
increased only in the lungs. In contrast, pro-inflammatory GM-CSF, IL-12p70 and TSLP, 
anti-inflammatory IL-5 and IL-10 and regulatory VEGF were increased exclusively in 
serum and not in the lungs. From these data we concluded that kinetics of cytokines 
differed in each compartment, which is in line with previously published data, showing 
that systemic levels of cytokines and chemokines do not always correspond with local 
levels of cytokines (9).
Cytokine kinetics in caspofungin-treated rats
In order to investigate the influence of caspofungin on the cytokine responses in neu-
tropenic rats, we conducted several experiments. To test whether caspofungin itself 
has any immunomodulatory effects, we measured cytokine levels in sham-infected, 
caspofungin-treated rats (group D) and compared them with those in sham-infected, 
untreated rats (group C). We found only minimal non-significant differences between 
levels of cytokines and we concluded that caspofungin itself, at the dose used, has no 
immunomodulatory effects.
As described before, caspofungin itself has poor in vitro fungicidal activity. However, in 
vivo, patient outcomes improve in response to treatment with caspofungin. In order to 
test whether the innate immune system plays a role in this paradox, we compared levels 
of cytokines in infected, untreated rats (group A) with those in infected, caspofungin-
treated rats (group B).
IPA itself caused a rise in many cytokines in the lung, as described above. However, 
treatment with caspofungin did not essentially alter the nature of the cytokine respons-
es, although some attenuation in the cytokine response, especially in the last phase in 
infection, day 6, seemed to occur in caspofungin-treated hosts (Figure 2A,B).
To further assess the capacity of caspofungin to influence the cytokine response, 
we compared the immune response in untreated rats (groups A and C) with that in 
caspofungin-treated rats (groups B and D; for calculations and statistics: see Material 
& Methods). The Δ-cytokines caused by IPA was compared between untreated rats on 
the one hand, and caspofungin-treated rats on the other hand. The differences between 
ΔUNTREATED and ΔTREATED thus calculated were significant only for two cytokines in different 
compartments. The ΔUNTREATED of IL-22 in the lungs on day 3 after infection was signifi-
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cantly different from ΔTREATED, however the difference was small (the infection caused an 
increase of 0.35 pg/ml on day 3 in untreated rats vs. no difference in treated rats, respec-
tively; p=0.047). Furthermore, the ΔUNTREATED of MCP-1 in serum on day 6 after infection 
was significantly different from ΔTREATED (the infection caused an increase of 376 pg/mL on 
day 6 after infection in untreated rats vs. 59 pg/mL in treated rats, respectively; p=0.032). 
These results show that in this model, caspofungin leads to attenuation of the increase 
in MCP-1 in serum on day 6 after infection and, to a lesser extent, of the increase in IL-22 
in the lungs on day 3 after infection. The ΔUNTREATED and ΔTREATED for all other cytokines 
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Figure 5. Concentration of cytokines in lungs of infected, untreated rats (blue crosses) and of infected, 
caspofungin-treated rats (red circles) on day 3 (panel A) and day 6 (panel B) after infection. Bars show me-
dians. Each sample was measured in duplicate and duplicates were averaged. N=5 for each group, except 
infected rats left untreated on day 6 (n=4).
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and chemokines at any other moment during infection were not significantly different 
between caspofungin-treated and untreated rats.
absolute cytokine levels in infected rats
As shown in the section above, the Δ-cytokine was very similar in caspofungin-treated 
rats as compared to untreated rats. However, the rat survival in both groups was very 
different. In addition to evaluating the relative increase in cytokine levels (see previous 
section), we also assessed absolute cytokine levels. The absolute levels of pulmonary 
cytokines in infected rats varied considerably from rat to rat within a group of treated or 
untreated rats on the same day after infection. On day 3 after infection, median levels 
of cytokines are similar in caspofungin-treated rats versus untreated rats (p>0.05; data 
not shown).
On day 6 after infection, absolute cytokine levels were very similar as well, though 
some differences can be noted. Median levels of MCP-1 in the lungs were >10× lower in 
caspofungin-treated rats when compared to untreated rats (18849 pg/mL in untreated 
rats and 1528 pg/mL in caspofungin-treated rats, p=0.032). Median levels of KC in the 
lungs were 8796 pg/mL in untreated rats and 356 pg/mL in caspofungin-treated rats 
(p=0.064). Although this latter difference did not reach statistical significance, probably 
due to the small numbers of rats used per group, such difference in cytokine response 
might be crucial in the survival of the caspofungin-treated rats. Levels of other cytokines 
in the lungs and levels of all cytokines in serum were in the same range in caspofungin-
treated rats compared to untreated rats.
In summary, treatment with caspofungin caused a limitation of the increase in MCP-1 
and KC in the lungs that is caused by IPA.
dIsCussIoN
IPA remains a disease in the immunocompromised host and always shows a fatal 
course, despite treatment with antifungal agents. Caspofungin is one of the regularly 
used antifungal agents, though it is not well understood why patients recover from IPA 
after treatment in view of the limited in vitro susceptibility of Aspergillus fumigatus to 
caspofungin (7). The aim of the present study was to further investigate the mechanism 
of action of caspofungin and to examine the hypothesis that the hosts’ immune system 
plays a role. We used our earlier developed animal model of IPA in transiently neutro-
penic rats showing 100% mortality of rats within 6-7 days (10). In a previous study we 
demonstrated that early treatment with caspofungin in the human pharmacokinetic 
equivalent dose resulted in 100% rat survival (3, 11). In another study we showed that 
host’s chitinase activity is increased in the lungs of neutropenic rats when inoculated 
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with A. fumigatus (7). As chitinases do not have a direct fungistatic or fungicidal effect, 
other factors are probably involved in the success of treatment with caspofungin. To 
determine whether the caspofungin-induced change in cell wall composition resulted 
in a change in cytokine response to infection, which could be responsible in part for 
the in vivo efficacy of this drug, we measured cytokines in caspofungin-treated rats. To 
our knowledge, no other studies were published regarding the cytokine profile after 
treatment with caspofungin.
In the present study we investigated the role of cytokines during the course of IPA in the 
neutropenic host. The strength of our study is that we investigated a broad panel of 24 
cytokines and chemokines. We found that IPA resulted in a rise in the levels of multiple 
cytokines and chemokines, indicating that the neutropenic host is still able to produce 
many pro- and anti-inflammatory cytokines. Similar observations for a few cytokines 
were made by other investigators (12, 13). As IPA is an opportunistic infection that 
exclusively develops in the immunocompromised host, we performed our experimental 
studies in immunocompromised rats with neutropenia, induced by cyclophosphamide. 
This agent is clinically used particularly in hematologic patients, resulting in prolonged 
neutropenia and thus at risk to develop IPA (http://www.drugs.com/pro/ cyclophospha-
mide.html).
Several studies investigated the cytokine response in immunocompetent rats with IPA 
(5, 14-17). In these papers, TNF-α, IL-1α, IL-1β, MIP-1α, MIP-1β, KC, IL-17a, IL-12p40, IL-23, 
TSLP, IL-10, IFN-γ were found increased after infection with A.  fumigatus. Conflicting 
results were reported for IL-4. El Muzghi et al found increased levels of IL-4 (14) whereas 
Urb et al found no increase (16). Differences in experimental setup may explain the 
discrepancy in results.
It should be noted that immunocompromised hosts respond differently to infection 
than immunocompetent hosts, which was confirmed by Herbst et al (17). They showed 
that cytokine response after exposure to A. fumigatus was attenuated in immunocom-
promised rats compared to immunocompetent rats. In the studies describing cytokine 
panels in animal models of the immunocompromised host, different methods were used 
to induce immunosuppression, including corticosteroid treatment, neutrophil neutral-
izing antibodies and cyclophosphamide (12, 13, 17-20). Cytokines and chemokines were 
measured in several compartments, including lung homogenate, broncho-alveolar 
lavage (BAL) fluid and culture supernatants in which spleen cells were incubated. These 
studies performed in different models of IPA showed that levels of TNF-α, IFN-γ, IL-1β, 
IL-12p70, MIP-2, KC and IL-10 were all increased. Our results are partly in agreement with 
these findings. We found no increase in IFN-γ and in IL-1β. However, for TNF-a, IL-12p70, 
KC and IL-10 we did find increased levels occasionally during the infection. MIP-2 levels 
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were not investigated in our study. In other infections, including scrub typhus in humans 
and severe Staphylococcus aureus bacteremia in mice, it was shown that increased levels 
of IL-8 or KC, the murine equivalent of human IL-8, were associated with disease severity 
or fatal outcome (21, 22). Even though KC levels did not reach statistical significance in 
our study, we observed a trend for a similar correlation.
As IPA presents heterogeneously in patients at risk for IPA, it is difficult to interpret 
cytokine responses in these patients. Data obtained from a well-defined experimental 
animal model as used in the present study may provide further insight into changes in 
the cytokine profile during the course of IPA. However, it should be noted that cytokine 
responses in rodents differ, at least in some aspects, from cytokine responses in humans. 
For example, we found no increase in IL-17 in rats as a result of IPA. Both Werner et 
al and El Muzghi et al showed that IL-17 was produced in pulmonary aspergillosis in 
non-neutropenic mice (14, 23) though production of IL-17 was not induced in human 
peripheral blood mononuclear cells after exposure to live A.  fumigatus conidia or in 
patients with probable or proven aspergillosis (24). Thus, extrapolation of the present 
data to the human situation should be done with caution. In addition, IL-17 and the 
IL-17 receptor were shown to be of major importance in neutrophilic inflammation 
of the airways (25). In our study we found no increase in IL-17. In our model rats are 
neutropenic, which could explain the difference between previously found increased 
IL-17 in IPA and the undetectable levels of IL-17 that we found. The discrepancy in data 
means that extrapolation of the findings obtained in the present study in rats with IPA, 
to patients with IPA should be done with caution. Furthermore, the use of only one 
strain of A.  fumigatus, albeit from a human case of IPA, does not allow generalization 
of the findings in our animal model. Finally, stress in the rats during blood withdrawals 
could have influenced the cytokine response, however since no immune modulating 
anesthetics, such as isoflurane, were used, we believe the influence is limited (26-32).
From previous studies it is known that A.  fumigatus has immunomodulatory effects. 
Certain constituents of the fungal cell wall are known to act as pathogen-associated 
molecular patterns (PAMPs), which are recognized by certain pattern recognition recep-
tors (PRRs). β-glucan for example is recognized by C-type lectin receptor Dectin-1 and 
by Toll-like receptor-2 (TLR-2) and TLR-4 (33-40). Recognition of β-glucan leads to acti-
vation of multiple intracellular pathways, leading to induction of many cytokines and 
chemokines including GM-CSF, G-CSF, TNF-α, IL-1α, IL-1β, IL-2, IL6, IL-10, MCP-1, MIP-1α, 
MIP-2, IL-8 and IL-23 (33, 36, 41, 42). Tomee et al showed that in human epithelial cell 
lines exposed to A. fumigatus indeed IL-6, IL-8 and MCP-1 were increased (42). Although 
the exact receptor for chitin is not known yet, it is considered a PAMP and da Silva et al 
showed that chitin is a ligand for Dectin-1 and TLR-2 (33, 43). Stimulation with chitin 
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results in induction of cytokines including IL-17, IL-12/23p40, IL-23, TNF-α, RANTES and 
MIP-2, eventually leading to IFN-γ production (44-47). However, Chai et al showed that 
chitin has no effects on the TLR-2 and TLR-4 induced response in the host (34). Shibata 
showed that the size of chitin particles is important for the mounted immune response 
(48), which could explain these differences. Particles of 1-10 μm induce IL-12, TNF-α and 
IFN-γ, whereas larger particles of 50-100 μm do not induce IL-12 and IFN-γ (48). The exact 
size of chitin polymers or particles used in our study is not known. Since in our rat model 
used A.  fumigatus conidia were used to initiate the infection, developing into hyphae 
and not a certain size of chitin particles, the immune response reported was induced 
by the combination of chitin, β-glucan and mannan. This could explain why our results 
do not completely match the hypothesized cytokine response for chitin particles. Based 
on our findings we cannot conclude whether the change in cytokines attributable to 
treatment with caspofungin is the result of a decrease in β-glucan exposure, or that it 
is caused by an increase in chitin and, by inference, leads to the activation of a different 
pathway.
The immunomodulatory effects of A. fumigatus have also been investigated. Chai et al 
showed that β-glucan modulates the host immune response through the TLR-4 pathway. 
β-glucan had a dose-dependent TLR-4 suppressive effect, resulting in a lower level of the 
pro-inflammatory IL-6 (34). Based on these findings, one would expect that a decrease 
in β-glucan in caspofungin-exposed A.  fumigatus would result in higher IL-6 levels. In 
contrast, we found that in our caspofungin-treated rats, where the mycelium contained 
less β-glucan than in untreated rats, IL-6 levels were lower instead of higher. This might 
be explained by the mode of action of caspofungin. Treatment with caspofungin causes 
unmasking of galactomannan in the fungal cell wall, resulting in increased exposure 
of β-glucan and chitin to cell wall degrading enzymes such as chitinases and to other 
immune cells (39, 40, 49-52). This increased exposure is thought to activate the immune 
system and, thereby, contribute to the favorable clinical outcome upon administration 
of caspofungin (49, 50). Increased exposure of deeper cell wall layers lead to enhanced 
degradation of chitin into smaller particles. These smaller chitin particles skew the im-
mune response towards Th1 instead of the Th2 response that is mounted by large chitin 
polymers (47). Strong et al confirmed that application of chitin microparticles (mostly 
<1 μm) increased levels of Th1 cytokines IL-12, IFN-γ and TNF-α, finally resulting in a 
decrease of lung inflammation (53). Again our results in the present study do not com-
pletely match this cytokine profile, probably due to the difference in immune response 
to chitin particles and to live A. fumigatus.
In summary, in the present study we demonstrated that in neutropenic rats, IPA caused 
a significant increase of IL-1α, IL-6, IP-10 KC, MIP-1α and MCP-1 in the lung, and of MCP-1 
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in serum (Figure 6). Treatment with caspofungin increases the exposure of the chitin 
moiety of the fungal cell wall, resulting in attenuation of the hosts’ cytokine responses 
and in host survival.
Figure 6. Summary of changes in cytokine levels in rats with IPA on day 6 after infection. The effects of 
treatment with caspofungin are also listed. Only cytokines that were significantly different are shown. Only 
cytokines that increased >10× compared to sham-infected rats were included.
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table s1. Cytokines and chemokines that were significantly increased or decreased in lungs from infected 
rats with IPA compared with sham-infected rats, at various time points after infection. Only p-values that 
were significant (<0.05) are shown.
Cytokine/chemokine
Elevated or decreased in infected 
untreated rats
Elevated or decreased in infected, 
caspofungin-treated rats
Day 1 Day 3 Day 6 Day 3 Day 6
IFN-gamma 0.047
IL-1alpha 0.016
IL-6 0.016 0.008 0.047
IL-18 0.032 0.008
IL-21 0.047
IL-22 0.047
TNF-alpha 0.032 0.032 0.016
IP-10 0.008 0.016 0.008
KC 0.008 0.016 0.008 0.032
MCP-1 0.029 0.008 0.016 0.008
MIP-1alpha 0.032 0.047
RANTES 0.032 0.008
table s2. Cytokines and chemokines that were significantly increased or decreased in serum from infected 
rats with IPA compared with sham-infected rats, at various time points after infection. Only p-values that 
were significant (<0.05) are shown.
Cytokine/chemokine
Elevated or decreased in infected rats 
left untreated
Elevated or decreased in infected 
rats, treated with caspofungin
Day 1 Day 3 Day 6 Day 3 Day 6
GM-CSF 0.016
IL-12p70 0.047
IL-18 0.047
TSLP 0.047
IL-5 0.047
IL-10 0.047
IP-10 0.032
KC 0.047
MCP-1 0.032 0.016
RANTES 0.032
VEGF 0.047
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aBstraCt
Caspofungin, currently used as salvage therapy for invasive pulmonary aspergillosis 
(IPA), strangely only causes morphological changes in fungal growth in vitro but does 
not inhibit the growth. In vivo it has good efficacy. Therefore the question arises how this 
in vivo activity is reached. Caspofungin is known to increase the amount of chitin in the 
fungal cell wall. Mammals produce two chitinases, chitotriosidase and AMCase, which 
can hydrolyse chitin. We hypothesized that the mammalian chitinases play a role in the 
in vivo efficacy of caspofungin.
In order to determine the role of chitotriosidase and AMCase in IPA, both chitinases 
were measured in rats which did or did not receive caspofungin treatment. In order to 
understand the role of each chitinase in the breakdown of the caspofungin-exposed 
cells, we also exposed caspofungin treated fungi to recombinant enzymes in vitro.
IPA in immunocompromised rats caused a dramatic increase in chitinase activity. This 
increase in chitinase activity was still noted when rats were treated with caspofungin. 
In vitro, it was demonstrated that the action of both chitinases were needed to lyse the 
fungal cell wall upon caspofungin exposure.
Caspofungin seemed to alter the cell wall in such a way that the two chitinases, when 
combined, could lyse the fungal cell wall and assisted in clearing the fungal pathogen. 
We also found that both chitinases combined had a direct effect on the fungus in vitro.
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INtroduCtIoN
Aspergillus fumigatus is a ubiquitous saprophytic fungus, producing conidia that are in-
haled daily by humans. Usually inhalation of these spores causes no problem; however, 
A. fumigatus can cause a broad range of diseases in hosts with underlying conditions. 
Patients with inflammatory conditions, such as asthma and cystic fibrosis, can develop 
allergic bronchopulmonary aspergillosis (ABPA)(1, 2). Patients with prolonged neutro-
penia are at risk to develop invasive pulmonary aspergillosis (IPA)(3). In neutropenic 
patients, IPA may be characterized by necrotizing pneumonia or hemorrhagic infarc-
tions. Due to the progressive character of IPA, the morbidity and mortality is high. The 
response to treatment is limited, despite the application of several antifungal agents 
with different mechanisms of action.
The current first choice antifungal agent for IPA is voriconazole, with amphotericin 
B as the alternative therapy (3). Caspofungin is available as salvage therapy, in case of 
refractory disease or intolerance of voriconazole or amphotericin B by the patient. Strik-
ingly, in vitro caspofungin has only a mediocre activity against A. fumigatus. It does not 
have fungicidal or fungistatic activity. Only at a very high concentration growth inhibi-
tion is noted. However, in in vivo animal models caspofungin seems to be very potent. In 
our transiently neutropenic rat model with unilateral invasive pulmonary aspergillosis, 
the human equivalent dosage of caspofungin results in 100% efficacy (4). Therefore 
the question arises what the reason is for this discrepancy between in vivo and in vitro 
results.
One hypothesis would be that the immune system of the host plays a role. Caspofun-
gin acts by inhibiting β-glucan synthase thereby decreasing the β-glucan contents of 
the fungal cell wall. To restore the stability of the cell wall, the fungus reacts by increas-
ing its other major cell wall component, chitin, as demonstrated in vitro (5, 6).
Chitin can be cleaved by chitinases, which belong to family 18 of glycosyl hydrolases 
and are produced in cooperation with the immune system. Chitinases are classified into 
endochitinases and exochitinases. Exochitinases act at the non-reducing ends of chitin 
with the release of successive diacetyl chitobiose units. In contrast, endochitinases ran-
domly cleave at internal points in the chitin chain (7, 8). Mammals are known to produce 
two types of chitinases: chitotriosidase and acidic mammalian chitinase (AMCase)(9). 
Chitotriosidase is produced by macrophages and polymorphonuclear neutrophils (10, 
11) and can be found in the lungs of mammals (12, 13) as well as in lacrimal glands 
(14). AMCase is an exochitinase produced by macrophages and epithelial cells (15) and 
is found mainly in the gastro-intestinal tract of mammals to digest nutritional chitin, 
though it was also found in the lung at low concentrations (10). The exact role of chitin-
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ases remains to be clarified. However, an important role for chitinases in allergic diseases 
has been suggested (16, 17).
In the past it was already demonstrated by Overdijk et al that chitinase activity was 
increased in plasma isolated from guinea pigs with a systemic A.  fumigatus infection. 
Furthermore, high chitinase levels were detected in the spleen, followed by lungs and 
kidneys (18, 19). However, these results did not reveal whether the chitinase activity was 
due to chitotriosidase or AMCase activity, or a combination of both since at that time, 
AMCase had not been discovered as a chitinase yet (10).
Summarizing the above, we can state that the chitin content in the A.  fumigatus cell 
wall is increased upon exposure to caspofungin and mammalian chitinases are induced 
during invasive aspergillosis. We therefore hypothesized that either chitotriosidase, AM-
Case or both play a role in the clearing of A. fumigatus from the lung when treated with 
caspofungin. In order to test this hypothesis, we first determined which of these two 
chitinases was induced upon A. fumigatus conidia in both immunocompetent rats, clear-
ing the conidia, and in immunocompromised rats, suffering from invasive pulmonary 
aspergillosis. In these experiments we determined if chitinases could be induced in the 
first place during the neutropenic state. Next, we determined if both chitotriosidase and 
AMCase were more extensively expressed during caspofungin treatment. Afterwards we 
investigated how these two chitinases and caspofungin interact and what the combined 
effect is on the A. fumigatus hyphae in vitro.
matErIals & mEthods
Experimental animal model
The rat model of invasive pulmonary aspergillosis (IPA) in immunocompromised rats 
used, was described previously (20). Some minor changes have led to the following 
experimental set up.
In order to determine if Aspergillus fumigatus conidia induce chitinase activity, immu-
nocompetent female albino RP rats were inoculated intratracheally with a clinical isolate 
of A. fumigatus originally isolated from a hemato-oncological patient with IPA. Left-sided 
pulmonary inoculation was established by intubation of the left main bronchus, while 
the rats were under general anaesthesia. A cannula was passed through the tube and 
the left lung was inoculated with 20 μl phosphate buffered saline (pbs) containing 6 ×104 
conidia of A. fumigatus. Rats were sacrificed at day 1, 3 and 6 after fungal inoculation to 
determine the chitotriosidase and AMCase activity both enzymatically and immunohis-
tochemically. For this, blood samples were taken by puncture of the orbital plexus and 
rats were sacrificed by CO2 exposure. The left lung was removed and either stored at 
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−80°C until analysis, or fixated in formalin for immunohistochemistry. Serum was also 
stored at −80°C until analysis. The groups consisted of a minimum of 4 rats. Infected 
organs and blood from rats found dead were always cultured to exclude bacterial super-
infections. Fungal load was assessed by determination of serum galactomannan index 
(GM-index), using the commercially available Platelia Aspergillus EIA Platelia Aspergillus 
system of BioRad (Marnes-la-Coquette, France).
In order to determine if A. fumigatus conidia induce chitinase activity in neutropenic fe-
male albino RP rats developing IPA, transient neutropenia was induced by intraperitone-
ally (i.p.) administered cyclophosphamide (Endoxan, Baxter, Utrecht, The Netherlands) in 
doses of 75, 60, 50 and 40 mg/kg bodyweight at 5 and 1 days before fungal inoculation, 
and at 3 and 7 days after fungal inoculation, respectively. Whereas the normal leukocyte 
counts in our rats is 5.8 ×109/L, the leukocyte counts decreased following cyclophospha-
mide treatment and were 6.5 ×107/L on the day of fungal inoculation and 6.4 ×107/L on 
day 5 and day 9 after inoculation. After the last dosage of cyclophosphamide, leukocyte 
counts rose to 2.6 ×109/L on day 13 and to 6.0 ×109/L on day 21 after infection. Granu-
locyte counts decreased from 2 ×108/L before cyclophosphamide was given (normal 
counts in our rats) to 2 ×104/L from the day of fungal inoculation to day 9. After the final 
dosage of cyclophosphamide, granulocyte counts increased again to 1.2 ×107/L and 1.2 
×109/L on day 13 and 21 after infection, respectively.
To prevent bacterial superinfections, rats were given ciprofloxacin (500 mg/L) and 
colistin (100 mg/L) in their drinking water. Furthermore, rats were given teicoplanin 
intramuscularly (i.m.) in doses of 30 mg/kg on days 5 and 1 pre- inoculation, and 15 mg/
kg on days 1, 3, 6, 8 and 10 post-inoculation. Immunocompetent rats were injected with 
saline i.p. instead of cyclophosphamide.
Left-sided pulmonary infection was established, by intubation as described for the 
immunocompetent rats. Again, rats were sacrificed at day 1, 3 and 6 after fungal in-
oculation to determine the chitotriosidase and AMCase activity both enzymatically as 
immunohistochemically as described for the immunocompetent rats.
Since rats were sacrificed at these predetermined time points, death of rats was no 
primary endpoint. Rats were monitored according to a discomfort scale by the research-
ers several times a day, during the entire experiment. In order to limit suffering, rats 
were euthanized in case of high discomfort, shown by e.g. increased breathing exercise, 
increased respiratory rates and altered behaviour, like decreased movements and 
unkempt appearance (dull haircoat). The experimental protocols adhered to the rules 
specified in the Dutch Animal Experimentation Act (1977) and the Guidelines on the 
Protection of Experimental Animals published by the Council of the EC (7a). The present 
protocols were approved by the Institutional Animal Care and Use Committee of the 
Erasmus MC Rotterdam.
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antifungal treatment
Caspofungin (Merck & Company, Rahway, NJ, USA) was diluted in saline and adminis-
tered intraperitoneally once daily in a dose of 4 mg/kg/day. Treatment was started at 
24h (early stage IPA) or at 72h (late stage IPA) after fungal inoculation. Treatment was 
continued for six days.
recombinant expression of rat amCase
Recombinant rat AMCase was generated using the pMIB insect cell expression system 
by Invitrogen as previously described for human chitotriosidase (14). The primers had 
SphI (forward primer) and Xba1 (reverse primer) restriction sites at the 5’ ends that fa-
cilitated the in-frame cloning into pMIB/V5-His (Invitrogen). The primer sequences were 
as follows: RnCHIA-F 5’-GCCCGGGCATGCATtacaatctggtatgctacttcac-3’ and RnCHIA-R 
5’- GCCCGGTCTAGAtggccagttgcagcaattacagctg-3’ (restriction sites underlined). The PCR 
reactions for generation of full length AMCase for expression cloning were conducted 
using Pfu DNA polymerase (Stratagene) following the manufacturer’s instructions for 
a 50μl reaction using cDNA obtained from rat lung tissue. The final sequence of the 
recombinant plasmid was confirmed by DNA sequencing. The activity of the recombi-
nant rat AMCase produced here and the purchased recombinant chitotriosidase were 
determined with the chitinase assays as described below.
Chitinase assay
Chitinase activity was determined in homogenized lung tissue. Activity of 4-Methylu-
mbelliferyl N,N’-diacetyl-β-D-chitobioside (chitobiosidase activity, corresponding with 
AMCase activity) and 4-Methylumbelliferyl β-D-N,N’,N’’-triacetylchitotriose (endochi-
tinase activity, corresponding with chitotriosidase activity) were determined using the 
commercial fluorimetric Chitinase Assay Kit (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany). Chitinase activity in each sample was measured in duplicate. Chitinase ac-
tivity was expressed in arbitrary units (a.u.) and median chitinase activity levels were 
compared for different groups of rats. Chitinase activity from Trichoderma viride (control 
enzyme from the Chitinase Assay Kit described above) was used as a positive control. A 
positive and a negative control were used in each run, in order to validate the experi-
ment.
Chitotriosidase and AMCase activity were measured in homogenized lungs. It was 
confirmed that all chitinase activity was indeed of host origin as follows: A. fumigatus 
conidia were cultured for 48 hours at 37°C in Sabouraud’s broth or RPMI, with and with-
out caspofungin 1 mg/L. The broth was filtered after 48h and chitinase activity in the 
broth was measured in triplicate. Activity of chitotriosidase and AMCase was measured 
with the commercial fluorimetric Chitinase Assay Kit and was found to be < 5 a.u. in all 
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samples tested. We thus concluded that the chitinases measured in the lung tissue were 
indeed of host origin and not of fungal origin.
Immunohistochemistry of lungs and in vitro cultures
Lungs were fixed in formalin, embedded in paraffin and processed for immunohisto-
chemical evaluation. First, lungs were deparaffinised in xylene, then rehydrated in 
decreasing concentrations of ethanol. Endogenous peroxidase was blocked in methanol 
with 0.3% H2O2 and non-specific binding sites were blocked with rabbit or goat serum. 
Subsequently, coupes were incubated overnight with rabbit polyclonal antibody di-
rected against chitotriosidase (H-66, 1:75, Santa Cruz Biotechnology, Santa Cruz, USA) 
or with goat polyclonal antibody directed against AMCase (Y-14, 1:50, both Santa Cruz 
Biotechnology, Santa Cruz, USA). As a control we used a goat polyclonal IgG antibody 
directed against swine IgM (A100-100A, 1:50, Bethyl Laboratories, Montgomery, USA). 
From the VectaStain® Elite ABC kit (Vector Laboratories Burlingame, CA, USA), anti-rabbit 
IgG or anti-goat IgG was used as a secondary antibody and the coupes were developed 
using the protocol from the kit. Hematoxylin was used as counter staining. In order to 
ascertain that the antibodies did not react with chitinases expressed by A.  fumigatus 
itself, A. fumigatus was grown on the same histological slides and fixated. These fixated 
A. fumigatus slides were stained according to the same protocol used for the histological 
slides. No staining of either chitotriosidase or AMCase was observed.
in vitro binding of chitinases to fungal hyphae
Aspergillus fumigatus was cultured for 48h at 37°C on Sabouraud’s agar with or without 
1 μg/ml caspofungin, on which a cover slip had been placed. The fungus adhered to the 
cover slip and after 48h the cover slips were removed and processed. Cover slips were 
incubated with 0.5 mg/L recombinant chitotriosidase (purchased from Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany) or with 0.5 mg/L recombinant AMCase (recAM-
Case; School of Pharmacy, Nottingham, UK), both or with aquadest for 2 hours at 37°C. 
Afterwards, cover slips were fixed in 70% and 100% ethanol. Non-specific binding sites 
were blocked with rabbit or goat serum. Cover slips were further processed identical to 
the lung coupes; however no counter staining was used.
determination of in vitro inhibitory concentrations
Minimal inhibitory concentrations (MICs) were determined for recAMCase, recChito and 
chitinase from T.  viride (see section “Chitinase assay”) according to the microdilution 
methods described by the CLSI (21). Final concentrations of recAMCase were 0.031 – 128 
mg/L. Final concentrations of recChito were 0.031 – 16 mg/L. Final concentrations of 
chitinase from T. viride were 0.031 – 16 mg/L. Minimal effective concentration (MEC) was 
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determined for caspofungin, according to the same guidelines (21). Final concentrations 
of caspofungin were 0.063 – 128 mg/L.
Checkerboard titrations were conducted in triplicate for caspofungin combined with 
recAMCase, recChito and chitinase from T.  viride as a positive control and fractional 
inhibitory concentration indices (FICIs) were calculated as previously published (6). 
MEC was used for caspofungin and MICs were used for chitotriosidase and AMCase. 
Drug interactions were classified as synergistic (FICI ≤ 0.5), indifferent (0.5 < FICI < 4) or 
antagonistic (FICI ≥ 4).
Fungal cell wall assessment by fluorescent microscopy
Aspergillus fumigatus was cultured on a cover slip as described above. Cover slips were 
incubated with either recombinant chitotriosidase alone, recombinant AMCase alone, 
both recombinant chitinases or with aquadest as negative control for 2 hours at 37°C. 
Cover slips were washed in aquadest and incubated with 25 μM Calcofluor White (Mo-
lecular Probes®, Leiden, The Netherlands) for 30 minutes at 37°C in the dark. Afterwards, 
cover slips were washed in aquadest and placed on a microscopic slide and assessed by 
fluorescent microscopy.
statistics
Differences in chitinase activity levels between groups were analysed using the Mann-
Whitney U-test (GraphPad Prism Software, San Diego, USA). A p-value of < 0.05 was 
considered significant.
rEsults
Chitinases in immunocompetent rats inoculated with A. fumigatus
In order to determine if A. fumigatus conidia induce chitinase activity, immunocompe-
tent rats were inoculated intratracheally with A.  fumigatus conidia. After inhalation of 
the inoculum, all rats remained asymptomatic and none of the rats developed invasive 
pulmonary aspergillosis (IPA), their serum galactomannan indices remained <0.2 and no 
hyphae were observed in Grocott-stained lungs on day 1, day 3 and day 6. Compared 
to the situation before inoculation, both chitotriosidase and AMCase activity in the lung 
increased on day 1 after inoculation, from 25 to 119 arbitrary units (a.u.)(chitotriosidase; 
p=0.011) and from 17 to 60 a.u. (AMCase; p=0.006). After the initial increase in chitinase 
activity on day 1, enzyme activity of both chitinases remained elevated on day 3 and 
day 6 but did not increase further when compared to day 1 (p>0.05; data not shown). 
Thus, exposure of the rats to conidia resulted in increased activity of both chitotriosidase 
and AMCase for several days. However, the data obtained with immunohistochemistry 
Chitinases in experimental pulmonary aspergillosis 65
4
suggested that inoculation with conidia did not result in increased presence of chitot-
riosidase and AMCase in the lung.
Chitinases in immunocompromised rats with IPa
To determine if chitinases were also induced during the neutropenic state, we investi-
gated chitinase activity in immunocompromised rats. Neutrophil depletion was induced 
using cyclophosphamide as described in the experimental procedures section and im-
munocompromised rats were inoculated intratracheally with A.  fumigatus conidia. As 
previously described, all rats developed IPA and died within ten days, if left untreated 
(20). Bacterial superinfections were never found. IPA was confirmed by galactomannan 
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Figure 1. Galactomannan (GM) index and chitinase activity in immunocompromised rats inoculated with 
A. fumigatus conidia. Squares: uninfected untreated rats; circles: infected untreated rats; triangles: infected 
rats, treated with caspofungin at 24h post infection. Bars represent medians. For each group n ≥ 4.
A. GM-index, measured by Platelia assay. GM-index of <0,5 is considered negative.
B and C. Chitotriosidase and AMCase activity, expressed in arbitrary units (a.u.). *p<0.05; significant differ-
ence between the indicated groups.
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indices in serum (Figure 1A) and histopathology of the lung (Grocott staining; Figure 
2D), which showed invasive fungal disease.
Chitotriosidase and AMCase activity increased during fungal infection (Figure 1B, C).
Chitotriosidase activity increased from 75 a.u. before inoculation to 105 a.u. on day 
1 (p=0.041), to 281 a.u. on day 3 and to 501 a.u. on day 6 (both p<0.001). AMCase ac-
tivity increased from 41 a.u. before inoculation to 61 a.u. on day 1 (p=0.066), 164 a.u. 
on day 3 and 491 a.u. on day 6 (both p< 0.001; see Figure 1B,C). The initial increase in 
chitinase activity on day 1 was similar to that in immunocompetent rats. However, im-
munocompromised rats developed invasive fungal disease and the chitinase activities 
further increased, indicating that a higher fungal content was related to both a higher 
chitotriosidase and AMCase activity in the lung. Both chitotriosidase and AMCase activ-
ity were host specific, since no activity was found when A. fumigatus culture supernatant 
were measured.
The histology of lungs of immunocompromised rats with IPA showed disturbed lung 
morphology. There was an inflammatory area around fungal foci, where the normal 
structure of alveoli was lost (Figure 2D, E, F). After inoculation, AMCase and chitotrio-
sidase were increasingly expressed around the fungal focus (Figure 2E, F), which was 
consistent with the increased chitinase activity levels as described above. The staining of 
both chitinases was deemed specific for host chitinases, since no staining was observed 
when A. fumigatus was cultured on a slide and stained afterwards (see above).
Chitinase activity in immunocompromised rats with IPa treated with 
caspofungin
In order to determine if chitinase expression and activity differed in rats treated with 
caspofungin, another group of immunocompromised rats was inoculated with A.  fu-
migatus. Treatment with caspofungin was started at 24h post fungal inoculation, repre-
senting early stage IPA. Treatment started at this early time point resulted in survival of 
90% of the rats (20). Chitotriosidase and AMCase activity initially increased after fungal 
inoculation, as described above. In infected caspofungin-treated rats, at day 3 chitotrio-
sidase and AMCase levels were similar to the levels in infected untreated rats (Figure 1B, 
C). On day 6, a trend was observed that chitotriosidase and AMCase levels were lower 
in infected caspofungin-treated rats compared to infected untreated rats (Figure 1B, C), 
however the differences were not statistically significant. The same trend was found for 
fungal load, in terms of GM-index (Figure 1A); GM-index was 5.7 for untreated rats and 
2.8 for treated rats (p=0.053). On day 3, GM-index was lower for untreated rats than for 
caspofungin-treated rats, in contrast to chitinase activity. Apparently, chitinase activity 
is increased before GM-index rises.
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Immunohistochemistry showed a similar pattern of expression of chitotriosidase 
and AMCase in infected caspofungin-treated and infected untreated rats. Expression of 
both chitinases was highest around the fungal focus. In other relatively healthy parts of 
the lung, expression of chitinases was similar to that in uninfected rats. Figure 2 shows 
the fungal focus and the location of the AMCase and chitotriosidase expressing cells. 
AMCase was expressed by several cells throughout the lung, though expression was 
also highest around the fungal focus (Figure 2E). After treatment with caspofungin, 
AMCase was found to bind to the fungal cell wall (Figure 2H), though not all hyphae 
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Figure 2. Grocott staining (A, D, G) and presence of AMCase (B, E, H) and chitotriosidase (C, F, I) in several 
rats. Panels A, B, and C show the lung of an uninfected rat. Panels D, E and F show the fungal focus in an 
infected, untreated rat. Panels G, H and I show the fungal focus in an infected, caspofungin treated rat. 
Original magnification × 400. Scale bar 20 μm. All panels represent lungs on day 6 after inoculation. Slides 
were stained according to the described protocols. In Grocott staining (A, D, G), fungal hyphae are coloured 
black. Chitotriosidase- or AMCase-presenting cells are coloured red (B, C, E, F, H, I).
In uninfected rats, normal morphology can be found in the lungs (A, B, C). In infected rats, normal morphol-
ogy of alveoli is lost (D, E, F). Grocott staining shows many hyphae (D). An inflammatory response is found 
around the fungal focus, where chitotriosidase and AMCase are increasingly present (red zones) compared 
to an uninfected rat (E, F). After treatment with caspofungin, Grocott staining shows fungal material in 
an infected rat (G). AMCase bound fungal hyphae after treatment with caspofungin (H) and thus hyphae 
became visible. After treatment with caspofungin, chitotriosidase seemed to also bind the fungal cell wall 
and locate inside hyphal cells (I).
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were stained. This was not seen in hyphae of untreated animals. In unaffected parts of 
the infected lung, where normal morphology was maintained, AMCase expression was 
comparable with that in uninfected rats (data not shown). Without caspofungin treat-
ment, chitotriosidase was found also mainly around foci of fungal growth. No distinct 
cell type expressing chitotriosidase could be assigned (Figure 2F). After treatment with 
caspofungin, chitotriosidase was found to bind the hyphal cell wall and inside the cell 
(Figure 2I). Expression of both chitinases was highest in close proximity to the fungal 
focus, regardless of treatment. Apparently, treatment with caspofungin caused such an 
alteration in the fungal cell wall that AMCase was able to bind the fungal hyphae and 
chitotriosidase was taken up by the fungus.
In order to investigate late stage IPA, we also determined chitinase activity levels in a 
group of rats that received caspofungin treatment starting at 72h post fungal inoculation 
(late stage IPA). GM-index and immunohistochemistry revealed increased fungal load 
compared to rats that were treated with caspofungin starting at 24h post inoculation 
(early stage IPA). For chitinase activity, we observed levels that were not significantly 
different between the two groups (data not shown).
in vitro binding of recombinant chitinase to hyphae of A. fumigatus
As described above, we observed binding of AMCase and hyphal uptake of chitotrio-
sidase in the lung after treatment with caspofungin. We hypothesized that treatment 
with caspofungin was required for binding of both chitinases, since caspofungin causes 
increased chitin contents in the fungal cell wall (6) and thus increases the substrate 
for chitinases. In order to confirm our hypothesis, we investigated in vitro binding of 
recombinant AMCase and recombinant chitotriosidase to A. fumigatus hyphae on slides. 
A. fumigatus was cultured on cover slips in presence or absence of caspofungin, which 
was followed by exposure to recombinant AMCase or recombinant chitotriosidase or 
both for two hours. Binding of the enzyme was detected in the same way as expression 
was detected in the lungs taken from rats with IPA. Additionally, we tested antifungal 
activity of recombinant AMCase or recombinant chitotriosidase alone and combined 
with caspofungin in a checkerboard titration according to the CLSI criteria.
Recombinant AMCase did bind similarly to fungal hyphae both in unexposed and in 
caspofungin-exposed fungal cells (Figure 3C, F) showing that caspofungin exposure 
was not needed for binding of AMCase. Susceptibility testing showed a median minimal 
inhibitory concentration (MIC) of recombinant AMCase of >16 mg/L. Combination of 
recombinant AMCase with caspofungin in a checkerboard titration showed no synergy 
(median fractional inhibitory concentration index (2) 2.0). Thus exposure to caspofungin 
and recombinant AMCase was not sufficient for antifungal activity in vitro.
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Recombinant chitotriosidase was not taken up by A.  fumigatus hyphae during 
incubation with this enzyme regardless of caspofungin exposure (Figure 3A, D), in 
contrast to what was seen in infected lungs. Susceptibility testing showed an MIC of 
recombinant chitotriosidase of >16 mg/L. Combination of recombinant chitotriosidase 
with caspofungin in the checkerboard titration showed again no synergy (median FICI 
2.0). Thus exposure to caspofungin and recombinant chitotriosidase alone was also not 
sufficient for antifungal activity in vitro. Strikingly the binding pattern of recombinant 
chitotriosidase in the infected lungs was different to the pattern found in vitro. In vivo, 
both chitinases were present, though only one chitinase was stained at a time. Hence 
we additionally investigated the binding of recombinant chitotriosidase to the fungus 
in presence of both recombinant enzymes in vitro. When hyphae were not exposed to 
caspofungin, chitotriosidase seemed to locate inside the hyphae and was also bound to 
the conidial heads (Figure 3B). When hyphae were exposed to caspofungin and to both 
recombinant chitinases, chitotriosidase also located inside the cell wall and strikingly, 
the cell wall seemed to dissolve (Figure 3E). From these experiments, we observed that 
recombinant chitotriosidase could only be taken up by hyphae, provided recombinant 
AMCase was present. Furthermore we observed that caspofungin modifies the fungal 
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Figure 3. In vitro binding of recombinant chitinases to A. fumigatus hyphae. Binding of recombinant chitot-
riosidase (A, D). Binding of recombinant chitotriosidase when incubated in combination with recombinant 
AMCase (B, E) and binding of recombinant AMCase (C, F). Panels A, B and C show unexposed hyphae. Panels 
D, E and F show caspofungin-exposed hyphae. A, D Original magnification ×100, scale bar 25 μm. B, C, E, 
F Original magnification ×400, scale bar 20 μm. Slides were stained according to the described protocols. 
Binding of either recombinant enzyme is characterized by a red colour. A, D Recombinant chitotriosidase 
did not bind to unexposed hyphae (A) or to caspofungin-exposed hyphae (D). B, E When incubated with 
a combination of recombinant chitotriosidase and recombinant AMCase, recombinant chitotriosidase did 
bind to unexposed hyphae (arrow) and to conidial heads (C) and seemed to be taken up by the fungal 
cells after caspofungin exposure (E). Also the cell wall seemed to be lysed at several locations (arrows). C,F 
Recombinant AMCase did bind to unexposed (C) and to caspofungin-exposed hyphae (F).
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cell wall in such a way, that a combination of recombinant AMCase and recombinant chi-
totriosidase can lyse the fungal cell wall. The uptake of chitotriosidase and morphologic 
disruptions suggest chitinolytic results and thus clinical significance in the clearance of 
fungal material.
We aimed to confirm this important finding in an alternative experiment. It was not 
possible to conduct a checkerboard titration with caspofungin and both recombinant 
chitinases, due to limited availability of recombinant enzymes. Other types of viabil-
ity assays were unfortunately also not successful. Instead of a viability assay, we then 
stained the fungal cell wall with Calcofluor White after exposure to caspofungin and both 
recombinant chitinases. Figure 4A shows unexposed fungal cells and Figure 4B shows 
caspofungin-exposed cells, both after incubation with a combination of recombinant 
chitotriosidase and recombinant AMCase. These panels are representative for the com-
plete culture. In other words, most fungal hyphae that were exposed to both chitinases 
and caspofungin were disrupted. The cells unexposed to caspofungin look very regular 
with a normal cell wall, with Calcofluor staining mainly seen in regularly spaced septa, 
whereas the caspofungin-exposed cells show an irregular cell wall with a fragmented 
aspect. When fungal cells were incubated with a single recombinant chitinase, the cell 
Figure 4. Calcofluor White staining of in vitro cultured A. fumigatus hyphae after incubation with recombi-
nant chitotriosidase and recombinant AMCase. Magnification ×400, scale bar 25 μm. When hyphae were 
cultured on Sabauroud’s agar (A), the cell wall remained regular and intact after incubation with the two 
recombinant chitinases. When hyphae were cultured on Sabauroud’s agar with 1 mg/L caspofungin (B), the 
cell wall was irregular and disrupted after incubation with the two recombinant chitinases.
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wall remained regular. When fungal cells were exposed to caspofungin only, the cell wall 
looked very regular and similar to that in Figure 4A. Thus, in this assay, we confirmed the 
earlier observations of disruption of the fungal cell wall after exposure to caspofungin 
and both chitinases. The observed damage to the fungal cell wall makes it very unlikely 
that the fungal cells remain viable.
dIsCussIoN
The role of mammalian chitinases in the response of invasive fungal infections is a 
relatively unexplored area of research. In the past it has been shown that chitinase 
activity was increased in guinea pigs upon A. fumigatus systemic infection, but it was 
not known which chitinase was involved (18, 19). In the present study we confirmed 
that chitinases in the lung of immunocompetent rats and of immunocompromised 
rats were increased after exposure to A. fumigatus conidia. We demonstrated that both 
chitotriosidase and AMCase play a role. We showed that in immunocompetent rats with 
an appropriate immune system, transient exposure to a high load of conidia without 
subsequent lung infection resulted in only a moderate increase in the production and 
activity of chitinases in the lung. Based on our findings, we expect that in certain groups 
of immunocompetent A. fumigatus-colonized patients (such as cystic fibrosis patients), 
chitinase activity levels would be slightly increased on a permanent basis. We studied 
chitinase activity in rats with IPA, though extrapolation to the human situation should 
be done with care.
In all immunocompromised rats developing IPA after inhalation of conidia, chitinases 
were produced, even though the rats were in neutropenic state. Since A. fumigatus itself 
also produces chitinases, we had to determine if the chitinases measured with our assays 
were of host origin. We therefore included in vitro controls for both the enzyme-assays 
and immunohistochemistry experiments. These controls were prepared by growing 
A.  fumigatus in vitro, without animal cells. No enzyme-activity was observed with the 
substrates used and no binding of the AMCase and chitotriosidase was observed. Since 
in vitro simulations are not completely representative for the in vivo situation, it is not 
easy to rule out that the fungal chitinases, which might be induced in vivo only, were 
not cross-reacting in our assays. The assays used in our study were similar to the assays 
used by Overdijk et al (18, 19). He demonstrated with a Bio-Gel P-100 gel filtration assay 
that the chitinase activity in the lung consisted of two peaks, one of 35 kDa and one of 
15 kDa, which both appeared to be true chitinases (19). To rule out a fungal origin of the 
chitinase activity measured in the lungs of A. fumigatus infected guinea pigs, Overdijk et 
al demonstrated that the A. fumigatus chitinases eluted much earlier from the column 
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than the mammalian chitinases (19). Furthermore, allosamidin reduced the chitinase 
activity in infected and in uninfected guinea pigs by 94% (18). His final proof was that 
the activity ratio with the substrates 4-methylumbelliferyl-N-acetylglucosamine and 
4-methylumbelliferyl-N-acetylgalactosamine differed significantly between A.  fumiga-
tus chitinases and chitinases present in guinea pig serum (18).
It is known that chitotriosidase and AMCase are produced by several cells, such as al-
veolar macrophages, epithelial cells and neutrophils (11, 22, 23). Our observations show 
that chitinase activity was increased significantly during A. fumigatus infection, even in 
rats with decreased numbers of neutrophils and macrophages. During progression to 
IPA, both the amount of fungal material and the chitinase activity increased in the lung 
over time.
Treatment with antifungal agents reduces the fungal mass present in the lung. There-
fore it was not surprising that Overdijk et al found that treatment of systemic aspergil-
losis with itraconazole or amphotericin B limited the increase in chitinase activity in 
guinea pigs (18). Caspofungin belongs to another class of antifungal agents. It restricts 
the growth of A.  fumigatus in the lung and it alters the cell wall composition by de-
creasing the amount of β-glucan and increasing the amount of chitin in the fungal cell 
wall (6). Since caspofungin both reduces the fungal mass in the lung but also increases 
the relative chitin concentration within this mass, resulting in more substrate for the 
chitinases, the chitinase activity could either be decreased or increased upon treatment. 
In our study we found a trend towards a blunting of the chitinase response following 
treatment with caspofungin, suggesting that the total amount of fungal cells seems to 
be more important than the composition of the cell wall in the induction of chitinase ex-
pression. The total chitinase activity was lower in lungs of caspofungin treated rats than 
in untreated rats. In contrast, expression of both chitinases seemed to be higher around 
the fungal focus in caspofungin treated rats. This could be explained by the methods 
used. Chitinase activity was measured in homogenate of a complete lung, whereas the 
immunohistochemistry shown displays only the fungal focus. Thus the images shown 
are not representative for the complete lung, since the fungal focus is located in only a 
limited segment of the lung. Furthermore it became clear again that caspofungin does 
not have fungicidal or fungistatic activity. This was supported by the high GM-index of 
infected, caspofungin-treated rats (Figure 1A). The high GM-index on day 3 could be ex-
plained by the detachment of the galactomannan chain from the β-glucan polymeres, 
caused by caspofungin treatment. Caspofungin is currently in use as salvage therapy for 
fungal infections. Future studies will be performed to determine if the chitinases also 
work synergistic with other antifungal agents such as the azoles and polyenes.
Although total chitinase activity in infected rats was not influenced by treatment with 
caspofungin, the location of the individual chitinases was substantially changed. Upon 
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caspofungin treatment, both AMCase and chitotriosidase seemed to bind to the fungal 
hyphae, which was not found in untreated infected rats. Furthermore, galactomannan 
is released from the cell wall resulting in the unmasking of β-glucan and chitin on the 
A. fumigatus cell wall. Unmasking β-glucan has been shown to result in an increased in-
flammatory response compared to untreated hyphae (24). The unmasking of the chitin 
polymers, the target of the chitinases, seems to cause enhanced binding of chitinases 
to chitin. Possibly, treatment with caspofungin increased the available mammalian chi-
tinase binding domains in the fungus, which might be responsible for the good clinical 
outcome of treatment with this agent.
It appeared that AMCase was located on the fungal cell wall, while chitotriosidase was 
located inside the fungal cells. The observed expression patterns suggest that AMCase 
and chitotriosidase each have a distinct target location and bind to different parts of the 
fungal cell. It was shown that recombinant AMCase in vitro indeed bound the hyphae 
but that recombinant chitotriosidase was taken up by hyphae only after exposure to 
both chitinases, thus mimicking the in vivo situation where also both chitinases are 
present. It seemed that recombinant chitotriosidase needed the exochitinase activity of 
recombinant AMCase in order to be taken up by the fungus. This suggests a synergy be-
tween endochitinases and exochitinases. Bolar et al also suggested that endochitinases 
and exochitinases act synergistically in plants (25). They showed that plants expressing 
both types of chitinases were less susceptible to Venturia inaequalis, the fungal causal 
agent of apple scab, than plants expressing one of the chitinases (25). Our observations 
suggest that such a type of synergy may also be present in mammals.
The synergy between chitotriosidase and AMCase seemed most important when 
A. fumigatus was exposed to caspofungin in vitro. When A. fumigatus was incubated with 
caspofungin and both chitotriosidase and AMCase, a direct cell wall degrading effect 
was noted. No degradation was found when only one of the chitinases was used or 
when the fungus was not exposed to caspofungin. Also, when the in vitro susceptibility 
assays were performed with each chitinase alone, or when combined with caspofungin, 
no direct fungicidal effect was observed. Several other authors also investigated activity 
of chitotriosidase and AMCase, with varying results (11, 26). Differences in experimental 
setup could explain the differences found in antifungal activity.
The cell wall degrading properties of both chitinases in combination with exposure to 
caspofungin could explain why treatment with caspofungin results in decreased mortal-
ity in IPA, in spite of the limited fungicidal properties in vitro. However, chitotriosidase 
and AMCase are not expected to be the only type of host response that will be changed 
upon caspofungin treatment. Since caspofungin alters the composition of the fungal 
cell wall, it will also alter the pathogen associated molecular patterns (PAMPs) exposed 
on fungal cells. This alteration in PAMPs could result in a changed production and 
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expression of other signalling molecules, e.g. cytokines and chemokines, contributing 
to the process of fungal killing. It is expected that killing of fungal cells is achieved by 
caspofungin treatment in combination with the immune system by using direct and 
indirect signalling molecules including chitinases. However, the combined action of 
signalling molecules and mediators with chitinases needs to be elucidated in the future.
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aBstraCt
Chitin is a major fungal cell wall component and the human host produces chitin-
ases chitotriosidase and AMCase upon fungal exposure in order to clear the fungus. 
Previously, many polymorphisms were described that influence the activity of these 
chitinases. We investigated the association between 4 of these polymorphisms in the 
genes encoding for chitotriosidase and AMCase and the incidence of IPA in an immuno-
compromised population. Four polymorphisms involved in the chitinase activity were 
studied in 89 subjects at risk for the development of IPA. These included a 24-bp inser-
tion in the chitotriosidase gene (rs3831317), resulting in impaired chitinase activity and 
single nucleotide polymorphism (SNP) in the AMCase gene (rs61756687), resulting in 
decreased AMCase activity. Also, a SNP (rs41282492) and a 10-bp insertion in the 5’UTR 
region of the AMCase gene (rs143789088) were studied, both resulting in increased 
AMCase activity. DNA was isolated from blood and genotypes were determined using 
PCR-RFLP. According to clinical, radiological and mycological criteria, 18 patients devel-
oped proven or probable IPA and 71 subjects were controls.
No association with increased or decreased rate of aspergillosis was found with any of 
the polymorphisms (p>0.05). Also, classification of patients and controls based on theo-
retical chitinase activity could not prove an association between decreased chitinase 
activity and an increased risk for developing IPA. In conclusion, the four polymorphisms 
investigated here were not associated with increased or decreased risk for IPA.
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INtroduCtIoN
Invasive Pulmonary Aspergillosis (IPA) is a life-threatening infection caused mainly by the 
opportunistic fungal pathogen Aspergillus fumigatus. The incidence of IPA infection has 
increased over the last decades due to a rise in the use of immunosuppressive and im-
mune modulatory drugs (1). Although almost all IPA patients are immunocompromised, 
only a small minority of immune compromised patients develops an invasive fungal 
infection. The question arises which underlying factors are involved in the development 
of IPA in these immunosuppressed patients.
One hypothesis is that the genetic make-up of the patient’s immune system plays 
a role. The innate immune system is involved in the recognition of pathogens. Mam-
malian cells express several pattern recognition receptors (PRRs) to sense pathogens. 
PRRs involved in fungal sensing include toll-like receptor (TLR)-2, TLR-3, TLR-4, TLR-6 and 
TLR-9 and C-type lectin receptors dendritic cell-specific intercellular adhesion molecule-
3-grabbing non-integrin (DC-SIGN), dectin-1 and dectin-2 (2-4). These PRRs sense fungal 
cell wall structures and pathogen-associated molecular patterns (PAMPs) expressed on 
the fungal cell wall, including mannan, β-glucan and nucleic acids (2, 4). Recognition of 
PAMPs results in activation of a signaling pathway and in the release of pro-inflammatory 
cytokines such as TNF-α and INF-γ, and of anti-inflammatory cytokines such as IL-4 and 
IL-10 (2). In previous reports, it was shown that polymorphisms in the genes for dectin-1, 
DC-SIGN (3), TNF receptor 1 (5) and in the IL-10 promoter gene (6) can lead to increased 
susceptibility to aspergilli in immune compromised patients.
Whether chitin is recognized as a PAMP is not known yet, however it is considered 
a possibility (2, 7). Chitin is an abundant polysaccharide that is found in fungi, insects 
and in nematodes and it is cleaved by chitinases. Chitin is the main cell wall component 
of the fungal cell wall. Although mammals do not produce chitin, they are capable of 
producing chitinases (8), in general in reaction to exposure to chitin. Two mammalian 
chitinases have been described: acidic mammalian chitinase (AMCase) and chitotriosi-
dase.
In previous work, we described that both chitinases were increased in rats with inva-
sive pulmonary aspergillosis (IPA)(9). We also described that both AMCase and chitot-
riosidase were necessary to degrade chitin after treatment with caspofungin (9). Hence 
we hypothesized that malfunction of the chitinases will impair the clearance of fungal 
material from the lungs and patients thus would be more prone to fungal infections.
Several genetic polymorphisms that influence chitinase activity in the human host 
were described. The most commonly described is a 24-bp insertion in the chitotriosidase 
gene (10-12), resulting in enzymatic inactivity in case of homozygosity. It is found in 
circa 6% of the Caucasian population (11). For the AMCase gene, several polymorphisms 
were described with an effect on the enzyme activity (13, 14). We hypothesized that 
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polymorphisms in the genes for chitinases, related to a reduced chitinase activity, were 
associated with a higher risk for the development of IPA. To test this hypothesis, four 
polymorphisms in either AMCase or chitotriosidase were determined in 86 patients with 
hematologic diseases, at risk for the development of IPA. The allele frequencies of these 
SNPs were compared between the patients who did develop IPA and those who did not.
matErIals & mEthods
study population
Patients were included between November 2002 and April 2006 at Erasmus University 
Medical Center (Rotterdam, The Netherlands). Hospitalized adult patients with hemato-
logic disease were eligible to participate in this study. Inclusion criteria were individuals 
who were at risk for prolonged neutropenia (neutrophil count < 500 cells/mm³ for at 
least10 days), based on stem cell transplantation or chemotherapy. Exclusion criteria 
were evidence of fungal infection in lungs or sinuses, diagnosis of pneumonia at the 
time of study inclusion or a life expectancy of less than three months. Further details 
were described elsewhere (15). Patients who received prophylaxis with amphotericin B 
were excluded from the study. From all included subjects, blood samples were drawn 
routinely. Whole blood was stored at −80°C until processing. DNA was isolated from 
whole blood of these subjects using the MagNA Pure LC DNA Isolation kit - Large 
Volume (Roche Diagnostics Nederland BV, Almere, the Netherlands) according to the 
manufacturer’s instructions. DNA was stored at −20°C until processing.
The study was approved by the medical ethical committee at Erasmus MC. Written 
informed consent was obtained according to guidelines from medical ethical commit-
tee at Erasmus MC.
Patients were assessed for fungal infection, according to international guidelines (16). 
When a fungal infection was suspected, patient material such as sputum, blood or 
broncho-alveolar lavage (BAL) fluid was cultured on Sabouraud’s agar at 37°C for 96 
hours, according to routine procedures (17). “Proven” or “probable” aspergillosis was 
defined according to the definition by the European Organization for Research and 
the Treatment of Cancer-Mycoses Study Group (EORTC-MSG)(18). In short, subjects 
were diagnosed with IPA when there was a host factor (e.g. prolonged neutropenia), 
a radiological sign of fungal disease (e.g halo sign, air-crescent sign) and a mycological 
factor (e.g. positive galactomannan index, positive culture). Patients lacking a mycologi-
cal factor were classified as “possible” aspergillosis, according to the definitions. These 
patients were excluded from the analysis.
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genotyping
We searched PubMed Library for publications describing polymorphisms in the chito-
triosidase gene and in the AMCase gene. Only polymorphisms causing an alteration 
(either increase or decrease) of the chitinase enzymatic activity were included. All PCR 
primers and amplification conditions are shown in Table 1. Restriction enzymes are also 
shown in Table 1. All enzymes were purchased at Fermentas and were used according to 
manufacturer’s guidelines. Genotypes were determined by polymerase chain reaction 
restricted fragment length polymorphism (PCR-RFLP). PCR products were run at a 2.5% 
metaphor gel in 90 minutes. Two different persons assessed genotypes separately.
statistical analysis
We used Pearson’s χ² test to verify the Hardy-Weinberg equilibrium. Differences in allele 
frequencies were evaluated using Fisher’s exact test (GraphPad Prism Software, San 
Diego, USA). A p-value of p < 0.05 was considered significant.
rEsults
Blood samples were taken from 173 subjects in total. 84 subjects received Ambisome 
prophylaxis and were thus excluded from our study. The remaining 89 subjects were 
included and were genotyped. Of these 89 subjects, 15 subjects met the criteria for 
“proven” or “probable” aspergillosis and were classified as “patients”. 3 subjects had “pos-
sible” aspergillosis and were excluded from the analysis. The remaining 71 subjects were 
classified as “controls”.
table 1. PCR conditions for the different polymorphisms
Polymorphism Primer sequence (5’ → 3’) PCR program Restriction 
endonuclease
Activity Length 
(bp)
Ref
Chitotriosidase
24 bp insertion
rs 3831317
F: agctatctgaagcagaag
R: ggagaagccggcaaagtc
4’ 94°C + 40× (30” 
94°C + 30” 55°C + 
30” 72°C) + 7’ 72°C
None Normal
Decreased
124 bp
148 bp
(11, 19, 
20)
AMCase
A50G
rs 61756687
F: gtctcaccctgccttctttg
R: acccaattctcctcggaaag
4’ 94°C + 40× (30” 
94°C + 30” 58°C + 
30” 72°C) + 7’ 72°C
ApoI (XapI) Normal
Decreased
175 + 91
266
(21)
AMCase
A290G
rs 41282492
F: ctctgcctaccagctgacat
R: gccattccgcaccgtataca
4’ 94°C + 40× (30” 
94°C + 30” 58°C + 
30” 72°C) + 7’ 72°C
TaqI Normal
Increased
256 + 81 
+ 69
256 + 150
(14)
AMCase
10-bp insertion 
5’UTR
rs 143789088
F: ctgaccacagtatctaaacag
R: ctgaccacagtatctaaacag
4’ 94°C + 40× (30” 
94°C + 30” 58°C + 
30” 72°C) + 7’ 72°C
BfaI Normal
Increased
392 + 59
308 + 94 
+ 59
(13)
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Genotypes frequencies can be found in Table 2. The genotype distributions for all SNPs 
were consistent with the Hardy Weinberg equilibrium for both controls and patients.
the 24-bp insertion in the chitotriosidase gene is not associated with the 
development IPa
In the gene encoding for chitotriosidase, a 24-bp insertion was described previously (10, 
11, 19, 20). The activity of chitotriosidase is reduced when a patient is found homozygous 
for this insertion (10, 22). Among the patients, 0/15 (0%) were homozygous for the 24-bp 
insertion and 7/15 (46.7%) were heterozygous. Among the controls, 2/71 (2.8%) were 
homozygous and 30/71 (42.3%) were heterozygous. The difference in allele frequency 
was not statistically significant (p = 1.00). Based on these data, being homozygous for 
the 24-bp insertion on the chitotriosidase gene was not associated with an increased 
risk for IPA.
table 2. Distribution of insertion and SNPs in the genes for chitotriosidase and for AMCase.
Gene and genotype Enzyme activity* Patients (%)
N=15
Controls (%)
N=71
HWI**
p-value
p-value
Chitotriosidase 0.177 1.000
Wildtype Normal 8 (53.3%) 39 (54.9%)
Heterozygous 24-bp insertion Normal 7 (46.7%) 30 (42.3%)
Homozygous 24-bp insertion Impaired 0 (0%) 2 (2.8%)
AMCase A50G 0.320 0.576
AA Normal 12 (80.0%) 51 (71.8%)
AG Normal 3 (20.0%) 17 (23.9%)
GG Decreased 0 (0%) 3 (4.2%)
AMCase A290G 0.326 0.419
AA Normal 12 (80.0%) 47 (66.2%)
AG Normal 3 (20.0%) 23 (32.4%)
GG Increased 0 (0%) 1 (1.4%)
AMCase 10-bp insertion 5’UTR 0.320 0.740
Wildtype Normal 13 (86.7%) 56 (78.9%)
Heterozygous 10-bp insertion Normal 2 (13.3%) 15 (21.1%)
Homozygous 10-bp insertion Increased 0 (0%) 0 (0%)
*Genotype associated with an impaired, normal or decreased enzyme activity according to previous pub-
lications (11, 13, 14, 19-21).
**Hardy Weinberg Equilibrium (HWE) as assessed by Pearson’s χ² test. A p-value of >0.05 was associated 
with equilibrium.
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Neither the a50g and a290g sNP, nor the 10-bp insertion in the 5’utr region 
of amCase is associated with IPa development
Previously, several SNPs in the AMCase gene were described, resulting in either increased 
or decreased AMCase activity (13, 14, 21). As shown in Tables 2, we studied two SNPs 
(A50G and A290G) and one 10-bp insertion in the 5’UTR region of the AMCase gene.
Allele frequencies of A50G and A290G in the patients were statistically similar to those 
in the controls (p = 0.42 and p = 0.58, respectively). Furthermore no difference was found 
in the presence of the 10-bp insertion between patients and controls (p = 0.74).
Prevalence of genotypes for increased or decreased chitinase is similar in 
patients and controls
From above results we could conclude that in this cohort of patients, a single poly-
morphism resulting in inactivity of a single chitinase, did not result in an increased 
prevalence of IPA. In previous work, we described that a combination of AMCase and 
chitotriosidase was necessary to degrade the fungal cell wall in vitro (9). We therefore 
also investigated whether a combination of polymorphisms, resulting in impaired 
Figure 1. Flowchart in order to classify subjects as normal, increased or decreased chitinase activity, based 
on genotype of the 24-bp insertion for chitotriosidase and the polymorphisms and insertions for AMCase.
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activity of either chitotriosidase or AMCase, was more prevalent in IPA patients than 
in the controls. We made the following assumptions: a subject who had hypothetically 
decreased activity of either chitotriosidase, AMCase or both had an elevated risk for 
developing IPA. A subject who had hypothetically normal chitotriosidase activity and 
increased AMCase activity had a decreased risk for developing IPA. We thus divided the 
patients and the controls each into three groups (see also Figure 1). The subjects in the 
first group with a hypothetically decreased chitinase activity had either a homozygous 
24-bp insertion or a homozygous G-allele in the A50G SNP. The subjects in the second 
group with a hypothetically increased chitinase activity had no homozygous 24-bp 
insertion, no homozygous G-allele in the A50G SNP, and either a homozygous G-allele 
in the A290G SNP or a homozygous 10-bp insertion in the 5’UTR region. The third group 
with a hypothetically normal chitinase activity had no homozygous 24-bp insertion, 
no homozygous G-allele in the A50G SNP, no homozygous G-allele in the A290G SNP 
and no homozygous 10-bp insertion in the 5’UTR region. Based on this classification, all 
patients had the genotype for normal chitinase activity. No patient had the genotype 
for increased or decreased chitinase activity. 4/71 controls (5.6%) had the genotype for 
decreased chitinase activity, 66/71 (93.0%) had the genotype for normal chitinase activ-
ity and 1/71 (1.4%) had the genotype for increased chitinase activity. The prevalence of 
genotypes for decreased chitinase activity was similar between controls and patients 
(p = 1.00), as was the prevalence of genotypes for increased chitinase activity (p=1.00). 
Therefore, a genotype for decreased chitinase activity was not significantly correlated 
with an increased or decreased risk for IPA in this cohort of patients. Also, a genotype for 
increased chitinase activity was not proven to be protective for IPA.
dIsCussIoN
In our previous study we showed that the immunocompromised host still produces chi-
tinases in reaction to fungal exposure (9). Invasive pulmonary infection with Aspergillus 
fumigatus upregulated the production of chitotriosidase and AMCase in the lung. We 
showed that a combination of two chitinases and caspofungin could lyse the fungal cell 
wall. We hypothesized that chitinases are needed in the clearance of fungal material and 
that impaired chitinase activity or production is a risk factor for IPA in immunocompro-
mised patients.
This impaired chitinase activity could be caused by the genetic make-up of the 
individual. In humans, we already know that SNPs in genes encoding for several PRRs 
such as TLR-2, TLR-3, TLR-4, TLR-6, TLR-9, DC-SIGN, dectin-1 and dectin-2 are associated 
with an increased risk for developing IPA. For both chitotriosidase and AMCase, inser-
tions and SNPs were described which altered the enzyme activity. For chitotriosidase, 
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it was described that the carriers of the 24-bp insertion had a broad range of reduced 
activity (11, 19, 20). We thus considered heterozygotes of the 24-bp insertion as having 
normal chitotriosidase activity. We hypothesized that SNPs in the genes encoding for 
chitotriosidase and AMCase, resulting in an altered enzyme activity (13, 14, 21), were 
associated with the risk for developing IPA. In our study, we could not demonstrate an 
association between individual polymorphisms in the genes resulting in decreased chi-
tinase activity and the incidence of IPA. Also the polymorphisms resulting in increased 
chitinase activity were not found to be associated with a decreased risk for developing 
IPA. This was unexpected, but since our cohort of patients is of limited size, the lack of 
association could be caused by a lack of statistical power. It is very difficult to obtain a 
large enough study population of IPA patients due to the limited availability of patients 
with IPA and the heterogeneity of the study population. Furthermore, patients with IPA 
are missed since the diagnosis of IPA is often difficult or empirical therapy is given before 
the diagnosis is established with certainty. Therefore it is not surprising that only few co-
horts of patients with invasive pulmonary fungal have been described that investigated 
genetic polymorphisms as risk factor for IPA (3, 23-31). Enlarging the cohort by including 
patients from other geographical areas is prone to bias, since from other studies it was 
already demonstrated that the allele frequency differs in different geographical areas 
(10, 22, 32). In our population, homozygosity for the insertion was found in 2.8% of 
the mainly European Caucasian controls, which is lower than the 6% that was reported 
previously in European Caucasians (11). Allele frequencies could be different in certain 
populations or patient groups. Our population was at risk for prolonged neutropenia 
and the prevalence of the insertion might be different in this particular population.
Finally, even though we could not prove that the described polymorphisms were asso-
ciated with increased incidence of IPA, there might be an association with a more severe 
clinical course or a worse outcome of the infection. However this was not investigated 
in our study.
Summarizing, the SNPs and insertions in the genes for chitotriosidase and AMCase that 
were investigated here, did not show a significant association with the development 
of IPA. Clearly IPA may develop in individuals with genotypes associated with normal 
chitinase activity. Apparently, these genotypes by themselves do not determine the 
susceptibility of patients for IPA, although they may, in a much larger study, still be 
found to contribute to the risk. Other factors of the human immune system may play 
a role as well, such as different polymorphisms in other genes involved in the recogni-
tion of PAMPs. More studies could increase the insight in the genetic risk factors for the 
development of IPA.
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aBstraCt
Madurella mycetomatis is the most prevalent causative agent of eumycetoma in Sudan, 
an infection characterized by the formation of grains. Many patients are exposed to the 
causative agent, however only a small number develop infection. M. mycetomatis con-
tains chitin in its cell wall, which can trigger the human immune system. Polymorphisms 
in the genes encoding for the chitin-degrading enzymes chitotriosidase and AMCase 
were described, resulting in altered chitinase activity. We investigated the association 
between 4 of these polymorphisms and the incidence of M. mycetomatis mycetoma in a 
Sudanese population.
Polymorphisms studied in 112 eumycetoma patients and 103 matched controls in-
cluded a 24-bp insertion in the chitotriosidase gene (rs3831317), resulting in impaired 
chitinase activity and single nucleotide polymorphism (SNP) in the AMCase gene 
(rs61756687), resulting in decreased AMCase activity. Also, a SNP (rs41282492) and a 10-
bp insertion in the 5’UTR region of the AMCase gene (rs143789088) were studied, both 
resulting in increased AMCase activity. DNA was isolated from blood and genotypes 
were determined using PCR-RFLP.
Histological staining proved the presence of chitin in the fungal grain. The polymor-
phism resulting in decreased chitotriosidase activity was associated with increased odds 
of eumycetoma (odds ratio 2.9; p=0.004). No association was found for the polymor-
phisms in the genes for AMCase (all p>0.05). In conclusion, decreased chitotriosidase 
activity was associated with increased risk of M. mycetomatis mycetoma.
91
6
Chitinases in Madurella mycetomatis mycetoma
INtroduCtIoN
Mycetoma is a chronic infectious granulomatous disease that is frequently reported in 
tropical and subtropical climates between 30°N and 15°S of the equator. Mycetoma can 
be caused by bacteria (actinomycetoma) and fungi (eumycetoma), though the fungus 
Madurella mycetomatis is the most common causative agent in the world (1). In Sudan 
it accounts for over 70% of all mycetoma cases (1). The lower extremities are affected 
most, though other sites of the body can be affected as well (1). After traumatic inocula-
tion of the causative agent into the subcutaneous tissue, usually in the sole of the foot, 
the disease progresses and invades the deep structures and the skin. Multiple nodules 
and sinuses discharging pus are formed and grains develop. In the grains, the fungal 
mycelium is embedded in hard brown matrix containing melanin. This grain is thought 
to protect the fungus from the host immune system.
In endemic areas in Sudan, M. mycetomatis DNA was found in the soil (2) and antibodies 
against mycetoma causative agents have been detected in the majority of the inhab-
itants in these areas (3). However, it is not clear why only a minority of the exposed 
humans develop overt clinical infection. Several environmental and patient-related 
factors have been described to influence the risk for the development of mycetoma, 
including concurrent schistosomiasis (4). Furthermore, several associations with genetic 
polymorphisms in genes involved in hormone synthesis (5) and parts of the immune 
system, including collagenases and gelatinases were reported (3, 6, 7). However, the role 
of chitinases in eumycetoma caused by M. mycetomatis was not investigated previously.
Infection with M. mycetomatis often results in fungal grain development in the tis-
sue. The exact composition of the grain is not known. Ibrahim et al reported that the 
grains contain melanin, heavy metals, proteins and lipids, resulting in a cement matrix 
in which the mycelium is embedded (8). Probably, the grain also contains chitin, since 
chitin is one of the cell wall components of many fungi. Around the fungal grain, the 
host’s innate immune system mounts an inflammatory response, resulting in a reactive 
granuloma laden with neutrophils, macrophages and other inflammatory cells (9). 
Chitinases are part of the innate immune system and, in general, their production by 
macrophages and other cells is upregulated by the host’s tissue exposure to chitin. Chi-
tinases seem to play a role in allergic and infectious diseases caused by chitin-bearing 
organisms (10-12), however the exact role of these enzymes in pathogenesis is yet to be 
elucidated. Chitinases hydrolyze chitin, which is the main component of the fungal cell 
wall. Decreased chitinase activity could, therefore, result in an enhanced susceptibility 
towards infections by chitin bearing fungi. Currently, two true chitinases are known in 
humans: chitotriosidase and acidic mammalian chitinase (AMCase)(13). Polymorphisms 
in the genes for these chitinases have been described that are associated with either 
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increased or decreased enzyme activity (12, 14-17). Impaired or decreased activity of 
either one or both of these chitinases could result in increased susceptibility towards 
fungal infections including eumycetoma. The aim of this study is to investigate the role 
of chitinase activity in the development of mycetoma caused by M. mycetomatis. We 
hypothesized that chitotriosidase and AMCase polymorphisms, resulting in decreased 
chitinase activity, would be found more frequently in mycetoma patients than in con-
trols.
matErIals & mEthods
study population
Individuals presenting at Mycetoma Research Center, Khartoum between 2001 and 2008, 
were eligible for inclusion, when the diagnosis of Madurella mycetomatis mycetoma was 
confirmed. People living in the same endemic regions were included as controls. The 
demographic features are given in Table 1. Retrospectively, genotypes were determined 
of 112 Madurella mycetomatis infected patients and 103 healthy endemic controls, 
matched for sex and age. Whole blood was stored at −80°C until processing. DNA was 
isolated from whole blood of these subjects using the MagNA Pure LC DNA Isolation kit 
- Large Volume (Roche Diagnostics Nederland BV, Almere, the Netherlands) according 
to the manufacturer’s instructions. DNA was stored at −20°C until processing. Tissue of 
the foot and of the grain was obtained in 1998 from Sudanese subjects, infected with 
M. mycetomatis.
table 1. Study population demographic features.
Characteristic Mycetoma patients 
(n=112)
Endemic controls 
(n=103)
Gender (male/female) 79/33 77/26
Mean duration in years (range) 6.9
(1-27)
N/A
Mycetoma lesion site* Foot 87 N/A
Hand 12 N/A
Lower leg 14 N/A
Mycetoma lesion size Small (<5 cm) 55 N/A
Moderate (5-10 cm) 20 N/A
Massive (>10 cm) 38 N/A
* One patient had two lesions, one of the foot and one of the hand
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genotyping
PubMed Library was searched for publications describing polymorphisms in the chito-
triosidase gene and in the AMCase gene. We included only polymorphisms that were 
described elsewhere to result in an alteration (either increase or decrease) of the chitin-
ase enzymatic activity. PCR primers, amplification conditions and restriction enzymes 
used in this study are shown in Table 2. We purchased all enzymes at Fermentas (Thermo 
Fisher Scientific, Waltham, USA). Enzymes were used according to manufacturer’s guide-
lines. We determined genotypes by polymerase chain reaction restricted fragment 
length polymorphism (PCR-RFLP). PCR products were run at a 2.5% metaphor gel in 90 
minutes. Two different investigators assessed genotypes separately. 
Immunohistochemistry
Tissue biopsies were fixed in formalin, embedded in paraffin and processed for immu-
nohistochemical evaluation. To determine if the antibodies directed against human AM-
Case and chitotriosidase did not cross-react with any fungal proteins, heat-fixed in vitro 
grown M. mycetomatis hyphae were stained with the same protocol. Histologic sections 
(coupes) were deparaffinised in xylene, then rehydrated in decreasing concentrations 
of ethanol. Haematoxylin and eosin staining was used as standard staining. Calcofluor-
white staining was used to visualize chitin, according to manufacturer’s guidelines. 
Coupes were washed in aquadest and incubated with 25 μM calcofluor-white (Molecular 
Probes®, Leiden, The Netherlands) for 30 minutes at 37°C in the dark. Afterwards, coupes 
were washed in aquadest and assessed by fluorescent microscopy.
table 2. PCR conditions for the different polymorphisms.
Polymorphism Primer sequence (5’→3’) PCR program Restriction 
endonuclease
Activity Length 
(bp)
Ref
Chitotriosidase 
24-bp
insertion
(rs 3831317)
F: agctatctgaagcagaag
R: ggagaagccggcaaagtc
4’ 94°C + 40×
(30” 94°C + 30”
55°C + 30” 
72°C) + 7’ 72°C
None Normal
Decreased
124
148
(14, 
19,
20)
AMCase 
A50G
(rs 61756687)
F: gtctcaccctgccttctttg
R: acccaattctcctcggaaag
4’ 94°C + 40×
(30” 94°C + 30”
58°C + 30” 
72°C) + 7’ 72°C
ApoI (XapI) Normal
Decreased
175 + 91
266
(21)
AMCase 
A290G
(rs 41282492)
F: ctctgcctaccagctgacat
R: gccattccgcaccgtataca
4’ 94°C + 40×
(30” 94°C + 30”
58°C + 30” 
72°C) + 7’ 72°C
TaqI Normal
Increased
256 + 81 
+ 69
256 + 150
(17)
AMCase 10- 
bp insertion
5’UTR (rs 
143789088)
F: ctgaccacagtatctaaacag
R: ctgaccacagtatctaaacag
4’ 94°C + 40×
(30” 94°C + 30”
58°C + 30” 
72°C) + 7’ 72°C
BfaI Normal
Increased
392 + 59
308 + 94 
+ 59
(16)
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Presence of chitinase was determined as described previously (10). First, endogenous 
peroxidase was blocked in methanol with 0.3% H2O2 and non-specific binding sites were 
blocked with rabbit or goat serum. Subsequently, coupes were incubated overnight 
with rabbit polyclonal antibody directed against chitotriosidase (H-66, 1:75, Santa Cruz 
Biotechnology, Santa Cruz, USA) or with goat polyclonal antibody directed against AM-
Case (Y-14, 1:50, both Santa Cruz Biotechnology, Santa Cruz, USA). As a control, a goat 
polyclonal IgG antibody was used, directed against swine IgM (A100-100A, 1:50, Bethyl 
Laboratories, Montgomery, USA). From the VectaStain® Elite ABC kit (Vector Laboratories 
Burlingame, CA, USA), we used anti-rabbit IgG or anti-goat IgG as a secondary antibody 
and the coupes were developed using the protocol from the kit. Haematoxylin was used 
as counter staining.
Ethics statement
Written informed consent was obtained from patients and controls, according to guide-
lines from the medical ethical committee at Soba University Hospital, Khartoum, Sudan. 
The study protocol was approved by this medical ethical committee.
statistical analysis
Pearson’s χ² test was used to verify the Hardy-Weinberg equilibrium. Differences in allele 
frequencies were determined using the two-sided Fisher’s exact test (GraphPad Prism 
Software, San Diego, USA). A p-value of p < 0.05 was considered significant.
rEsults
mycetoma grains caused by Madurella mycetomatis contain chitin and chitinase
Tissue sections of the fungal grain caused by M. mycetomatis are shown in Figure 1. 
The sections were stained using haematoxylin and eosin (HE) (Figure 1A), grocott’s 
methenamine silver stain (Figure 1B) and calcofluor-white stain (Figure 1C). In Figure 
1A it is clearly seen that the grain itself contains cement material. The hyphae are em-
bedded within this cement material (Figure 1B). In Figure 1C, fungal chitin is stained by 
calcofluor-white (18). This figure shows that the chitin is mainly found in the hyphae 
inside the grain. The cement material itself is not stained. Since chitin is present in the 
hyphae inside the grain, we hypothesized that the host produces chitinases, in reac-
tion to exposure to chitin. Thus, tissue sections were stained for chitotriosidase and for 
AMCase (Figure 2). The presence of chitinases is shown by a red color, which was mainly 
located in the grain on the fungal hyphae and not in the cement component of the 
grain. This seems consistent with the presence of the chitin itself, which was also mainly 
found on the fungal hyphae and not in the cement material. We also found that both 
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Figure 1. Tissue sections of Mycetoma foot, showing the fungal grain. Magnification 400×. A. Haematoxylin 
and eosin staining. The grain, consisting of cement and fungal hyphae, is colored red. Around the grain, a 
zone with neutrophils is visible.
B. Grocott’s methenamine silver staining. The hyphae inside the grain are stained black. C. Calcofluor white 
staining. Chitin is stained by calcofluor white staining (18). This photo illustrates that hyphae inside the 
grain are stained, and not the cement component of the grain.
Figure 2. Tissue sections of Mycetoma foot stained for chitotriosidase and for AMCase. Magnification ×100 
(A and C) and ×400 (B and D).
A and B: Chitotriosidase.
C and D: AMCase.
Presence of both enzymes is shown by red color. The grain is clearly visible and colored red diffusely. Inside 
the grain, fungal hyphae are stained more intensely, showing an increased presence of chitotriosidase and 
AMCase around the fungal hyphae.
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chitotriosidase and AMCase were found in the tissue surrounding the fungal grain, how-
ever both chitinases concentrated in the grain. The staining reaction for chitotriosidase 
was specific, since no binding of the chitotriosidase specific antibodies was noted on in 
vitro grown fixated M. mycetomatis hyphae. In contrast, binding of the AMCase specific 
antibodies was noted on some in vitro grown, fixated M. mycetomatis hyphae, although 
the staining was less intense than that inside the grain. Therefore it is plausible that 
not only chitotriosidase but also AMCase are indeed binding to the hyphae inside the 
mycetoma grain.
Polymorphisms in the genes for chitinases cause a risk for infection with 
M. mycetomatis
We subsequently investigated whether genetic polymorphisms that resulted in either 
increased or decreased activity of either chitinase, were associated with an increased 
risk for invasive fungal mycetoma disease. Exactly 215 Sudanese subjects were included 
in the study and were genotyped. Of these, 112 subjects had active mycetoma disease 
and were classified as patients, and 103 subjects were healthy controls. Genotype fre-
quencies are shown in Table 3.
table 3. Distribution of polymorphisms in the genes for chitotriosidase and for AMCase.
Gene polymorphism Genotype Enzyme 
activity*
Patients 
(%)
n=112
Controls 
(%)
n=103
HWE**
p-value
p-value Odds ratio
(95% CI 
interval)
Chitotriosidase 24-bp 
insertion
Wildtype Normal 84 (75%) 94 (91%) 0.106 0.004 2.9 (1.4-6.1)
Heterozygous 
24-bp insertion
Decreased 27 (24%) 8 (8%)
Homozygous 
24-bp insertion
Impaired 1 (1%) 1 (1%)
AMCase A50G
AA Normal 92 (82%) 83 (81%) 0.940 0.647 1.1 (0.7-1.8)
AG Normal 14 (13%) 19 (18%)
GG Decreased 6 (5%) 1 (1%)
AMCase A290G
AA Normal 74 (66%) 67 (65%) 0.657 0.717 1.2 (0.6-2.1)
AG Normal 30 (27%) 33 (32%)
GG Increased 8 (7%) 3 (3%)
AMCase 10-bp 
insertion 5’UTR
Wildtype Normal 73 (65%) 66 (64%) 0.578 0.720 1.1 (0.7-1.8)
Heterozygous 
10-bp insertion
Normal 31 (28%) 34 (33%)
Homozygous 
10-bp insertion
Increased 8 (7%) 3 (3%)
*Genotype associated with an impaired, normal or decreased enzyme activity according to previous pub-
lications (14, 16, 17, 19-21).
**Hardy Weinberg Equilibrium (HWE) as assessed by Pearson’s χ² test. A p-value of >0.05 was associated 
with equilibrium.
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The genotype distribution for all polymorphisms was consistent with the Hardy Wein-
berg equilibrium.
the 24-bp insertion in the chitotriosidase gene is associated with invasive 
mycetoma
In the gene encoding for chitotriosidase, a 24-bp insertion in exon 10 was described 
previously (12, 14, 19, 20). It was described elsewhere that chitotriosidase activity is 
reduced when patients are heterozygous for this insertion and completely absent when 
they were homozygous for this allele (12, 14). Among the patients, 1/112 (0.9%) was 
homozygous for the 24-bp insertion and 27/112 (24.1%) were heterozygous. Among the 
controls, 1/103 (1.0%) was homozygous for the insertion and 8/103 (7.8%) were hetero-
zygous. The insertion containing allele was found significantly more frequently in the 
patients than in the control group (p=0.004). Based on these data, the 24-bp insertion in 
the chitotriosidase gene does increase the risk for invasive mycetoma disease caused by 
M. mycetomatis (odds ratio 2.9; 95% CI 1.4 – 6.1).
Neither the a50g and the a290g sNP, nor the 10-bp insertion in the 5’utr 
region of amCase is associated with invasive mycetoma
Several SNPs in the AMCase genes were described previously, resulting in either in-
creased or decreased AMCase activity (16, 17, 21). As shown in Table 2, we studied two 
SNPs (A50G and A290G) and one 10-bp insertion in the 5’UTR region of the AMCase 
gene. Allele frequencies of A50G and A290G in the patients were similar to those in 
the controls (p=0.65; odds ratio 1.2; 95% CI 0.6-2.1; and p=0.72; odds ratio 1.1; 95% CI 
0.7-1.8, respectively). Furthermore, no difference was found in the presence of the 10-bp 
insertion between patients and controls (p=0.72; odds ratio 1.1; 95% CI 0.7-1.8).
dIsCussIoN
Madurella mycetomatis is the most prevalent causative agent of eumycetoma worldwide 
and in Sudan in particular (1). Many inhabitants of Sudan are exposed to this causative 
agent, however few of them develop mycetoma. Currently, the predisposing factors for 
mycetoma are not known, but some genetic polymorphisms have been associated with 
the development of mycetoma (4, 6, 7).
In this paper, we first showed that chitin is present in the M. mycetomatis grain and 
that two human chitinases are found in the vicinity of this grain, in reaction to exposure 
to M. mycetomatis mycetoma. Both AMCase and chitotriosidase seemed to concentrate 
on the chitin-containing fungal hyphae, a phenomenon that was previously found in 
rats infected with Aspergillus fumigatus (10). Since in both mycetoma and in A. fumigatus 
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infected tissue AMCase and chitotriosidase concentrated on chitin-containing fungal 
hyphae, it needed to be determined if this was not due to cross-reaction of fungal 
proteins with the antibodies used. Staining in vitro grown M. mycetomatis hyphae with 
an antibody for chitotriosidase showed no staining on the hyphae. Also, no staining of 
A. fumigatus hyphae occurred (10), making it likely that the chitotriosidase antibodies 
were specifically directed against mammalian chitotriosidase and that fungi expressed 
no proteins which share epitopes with this enzyme. However, it should be kept in mind 
that in vitro grown fungi could express different proteins than could be expressed in a 
grain. In contrast to the specificity of the chitotriosidase antibody, the AMCase antibody 
seemed less specific. When stained with the AMCase antibody, some staining of the in 
vitro grown M. mycetomatis hyphae was noted. This was not the case for A.  fumigatus 
hyphae (10). Apparently, a protein with an epitope similar to that of AMCase is located 
on some fungal hyphae when grown in vitro. Therefore the AMCase stained in the tissue 
samples of the patients could be the result of both expressed human AMCase and a 
protein of fungal origin. Since the staining was more intense in the tissue sections, we 
feel that it is likely that AMCase was indeed present.
Next to demonstrating that AMCase and chitotriosidase were present at the site of in-
fection, we also provided evidence that a polymorphism in the gene for chitotriosidase, 
resulting in impaired enzyme activity, significantly increased the risk for the development 
of eumycetoma. Increased or decreased activity of the alternative human chitinase, AM-
Case, did not have a significant influence on the risk for eumycetoma. In M. mycetomatis 
mycetoma, chitotriosidase is apparently more crucial than AMCase. Although chitot-
riosidase and AMCase are both chitinases, the cleavage site of both chitinases differs. 
Chitotriosidase is an exochitinase, whereas AMCase is an endochitinase, referring to the 
site where the enzyme cleaves the chitin chain (22). Apparently, exochitinase activity 
is more important in the prevention of mycetoma than endochitinase activity. This is 
supported by the fact that in certain diseases an association was found with only one 
chitinase and not with both. In genetic association studies conducted in patients with 
bronchial asthma, an association was reported with only one chitinase, and not with 
both of them (21, 23, 24), indicating that both chitinases may have the same substrate, 
but have a distinct function in humans. Chitin and the produced chitotriosidase seem 
to be important in the development of the mycetoma grain. Since many mycetoma 
patients have the wild type chitinases associated with normal levels and activity of these 
enzymes, however, polymorphisms in these enzyme-encoding genes are clearly not the 
only factors that determine the risk for M. mycetomatis mycetoma.
Many previous reports showed that polarization of the immune response seems to 
play a role in the development of mycetoma (4, 7, 25-28). The development of mycetoma 
is associated with a Th2 response. Based on immunohistochemistry studies in various 
mycetoma causative agents, it appeared that the cytokine pattern surrounding the 
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mycetoma grain is a Th2 response. IL-10 and IL-4, both Th2-associated cytokines, were 
highly expressed around the fungal grain (7, 26, 27). A different study showed that after 
stimulation of peripheral blood mononuclear cells (PBMCs) with mycetoma antigens, a 
Th2 response developed in mycetoma patients and a Th1 response developed in healthy 
endemic controls (25). Indirect evidence for a Th2 response was also found in the as-
sociation between schistosomiasis, associated with a Th2 response, and eumycetoma 
(4). Not only cytokines, but also other mediators matching Th2 response were reported 
in mycetoma.
Sandler et al (28) showed that mice with a Th2 response have increased expression of 
matrix metalloproteinases (MMPs) and of tissue inhibitor of MMP-1 (TIMP-1). Further-
more, AMCase was induced in Th2-polarized mice (28), which was confirmed by several 
other studies (29-31). Furthermore, Geneuglijk et al confirmed that MMP-2 and MMP-9 
were expressed in the mycetoma lesion (7). In this paper we also demonstrated that 
AMCase and chitotriosidase are expressed in the mycetoma lesion.
In contrast to AMCase, which is induced in a Th2 response, chitotriosidase is produced 
in the environment of a Th1 response (32). In our study we showed that impaired func-
tion of chitotriosidase increases the risk to develop mycetoma.
Since Elagab et al already demonstrated that the PBMCs of healthy endemic controls 
produce Th1 cytokines when exposed to M. mycetomatis antigens, it is likely that they 
also produce high levels of chitotriosidase in order to eliminate M.  mycetomatis. In 
individuals with a genotype resulting in impaired chitotriosidase activity, elimination 
of M. mycetomatis could be less efficient, leading to the development of a mycetoma 
lesion. More research is needed to unravel the exact role of the host in the development 
of the mycetoma grain.
Based on the data of this study and of other studies, we created the following hypothesis. 
When a host is exposed to M. mycetomatis, it will try to eliminate the pathogen. Most 
individuals will respond with a Th1 polarized response. In this response acute inflamma-
tion develops, chitotriosidase is produced and no grain is formed. When the response is 
mainly Th2-polarized, a chronic inflammatory process in which both chitotriosidase and 
AMCase are produced, results in the formation of granulomas with grains. The chronic 
exposure to fungal material in combination with the Th2 response also results in an in-
crease in MMPs, which further modulates the collagen capsule surrounding the grain (2, 
8, 28). Polymorphisms in the genes for IL-10, CCL-5 and TIMP-1 were shown to increase 
the risk for mycetoma (7, 8). Chitinases degrade the chitin component of the fungal cell 
wall (10). A polymorphism in the gene for chitotriosidase results in impaired enzyme 
activity (14), which in its turn results in an increased risk of developing Madurella myce-
tomatis mycetoma, as we showed in this paper.
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In conclusion, in this study we demonstrated that the grain caused by Madurella myceto-
matis, contains chitin. The human immune system produced both AMCase and chitotrio-
sidase in the vicinity of this grain. Only the 24-bp insertion in the gene for chitotriosidase 
was associated with the development of mycetoma caused by M. mycetomatis.
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aBstraCt
In 2005, a new sibling species of Aspergillus fumigatus was discovered: Aspergillus len-
tulus. Both species can cause invasive fungal disease in immunocompromised patients. 
The species are morphologically very similar. Current techniques for identification are 
PCR-based or morphology-based. These techniques are labour-intense and not suf-
ficiently discriminatory. Since A. lentulus is less susceptible to several antifungal agents, 
it is important to correctly identify the causative infectious agent in order to optimize 
antifungal therapy. In this study we determined whether Raman spectroscopy and/or 
MALDI-TOF MS were able to differentiate between A. lentulus and A. fumigatus. For 16 
isolates of A. lentulus and 16 isolates of A. fumigatus, Raman spectra and peptide profiles 
were obtained using the Spectracell and the MALDI-TOF MS (VITEK MS RUO, bioMérieux), 
respectively. In order to obtain reliable Raman spectra for A. fumigatus and A. lentulus, 
the culture medium needed to be adjusted to obtain colourless conidia. Only Raman 
spectra obtained from colourless conidia were reproducible and correctly identified 25 
out of 32 (78%) of the Aspergillus strains. For VITEK MS RUO, no medium adjustments 
were necessary. Pigmented conidia resulted in reproducible peptide profiles as well in 
this case. VITEK MS RUO correctly identified 100% of the Aspergillus isolates, in a time-
frame of approximately 54 hours including culture. Of the two techniques studied here, 
VITEK MS RUO was superior to Raman spectroscopy in the discrimination of A. lentulus 
from A. fumigatus. VITEK MS RUO seems to be a successful technique in the daily identi-
fication of Aspergillus species within a limited timeframe.
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INtroduCtIoN
Over the last few decades, immunosuppressive therapies have become increasingly 
available. As a result, the number of immunocompromised patients and of difficult-to-
treat opportunistic infections among them, including invasive fungal infections, is still 
rising (1-4). Invasive pulmonary aspergillosis (IPA) is one of these difficult-to-treat op-
portunistic fungal infections. Several Aspergillus species are able to cause IPA in humans. 
The most prevalent species is Aspergillus fumigatus, macroscopically characterised by 
green-blue colonies on Sabouraud’s dextrose agar and microscopically by septated hy-
phae with conidiophores (5). With the introduction of genetic identification it appeared 
that several fungi were misidentified as A. fumigatus in the past (6). One of these species 
was Aspergillus lentulus (7). Owing to its similar morphology, both macroscopically and 
microscopically, discrimination of both species remains complicated. This can be dem-
onstrated by the fact that 16% of isolates, morphologically identified as A.  fumigatus, 
appeared to be A. lentulus, based on molecular analysis (6). Since both species are not 
equally susceptible to the antifungal agents currently in use (amphotericin B, itracon-
azole, voriconazole and caspofungin (8-10)), it is important to discriminate these two 
species. Early detection and identification of the causative agent results in the early start 
of appropriate treatment. This will enhance the success rate of treatment and limits the 
costs of hospitalization (11).
Since the discrimination of A.  lentulus from A.  fumigatus based on morphologic 
characteristics is almost impossible, PCR and sequencing remain necessary. In many 
medical mycology laboratories these PCR-based techniques are not routine procedures, 
thus requiring a time-consuming approach. Therefore, it would be ideal to define an 
easy method of distinguishing between the two fungal species quickly and reliably. In 
recent years, new diagnostic strategies based on biophysics became available for the 
detection and identification of many types of pathogenic micro-organisms. These new 
platforms are less labour-intensive than the conventional identification techniques and 
have significantly higher resolution and significantly shortening the diagnostic process 
in many instances. Raman spectroscopy and matrix-associated laser desorption/ioniza-
tion time-of-flight mass spectroscopy (MALDI-TOF MS) are two of these new techniques. 
Raman spectroscopy is a non-destructive optical technique, based on scattering of light 
by molecules. It generates a profile based on all cell components and was used success-
fully to identify bacterial species (12, 13). However, no procedure has as yet been sug-
gested for identification of fungi with Raman spectroscopy. MALDI-TOF MS generates 
a limited profile based on masses and has been proven useful in the determination of 
fungi (14-16). However, identification of A. lentulus by MALDI-TOF MS was not described 
extensively. In the present study we used a group of well-characterised A. lentulus and 
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A.  fumigatus isolates to determine whether either Raman spectroscopy or MALDI-TOF 
MS were able to discriminate these two Aspergillus species.
matErIals & mEthods
Fungal strains
A panel of 16 independently isolated A.  lentulus clinical isolates was kindly provided 
by Janet Staab (John Hopkins University School of Medicine, Baltimore, MD, USA). The 
A.  lentulus strains included were FH1, FH4, FH5, FH6, FH7, FH84, FH85, FH86, FH219, 
FH220, FH231, FH238, FH239, FH265, FH292 and FH293. These strains were confirmed 
to be A. lentulus based on multi-locus sequence typing (MLST) of five genes: the beta-
tubulin gene, the rodlet A gene, the salt-responsive gene, the mitochondrial cytochrome 
b gene, and the internal transcribed spacer regions (7). The A. fumigatus strains were 39, 
41, 44, 47, 293, D201-1, DP, k43, k52, k57, k65, k68, k74, k76, k80. These 15 heterogenic 
strains are all clinical A. fumigatus strains, collected at Erasmus MC, Rotterdam, the Neth-
erlands. Based on typing of the CSP gene, they were found genetically divers and unre-
lated. Furthermore A. fumigatus ATCC 204305 was included as laboratory strain. Species 
identification was confirmed by ITS sequencing as previously described (5). Fungi were 
cultured on Sabouraud’s dextrose agar (SDA; bioMérieux, Marcy l’Etoile, France) with or 
without 1% dimethyl sulfoxide (DMSO; Sigma-Aldrich, Zwijndrecht, the Netherlands).
raman spectroscopy
Strains were cultured for 96 hours at 37°C before conidia were harvested in phosphate 
buffered saline (PBS) containing 0.05% Tween (Sigma-Aldrich, Zwijndrecht, the Neth-
erlands). The conidia were washed twice and suspended in sterile water (aquadest, 
bioMérieux) and spotted on a microslide carrier. Samples were allowed to dry for 15 
min and Raman spectra were measured in the commercially available SpectracellRA® 
Bacterial Strain Analyzer (River Diagnostics, Rotterdam, the Netherlands). Results were 
analysed and dendrograms were created using the SpectracellRA® Bacterial Strain Ana-
lyzer software (version 1.7.8).
maldI-toF ms
Strains were cultured for 48 and 192 hours at 30°C. Fungal material was gently removed 
with a sterile swab, which was pre-moistened with medium suspension (bioMérieux, 
Ref. 20150), and suspended in medium suspension. Ethanol absolute (0.9 mL; Sigma-
Aldrich, Lyon, France) was added, samples were mixed and centrifuged for 2 min at 
15,000 × g and the supernatant was discarded. Next, 40 μl of 70% formic acid and 40 μl 
acetonitril (both Sigma-Aldrich, Lyon, France) were added and samples were mixed and 
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centrifuged for 2 min at 15,000 × g. The supernatant was spotted on a single-use target 
(VITEK-MSDS, bioMérieux, Marcy l’Etoile, France) and samples were allowed to dry. One 
microliter of α-cyano-4-hydroxycinnamic acid (CHCA; bioMérieux) was added as a ma-
trix and targets were allowed to dry. Spectra were determined in MALDI-TOF MS AXIMA 
Assurance (VITEK MS RUO; Shimadzu, Champs-sur-Marne, France) in a linear positive ion 
extraction mode within a mass range from 2,000 to 20,000 Da. The system was calibrated 
externally with the mass spectrum obtained from fresh cells of E. coli ATCC 8739 strain. 
Spectra were automatically processed with the Launchpad V2.8. software (Shimadzu 
Biotech, Columbia, MD, USA). The resulting peak lists were exported and analysed using 
SARAMIS software (bioMérieux VITEK MS RUO) for spectra comparison. Clusters were 
produced by hierarchical agglomerative clustering using SARAMIS absolute or relative 
similarity measure and single-linkage criterion. Cluster analysis was performed by SARA-
MIS computing dendrograms based on similarities between masses.
Reproducibility was tested by sampling and measuring one strain of both fungal spe-
cies in triplicate. Protein extracts were randomly performed on the 32 strains in order to 
prevent bias.
turn around time
The time frames of different techniques were compared from the inoculation of the 
strains on the first culture medium. Included were culture time, process of the fungal 
material to measurable content, measurement of the fungal material and analysis of the 
data (e.g. cluster analysis).
rEsults
raman spectroscopy does not distinguish all A. lentulus isolates from 
A. fumigatus isolates
When analysing the Aspergillus species with Raman spectroscopy, we noted that the 
green pigment resulted in a strong signal, masking the original spectrum. Raman spec-
tra of the triplicates were not reproducible. This problem was solved when the fungal 
isolates were incubated on SDA with 1% DMSO, resulting in white conidia (17). Obvi-
ously, when harvesting the conidia, most A.  lentulus strains demonstrated a typically 
slowly sporulating phenotype. Nevertheless, enough conidia were produced to prepare 
samples for Raman spectroscopy. Raman spectra could be obtained for all 32 strains. 
As shown in Figure 1, the isolates separated in two major clusters, the first consisting 
of mainly A.  fumigatus strains and the second consisting of mainly A.  lentulus strains. 
However, six A. fumigatus strains fell into the A. lentulus cluster: A. fumigatus 39, k74, k76, 
k68, k80 and D201-1. One A. lentulus isolate, A. lentulus FH292, fell into the A. fumigatus 
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cluster (Figure 1). Thus 10 out of15 A. fumigatus strains (67%) and 15 out of 16 of A. len-
tulus strains (94%) could be identifi ed correctly. Overall, Raman spectroscopy performed 
on white conidia correctly classifi ed 25 out of 32 (78%) of the fungal isolates included.
VItEk ms ruo distinguishes all A. lentulus isolates from A. fumigatus
For VITEK MS RUO, fungal strains were cultured on SDA for 48 h, according to stan-
dardized procedures. For one strain (A.  lentulus FH292), no reproducible spectra were 
obtained owing to poor growth. This strain was thus excluded from analysis of VITEK 
MS RUO results. The spectra obtained were compared to the currently known spectra 
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Figure 1. Clustering of 16 Aspergillus fumigatus and 16 Aspergillus lentulus strains, according to Spectracell 
BA Bacterial Analyzer.
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for Aspergillus species in the bioMérieux database. Using these culture conditions, the 
median number of peaks detected, was 103 (range 80-140) for both species, which was 
well within the expected number of peaks of 100-150 obtained for other moulds with VI-
TEK MS RUO. Analysis of mass spectra showed spectra that were closely related for both 
species, although subtle diff erences were observed (Figure 2). As can be seen in Figure 3, 
the 31 isolates fell into two separate clusters: one cluster with Aspergillus lentulus isolates 
only and one cluster with Aspergillus fumigatus isolates only. Two sequenced Aspergil-
lus fl avus and two sequenced Aspergillus niger isolates were included for comparison. 
These two species each fell into a separate cluster. Based on this technique, 16 out of 
16 isolates of A.  fumigatus (100%) and 15 out of 15 A.  lentulus (100%) were correctly 
identifi ed. Since it was previously reported that pigmented fungi yield spectra of poorer 
quality than less pigmented fungi when using VITEK MS RUO (14, 18), we also measured 
spectra of A. fumigatus and A. lentulus when cultured on SDA with 1% DMSO. The spectra 
did change slightly but the discriminatory power remained the same, again 16 out of 
16 A. fumigatus and 15 out of 15 A. lentulus isolates were correctly identifi ed (data not 
shown).
VItEk ms ruo reduces the time needed to correctly identify A. fumigatus and 
A. lentulus
For diagnostic purposes, not only a correct identifi cation but also the time frame in which 
this identifi cation is obtained, is highly relevant. We therefore also investigated whether 
Raman spectroscopy and/or VITEK MS RUO could identify A. fumigatus and A.  lentulus 
within a shorter time frame than PCR. For this comparison, the culture time was included 
for all techniques. The time frame for each step in the identifi cation process is shown 
in Figure 4. PCR-based identifi cation takes 57 h, while fungal identifi cation by Raman 
spectroscopy took 100 h and identifi cation by VITEK MS RUO only 50 h. The diff erence in 
% Int.
(a)
(b)
(a)
(b)
(a)
(b)
Figure 2. Results of VITEK MS identifi cation of Aspergillus lentulus (A) and Aspergillus fumigatus (B).
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Figure 3. Clustering of 16 A. fumigatus and 15 A. lentulus isolates based on VITEK MS RUO data. 1 A. lentulus 
isolate was excluded from analysis due to poor growth.
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Figure 4. Timing identifi cation of fungal strains using various methods.
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time frame is mainly caused by the longer culture time needed for Raman spectroscopy. 
Conidia cannot be harvested before 96h of culture time, whereas 48h of culture time is 
suffi  cient to obtain suitable fungal material for analysis by VITEK MS RUO.
dIsCussIoN
Both Aspergillus lentulus and Aspergillus fumigatus are able to cause invasive pulmonary 
infections in humans. However, since susceptibility to antifungal agents is not equal, 
it is important to correctly identify the causative fungal agent in order to optimize 
antifungal therapy. Since current techniques for identifi cation are time consuming and 
not discriminative enough, we compared the performance of two newer identifi cation 
techniques.
Raman spectroscopy was proven to be useful for the identifi cation of bacteria (12, 13), 
though the identifi cation of fungal species was not described previously. We showed 
here that Raman spectroscopy is an easy-to-operate technique, but a modifi cation was 
needed to obtain reproducible spectra from pigmented fungi, since the expression of 
melanin caused interference. Culture medium modifi cation resulted in reproducible 
spectra. Raman spectroscopy correctly classifi ed 78% of A.  fumigatus and A.  lentulus 
isolates, but it is not considered discriminative enough to distinguish A.  lentulus from 
A. fumigatus.
Regarding MALDI-TOF MS, it has also been reported that pigmented fungi yield 
spectra of poorer quality than less pigmented fungi (14, 18). We therefore determined 
whether or not modifi cation of the culture medium, as applied to Raman spectroscopy 
samples, resulted in more reliable spectra. Under both culture conditions, 100% cor-
rect identifi cations of the isolates were obtained. Therefore, modifi cation of the culture 
medium was not needed. Modifi cation of the culture medium would add 48h of culture 
time. Besides, Bernardo et al and Arnold et al showed that MALDI-TOF MS spectra can 
vary with growth medium of the fungal isolate (19, 20); thus we conclude that it is not 
advisable to alter the growth medium.
In the past MALDI-TOF MS had already been described as a diagnostic tool in the iden-
tifi cation of several Aspergillus species (14). Here we add A. lentulus to the list of species, 
which can be readily identifi ed by MALDI-TOF MS. In our study both A. fumigatus and 
A.  lentulus were identifi ed with 100% accuracy. Additionally, identifi cation of other 
species of the Aspergillus fumigatus species complex could be investigated, to test how 
specifi c MALDI-TOF MS can identify A. lentulus. Using the same technique, Hettick et al 
(14) were also able to identify A. fumigatus and Alanio et al (21) was able to identify 50 
isolates with 96% accuracy. The 7 A. lentulus isolates included in Alanio’s study were also 
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identified with 100% accuracy (21), on a different type of mass spectrometer (Bruker 
MALDI-TOF MS), but using similar methods. Surface-enhanced laser desorption ion-
ization time-of-flight mass spectrometry (SELDI-TOF MS) was also able to distinguish 
between the protein profiles of A. lentulus (n=2) and A. fumigatus (n=2)(22), although it 
is more time-consuming. A more extensive study comparing SELDI-TOF MS with MALDI-
TOF MS should be performed to determine which of these techniques is best suited as 
a diagnostic tool.
Other molecular techniques have been investigated recently as well. Araujo et al (23) 
and Serrano et al (24) identified A. fumigatus from several other fungal species, including 
A. lentulus, with a microsatellite-based PCR multiplex (23) and with a multiplex PCR based 
on β-tubulin and rodlet A partial gene sequences (24). Two and four A. lentulus strains 
respectively were included in the analysis. Furthermore Etienne et al (25) developed a 
microsphere-based Luminex assay to rapidly identify A.  fumigatus. Non-A.  fumigatus 
species were identified, though additional sequencing was required to identify the 
isolates. Using VITEK MS RUO, we correctly identified both A. fumigatus and A. lentulus 
in a single assay.
A. fumigatus and A. lentulus were proven the most prevalent species within the Asper-
gillus fumigatus complex (26). Though other species belonging to the section Fumigati, 
such as N. ugadawae, N. pseudofisheri and A. viridinutans, could be included in order to 
further investigate the discriminative power of MALDI-TOF MS for these species. Since 
these species were not readily available in the extended database of VITEK MS RUO 
spectra of bioMérieux, it was not possible to include these species in the current analysis.
For diagnostic purposes the time frame in which a correct identification is made is also 
relevant. Here we showed that fungal isolates could be identified within 100 h of the 
start of culture by Raman spectroscopy and within 50 h by VITEK MS RUO. This was less 
time-consuming than sequence-based identification, where culture is included. Direct 
diagnostics on patient material would be even less time-consuming, although sensi-
tivity and specificity remain a problem (27). Since fungal spores are ubiquitous, many 
patients are colonized with Aspergillus species and discrimination between colonisation 
and infection could be problematic when diagnostics are performed directly on patient 
materials.
In conclusion, VITEK MS RUO is less time-consuming than Raman spectroscopy and 
more reliable. Therefore it suits better as a non-sequence based identification tool for 
the discrimination between A. fumigatus and A. lentulus than Raman spectroscopy. Since 
no adjustments to the culture medium were needed for proper identification, VITEK MS 
RUO is a suitable technique for identifying A. lentulus in daily practice. Further research 
to optimise the laboratory process may further shorten the diagnostic timeframe 
in which A.  lentulus can be identified. Also, other species in the Aspergillus fumigatus 
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species complex could be tested. Still, both MALDI-TOF MS and Raman spectroscopy 
are dependent on a culture with a known low sensitivity (27). Identification techniques 
performed directly on clinical specimens could bypass fungal culture. If the causative 
infectious agent could be identified based on blood profiles or BAL profiles of patients, 
more time could be saved.
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aBstraCt
The treatment of fungal infections in immunocompromised patients remains a chal-
lenge. Serious side effects and increasing resistance interfere with the success of an-
tifungal therapy. Hence there is an ongoing need for new antifungal agents. A group 
of branched histidine and lysine-rich peptides (BHKPs) has been developed. These 
BHKPs have a mechanism of action similar to histatins. The aim of this study was to 
determine the antifungal spectrum of three BHKPs. Minimum inhibitory concentrations 
(MICs) were determined for 9 Aspergillus isolates, 5 Candida isolates, 21 Cryptococcus 
isolates and 8 Trichosporon isolates, according to the CLSI broth microdilution method. 
MICs were assessed in triplicate for the currently used antifungal agents amphotericin 
B, voriconazole, caspofungin, for the antimicrobial peptide histatin-5 (HST-5) and the 
BHKPs H2K4b, H3K4b(H) and H3K4B(G).
MICs of amphotericin B, voriconazole and caspofungin for the isolates tested were 
similar to MICs described in the literature. All isolates were resistant to HST-5 (MICs >16 
mg/L). Both Cryptococcus and Trichosporon isolates seemed to be susceptible to the 
BHKPs, while Aspergillus species and Candida species were found to be resistant.
This study is the first to assess the antifungal activity of the BHKPs against a variety of 
fungal species. Of the three BHKPs tested, H2K4b showed highest antifungal potential. 
Studies in animal models of fungal infection are needed to determine the therapeutic 
activity of these peptides.
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INtroduCtIoN
The number of immunocompromised hosts is increasing over the last decades (1). As a 
result, opportunistic infections, among which both superficial and invasive fungal infec-
tions, frequently develop (2-4). These infections remain difficult to treat (3-7). As the use 
of a number of antifungal agents is limited due to serious side effects (8), new agents 
with different mechanisms of action have been developed. The currently used antifungal 
agents are divided into three major classes: the polyenes, among which amphotericin 
B (9); the azoles, of which voriconazole is frequently used (8, 9); and the echinocandins, 
with caspofungin as most important agent (10). In general, newly developed antifungal 
agents are derivatives of agents belonging to one of these classes. The use of newer 
azoles encounters problems with drug interactions and emerging resistance (5, 7). As a 
result there is an ongoing need for new antifungal agents.
A group of such novel antifungal agents are the branched histidine and lysine-rich 
peptides (BHKPs), originally developed as gene delivery agents (11). The new BHKPs 
that exhibit antifungal characteristics do not belong to any of the existing classes of 
antifungal agents (12). It is thought that the mechanism of action of the BHKPs is similar 
to that of histatins, which are a group of naturally occurring peptides with antimicrobial 
activity (12). These cationic peptides are found exclusively in mammalian saliva. Of the 
histatins, histatin-5 is considered the most potent antimicrobial peptide (13-15).
In a search for new antifungal agents, we aimed to determine the in vitro antifungal 
spectrum of three BHKPs. As reference agents we included three representatives of the 
currently used antifungal agents, being amphotericin B, voriconazole and caspofungin, 
and histatin-5 as another peptide. Antifungal susceptibility was determined by the 
broth microdilution method described in the CLSI guidelines (16, 17). In addition, the 
quantitative viability-based XTT assay was used (18).
matErIals & mEthods
Fungal strains
A broad panel of clinical isolates of fungi and yeasts, 9 Aspergillus strains, 5 Candida 
strains, 21 Cryptococcus strains and 8 Trichosporon species were included for suscepti-
bility testing (Table 1). We included at least one reference strain for each species. The 
Aspergillus reference strains were Aspergillus fumigatus ATCC 204305, Aspergillus niger 
ATCC 16404, Aspergillus terreus CBS 594.65 and Aspergillus flavus CBS 625.66. The Candida 
reference strains were Candida albicans ATCC 90028 and Candida glabrata ATCC 66032. 
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table 1. Median minimum inhibitory concentrations (MICs) in mg/L for 9 Aspergillus strains, 5 Candida 
strains, 21 Cryptococcus strains and 8 Trichosporon strains. Median values of 3 determinations are shown.
Strain Antifungal agent
AMB VRC CAS HST-5 H2K4b H3K4b(H) H3K4b(G) MEC CAS†
A. fumigatus ATCC 204305 0.5 1 128 >16 >1024 >1024 >1024 0.125
EMC 1 0.5 0.5 128 >16 >1024 >1024 >1024 0.125
A. niger ATCC 16404 0.125 1 64 >16 16 32 128 0.125
21 0.125 1 128 >16 >1024 >1024 >1024 <0.063
27 0.25 1 64 >16 16 256 512 <0.063
A. terreus CBS 594.65 2 1 128 >16 >1024 >1024 >1024 <0.063
11 0.25 1 128 >16 >1024 >1024 >1024 0.125
A. flavus CBS 625.66 2 0.5 128 >16 >1024 >1024 >1024 <0.063
25 1 1 128 >16 >1024 >1024 >1024 0.063
C. albicans ATCC 90028 0.5 1 0.5 >16 >256 >256 >256 N/A
W111 0.5 1 1 >16 >256 >256 >256 N/A
W1016 0.5 4 1 >16 >256 >256 >256 N/A
C. glabrata ATCC 66032 0.25 1 0.5 >16 >256 >256 >256 N/A
1 0.5 0.5 0.063 >16 >256 >256 >256 N/A
C. neoformans ATCC 90112 0.25 0.125 16 >16 8 64 128 N/A
 var neoformans CBS 131 0.125 0.125 16 >16 4 2 1 N/A
CBS 889 0.016 0.016 16 >16 4 4 16 N/A
B 29739 0.016 0.008 32 >16 32 64 64 N/A
B 32287 0.031 0.125 16 >16 8 64 128 N/A
B 34336 0.125 0.063 8 >16 8 16 8 N/A
B 36203 0.008 0.016 8 >16 4 16 8 N/A
B 36535 0.125 0.031 8 >16 4 4 2 N/A
C. neoformans B32480 0.063 0.031 8 >16 4 16 8 N/A
 var grubii B 35735 0.031 0.031 16 >16 8 32 16 N/A
C. gattii CBS 10090 0.25 0.5 32 >16 4 4 4 N/A
CBS 10514 0.25 0.008 16 >16 2 4 4 N/A
CBS 10865 0.5 0.008 16 >16 2 1 4 N/A
CBS 11247 0.125 0.25 16 >16 4 4 4 N/A
CBS 11542 0.125 1 16 >16 4 4 4 N/A
CBS 11545 0.5 0.25 16 >16 2 4 4 N/A
CBS 11752 0.5 0.125 32 >16 4 4 8 N/A
CBS 11807 0.125 0.5 16 >16 2 2 4 N/A
CBS11816 0.125 1 16 >16 4 4 8 N/A
A 47496 0.063 0.008 32 >16 4 4 8 N/A
ICB 107 2 1 128 >16 4 2 2 N/A
T. asahii CBS 2479 1 0.25 32 >16 4 4 128 N/A
T. inkin CBS 5585 0.25 0.063 16 >16 4 8 128 N/A
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The Cryptococcus reference strains were Cryptococcus neoformans ATCC 90112 and Cryp-
tococcus gattii CBS 10090. The Trichosporon mucoides reference strain was Trichosporon 
mucoides CBS 6939. The other Trichosporon species tested were Trichosporon asahii CBS 
2479 and T. inkin CBS 5585.
antifungal agents
Amphotericin B (Bristol-Myers Squibb, Woerden, the Netherlands), caspofungin (Merck 
and Company, Rahway, NJ, USA) and voriconazole (Pfizer BV, Capelle a/d IJssel, the Neth-
erlands) were dissolved as indicated in the CLSI guidelines and stored at −80°C until use. 
Histatin-5 (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and H2K4b, H3K4b(H) 
and H3K4B(G) (Figure 1, Aparna BioSciences, Washington, USA) were dissolved in sterile 
water and stored at −80°C until use. Twofold serial dilutions were prepared. Ampho-
table 1. Median minimum inhibitory concentrations (MICs) in mg/L for 9 Aspergillus strains, 5 Candida 
strains, 21 Cryptococcus strains and 8 Trichosporon strains. Median values of 3 determinations are shown. 
(continued)
Strain Antifungal agent
AMB VRC CAS HST-5 H2K4b H3K4b(H) H3K4b(G) MEC CAS†
T. mucoides CBS 6939 0.063 0.5 16 >16 8 16 64 N/A
CBS 7616 0.063 0.125 32 >16 32 64 128 N/A
CBS 7625 0.063 0.25 16 >16 8 8 128 N/A
CBS 7626 0.016 0.008 8 >16 16 16 32 N/A
CBS 7653 0.016 0.008 8 >16 16 16 16 N/A
CBS 7722 0.063 0.125 16 >16 8 32 128 N/A
AMB, amphotericin B; VRC, voriconazole; CAS, caspofungin; HST-5, histatin-5. H2K4b and H3K4b(H) and 
H3K4B(G), BHKPs. † MEC CAS Minimum effective concentration for Caspofungin. N/A not applicable.
Figure 1. Schematic structure of branched Histidine and lysine rich peptides (BHKPs). The peptides consist 
of terminal branches, originating from a lysine core. This lysine core consists of three lysines. R represents 
KHKHHKHHKHHKHHKHHKHK for H2K4b, KHHHKHHHKHHHHKHHHK for H3K4b(H) and KHHHKHHHKHHGH-
KHHHK for H3K4b(G).
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tericin B, voriconazole and histatin-5 were tested in the concentration range of 0.008-16 
mg/L, caspofungin in the concentration range of 0.063-128 mg/L and the BHKPs in the 
concentration range of 0.5 – 128 mg/L.
in vitro antifungal susceptibility testing by broth microdilution method
All isolates were tested according to the broth microdilution methods for qualitative sus-
ceptibility testing of filamentous fungi and yeasts, respectively, described by the Clinical 
and Laboratory Standards Institute (16, 17). In short, for preparation of the inocula, fungi 
were cultured on Sabouraud’s dextrose agar (Oxoid Ltd, Basingstoke, England), conidia 
from filamentous fungi were harvested and washed in phosphate-buffered saline (PBS) 
containing 0.05% Tween 20 (Sigma-Aldrich Chemie GmbH, Steinheim, Germany). A stan-
dardized inoculum was prepared in RPMI-1640 (with l-glutamine but without bicarbon-
ate) (Lonza, Verviers, Belgium), buffered to pH 7.0 with 0.165 M 3-N-morpholinopropane-
sulphonic acid (MOPS) (Sigma-Aldrich Chemie GmbH, Steinheim, Germany). NaCl 3g/L 
was added to the RPMI to simulate physiological salt concentrations of human blood. 
To determine the antifungal activity of the BHKPs in the presence of serum, 5% fetal calf 
serum (not heat-inactivated, Gibco, Breda, the Netherlands) was added. The inoculum 
was standardized with a haemocytometer (Bürker-Türk, Marienfeld, Germany) to a final 
concentration containing 2.3 × 105 conidia/ml. For yeasts, colonies were suspended in 
sterile saline and adjusted to 0.5 McFarland, with a final inoculum of 1.5 × 103 CFU/ml.
MICs were determined in triplicate and read visually according to the CLSI guidelines. 
In short, MICs were defined as the lowest concentration of antifungal agent, which 
prevented visible growth of the fungus or yeast. For yeasts, the MIC for voriconazole and 
caspofungin was defined as the lowest concentration in which a prominent decrease in 
turbidity is observed. Minimum effective concentrations (MECs) for caspofungin were 
determined for all Aspergillus strains. The MEC was defined as the lowest concentration 
of caspofungin causing abnormal growth with broad-based, short branched hyphae (19, 
20). MECs also were read visually.
in vitro antifungal activity by viability-based Xtt assay
The viable fungal mass was assessed in a quantitative assay, as described earlier (18). In 
this assay, the metabolic activity of the fungal mass is quantified in terms of mitochon-
drial dehydrogenase activity converting XTT (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany) into formazan. The formazan excreted into the medium after 2 hours of 
incubation was determined spectrophotometrically at 450 nm. The percentage of viable 
fungal mass was calculated. We used this method to compare visually read MICs (CLSI 
method) to calculated MICs (XTT assay).
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statistical analysis
Differences in MICs were analyzed by two-tailed Mann-Whitney test (GraphPad Prism 
Software, San Diego, USA).
rEsults
Table 1 shows the in vitro susceptibilities of 9 Aspergillus isolates, 5 Candida isolates, 21 
Cryptococcus isolates and 8 Trichosporon isolates. All the isolates tested were found to be 
susceptible to amphotericin B and voriconazole.
Aspergillus species and Candida species
For Aspergillus species, MICs for caspofungin were high, with a median MIC of 128 mg/L. 
However, the MECs were much lower (median 0.063 mg/L). All Candida species tested 
were inhibited by ≤ 1 mg/L caspofungin (median 0.5 mg/L). Table 1 also shows that 
Aspergillus species and Candida species were not susceptible to histatin-5 (MICs >16 
mg/L) or to the three new peptides H2K4b, H3K4b(H) and H3K4B(G) (MICs >128 mg/L), 
with the exception of A. niger. The median MICs for A. niger were 16 mg/L for H2K4b 
and >128 mg/L for H3K4b(H) and H3K4B(G). This fungus was apparently susceptible to 
H2K4b only. Since caspofungin induces morphological changes at concentrations below 
MIC, we also determined the morphology of BHKP-treated fungi. Microscopic observa-
tions show that exposure to H2K4b tested at the concentration of 128 mg/L, which is 
below MIC, did not result in morphological changes of hyphae in A.  fumigatus ATCC 
204305 (data not shown).
Cryptococcus species and Trichosporon species
Unlike Aspergillus and Candida species, Cryptococcus species were more susceptible to 
the BHKPs. The median MICs for Cryptococcus species were 4, 4 and 8 mg/L for the three 
BHKPs, respectively. C. gattii species were inhibited by BHKPs at a lower concentration 
than C. neoformans species For H2K4b, the median MICs were 8 mg/L for C. neoformans 
species and 4 mg/L for C.  gattii species (p = 0.003). For H3K4b(H), the median MICs 
were 16 mg/L for C. neoformans species and 4 mg/L for C. gattii species (p = 0.004). For 
H3K4B(G), the median MICs were 16 mg/L for C.  neoformans species and 4 mg/L for 
C. gattii species (p = 0.035).
Based on the above, we noted that H2K4b is more potent in the inhibition of growth 
of Cryptococcus species when compared to the other BHKPs. The presence of a capsule 
(microscopic observation using Indian ink) did not influence susceptibility. Neither was 
the susceptibility of Cryptococcus species changed by the addition of 5% fetal calf serum 
(not heat-inactivated) (data not shown).
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Since Cryptococcus species were susceptible to the BHKPs, we wondered whether 
this phenomenon was also found in other pathogenic basidiomycetous species. We 
therefore determined MICs for 8 Trichosporon strains. The median MICs were 8 mg/L 
for H2K4b, 16 mg/L for H3K4b(H) and 128 mg/L H3K4B(G), respectively. Cryptococcus 
species and Trichosporon species were resistant to histatin-5. The median MICs were >16 
mg/L for all species tested. Cryptococcus species and Trichosporon species were both 
inhibited by the three BHKPs, though apparently H2K4b resulted in the most effective 
inhibition.
in vitro antifungal activity assessed by viability-based Xtt assay
In addition to the broth microdilution methods, we also investigated the viable fungal 
mass using the XTT assay. Increasing concentrations of voriconazole for example in-
duced a decrease in viable fungal mass, as observed by decreased concentration of col-
ored formazan (data not shown). For H2K4b, a concentration-dependent effect was not 
observed when using the broth microdilution method. However, in the viability assay, 
we noticed a peculiar phenomenon after exposure to high concentrations of the BHKPs 
(>64 mg/L). XTT was converted into formazan, though the formazan was not excreted. 
Due to an unknown change in the fungal cells, the XTT became trapped in the cell and 
the fungal mass remained dark red. Since calculating the viable fungal mass is based 
on measuring optical density and hence on the excretion of formazan, the percentage 
found did not represent the true percentage of viable fungal mass. This discrepancy 
between visually read MICs and calculated MICs by viability staining was similar for the 
three BHKPs and all Aspergillus species investigated.
dIsCussIoN
In this study, we explored the antifungal spectrum of three novel, potentially antifungal, 
branched histidine and lysine-rich peptides. MICs for BHKPs were compared to MICs 
for currently used antifungal agents. MICs obtained for amphotericin B, voriconazole 
and caspofngin were consistent with those described in the literature (16, 17, 21). The 
MEC values we found for caspofungin were much lower than the MIC values, which is 
also consistent with literature (16, 20). We showed that Cryptococcus species and Tricho-
sporon species were susceptible to the BHKPs H2K4b, H3K4b(H) and H3K4B(G), whereas 
Aspergillus species and Candida species were not. H2K4b seemed to be superior in 
Cryptococcus species and in Trichosporon species MIC values for H2K4b were lower than 
for H3K4b(H) and H3K4B(G).
Antifungal activity of BHKPs 125
8
We found a difference in susceptibility towards the BHKPs for Aspergillus species and 
Candida species, compared to Cryptococcus species and Trichosporon species. A possible 
explanation for this difference in susceptibility could be that Cryptococcus species and 
Trichosporon species differ from Aspergillus species and Candida species in phylogenetic 
affiliation (21, 22). The genera Cryptococcus and Trichosporon belong to the Basidiomy-
cota, whereas both Aspergillus and Candida belong to the Ascomycota (21, 22). Basidio-
mycota and Ascomycota differ with respect to their cell wall composition. For instance, 
Cryptococcus species and Trichosporon species both express glucuronoxylomannan on 
their cell wall, whereas Aspergillus species and Candida species lack glucuronoxyloman-
nan (23).
Zhu et al presumed that the mechanism of action of BHKPs is similar to the mechanism 
of action of histatin-5, since it is also a histidine-rich peptide (12). In Candida species 
histatin-5 binds to the Ssa1/2 surface protein (24), like other antifungal peptides, such 
as the human β-defensins 2 and 3 (25). The difference in susceptibility could also be the 
result of genetic differences in the Ssa1/2 receptor.
After binding the Ssa1/2 receptor, histatin-5 becomes internalized, where it opens the 
ion channels and causes dysfunction of the Trk-1p transporter (12). This transporter is 
the main target in cysteine-free peptides, like human neutrophil defensin 1 (25), lacto-
ferricin (25) and bactenecins (26) and is involved in their fungicidal activity. However, the 
Trk-1p transporter is required more explicitly in the antifungal activity of histatin-5 than 
of the other peptides mentioned (25). Perhaps the Trk-1p transporter is more essential in 
fungicidal activity for the BHKPs in Cryptococcus species and Trichosporon species than 
in Aspergillus species and Candida species, resulting in increased resistance for the latter 
species.
In C. albicans, the effects of Trk-1p transporter dysfunction are efflux of ATP and other 
small nucleotides and, finally, cell death (12). In Aspergillus, this mechanism might be 
different. When we performed the viability staining using XTT, XTT became trapped 
inside the Aspergillus cells. Internalization of the BHKPs possibly causes another type 
of dysfunction of the Trk-1p transporter in Aspergillus species than in Candida species. 
The function of the transporter might become blocked by BHKPs, and thus the influx of 
potassium and the efflux of chloride are inhibited. Other ions would accumulate in the 
cell as well. This explains the observed accumulation of formazan in the mycelium when 
performing the XTT assay.
From our results, we noted that growth of Cryptococcus species and Trichosporon species 
was inhibited at relatively low concentrations of all BHKPs tested. Therefore the BHKPs 
might be useful as a new class of antifungal agents for these fungal diseases, for which 
mortality and morbidity remain substantial (27). Infections with Trichosporon species 
are relatively rare, while infections with Cryptococcus species are more common. (28) 
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Trichosporon species cause both superficial and deep-seated infections, the latter mainly 
occurring in the immunocompromised patient (29). Infections due to these invasive 
infections are potentially life-threatening (30, 31) Treatment with triazoles has shown to 
improve survival of patients with trichosporonosis, though mortality remains substan-
tial (29, 30, 32) Cryptococcus species are the most common aetiological agents of fungal 
meningitis, occurring mainly in the immunocompromised host, though not exclusively 
(33-35). C.  neoformans causes infections in immunocompromised patients, whereas 
C.  gattii most commonly infects otherwise healthy patients (35-37). The spectrum of 
cryptococcal disease ranges from asymptomatic to invasive meningo-encephalitis (35, 
36). Even though these species are susceptible towards the existing antifungal agents 
(38), cryptococcosis remains to result in high mortality, especially in children (35, 39, 40). 
Most antifungal agents do not cross the blood-brain barrier, and are not able to reach 
the site of infection (41). For BHKPs, the capacity to cross the blood-brain barrier is not 
known and might be studied in an animal model of experimental cryptococcosis.
The antifungal activity of the BHKPs was proven, though tolerability and cytotoxicity 
should also be investigated. With respect to tolerability, Zhu et al (12) reported that a 
concentration of 100 mg/L of H2K4b caused less than 1% cell death in human cell lines 
(12). Leng et al histologically observed no toxic side effects in various organs of mice 
after intravascular injection of H2K4b (100 μg five times, every three days)(42). These 
data on potential toxic side effects combined with our data on antifungal activity, sug-
gest that BHKPs could be a new class of antifungal agents with little side effects.
In conclusion, the present study shows that the BHKPs have high antifungal activity 
against the basidiomycetes Cryptococcus species and Trichosporon species and may 
open new ways to reduce morbidity and mortality. Further studies are needed to explore 
the potential activity of these peptides in therapy of these difficult-to-treat infections.
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Invasive pulmonary aspergillosis (IPA) remains an infection with high morbidity and 
mortality in immunocompromised patients. It is most often caused by Aspergillus 
fumigatus (1) and both diagnosis and treatment of IPA can be challenging. The echi-
nocandin caspofungin is one of the currently used antifungal agents. Interestingly, in 
vitro the fungistatic action of caspofungin is evident only at high concentrations (2). 
However, the therapeutic results of treatment with caspofungin are more favorable. In 
this thesis we hypothesized that the cell wall composition of echinocandin susceptible 
A. fumigatus is altered by caspofungin. The altered fungal cell walls subsequently stimu-
late several components of the immune system resulting in a better clinical outcome. 
The data presented in this thesis document the modifying influence of caspofungin on 
the fungal cell wall composition, and its subsequent effect on the immune response of 
the host.
CasPoFuNgIN: EFFECts oN thE ComPosItIoN oF thE FuNgal CEll wall
The mechanism of action of the echinocandins is based on the inhibition of synthesis of 
β-glucan, one of two major constituents of the fungal cell wall (50-60% of the cell wall by 
dry weight)(3). The other major polysaccharide of the fungal cell wall is chitin (10-20%)
(3). Together with galactomannan these polysaccharides form a solid cell wall, providing 
turgor, which will prevent the fungal cell from collapsing. Furthermore, this rigid cell wall 
also protects the fungus against the immune system of the host. Caspofungin inhibits 
the synthesis of β-glucan in the cell wall of fungi and yeasts (4-6). As shown in Chapter 
2, exposure of A.  fumigatus to caspofungin resulted in a concentration-dependent 
decrease of β-glucan in the fungal cell wall to 80%. It was therefore envisioned that 
A. fumigatus would respond to caspofungin challenge by the upregulation of other cell 
wall components so as to maintain its strength and to keep turgor.
Indeed, in caspofungin-exposed A.  fumigatus, the chitin component of the cell wall 
proved to be upregulated, i.e. constituted a greater part of the cell wall mass. Exposure 
to chitin synthesis inhibitor nikkomycin Z resulted in a decrease of the chitin component 
of the fungal cell wall, but did not affect its β-glucan content, which remained similar. 
Also in other fungi including other Aspergillus species, Candida species and Saccharomy-
ces species increased chitin levels were detected after their exposure to caspofungin (4, 
7-14). Combination of caspofungin and nikkomycin Z led to a crippled cell wall and the 
fungus was no longer able to maintain a rigid cell wall. This resulted in dramatic morpho-
logic changes, even at low drug concentrations, as demonstrated in Chapter 2 and by 
others (7, 15, 16). Furthermore, this phenomenon was not only found when nikkomycin 
Z was combined with caspofungin, but also in combinations with other echinocandins 
such as anidulafungin (7) or micafungin (16). These in vitro results have been translated 
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into in vivo studies in experimental infections. Clemons et al showed that nikkomycin Z 
combined with micafungin led to prolonged survival in a murine model of pulmonary 
aspergillosis (17). Furthermore, in the samen infection model, Luque et al reported that 
combination treatment resulted in increased mouse survival rates from 20-30% after 
single agent treatment, and to 100% survival of mice when treated with combination 
therapy (18).
Although these in vitro and in vivo results look promising, there is currently no clinical 
data on this combination treatment in patients with IPA. This can partly be explained 
by the fact that nikkomycin Z is currently not freely available. The drug was developed 
in the 1970s, however clinical development of nikkomycin Z was not successful. In the 
early 2000’s, the University of Arizona invested in clinical research of nikkomycin Z in the 
treatment of Valley fever (coccidioidomycosis; https://www.vfce.arizona.edu/resources/
pdf/bio5_summary_nikz_ development_plan.pdf ).
Since combining nikkomycin Z with echinocandins was not possible in patients, other 
means have been tried in vitro and in vivo to inhibit chitin synthesis, combined with in-
hibition of β-glucan synthesis by echinocandins. Fortwendel and others demonstrated 
that the increase of chitin synthesis in response to caspofungin treatment was caused by 
a universal stress response pathway, mediated by calcineurin (8, 9, 11, 19-21). As a result, 
inhibiting the calcineurin mediated stress response also led to inhibition of the increase 
in chitin biosynthesis in reaction to caspofungin treatment. Based on these mechanisms, 
it is not surprising that the combination of caspofungin (blocking β-glucan synthesis) 
and calcineurin inhibitors (blocking the stress response leading to chitin increase), 
results in synergy between these agents (8, 9, 14, 19, 22). So in the future we might be 
able to enhance the therapeutic efficacy of caspofungin by inhibiting the increase in 
chitin synthesis through either direct inhibition of the chitin synthesis pathway with 
nikkomycin Z, or indirect inhibition using calcineurin inhibitors. Although in stdudies 
using an A. fumigatus strain with mutated proteins which resulted in impaired activity 
of the calcineurin pathway, synergy of nikkomycin Z and caspofungin in vitro was not 
confirmed (9).
As became clear from the above, inhibition of chitin synthesis is important to enhance 
the antifungal effect of echinocandins. It has been found that there is even a correla-
tion between the amount of chitin in the fungal cell wall and the susceptibility of the 
fungus towards caspofungin (23). In fungi and yeasts with naturally high levels of chitin 
in their cell wall, the antifungal effect of caspofungin is probably less. Therefore, a high 
chitin content in the fungus provides a mechanism for the fungus to escape from the 
fungistatic effect of caspofungin. In the treatment of these fungal isolates, combination 
therapy with chitin synthesis inhibitors and β-glucan synthesis inhibitors could result in 
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better killing of these relatively caspofungin-resistant fungal species. On the other hand, 
Lee et al observed that Candida species with increased chitin levels are less virulent in 
a murine model than species with normal chitin levels (24). An A. fumigatus isolate with 
increased chitin was also found to be less virulent compared to other isolates (25). Since 
treatment with caspofungin results in an increased chitin level in the fungal cell wall of 
A. fumigatus, this could result in decreased virulence, thus improving clinical outcome. 
We conclude that the mechanism(s) through which chitin exactly plays a role in IPA 
development remains to be fully elucidated.
CytokINE rEsPoNsE IN rats wIth IPa
Back to the mechanism of action of caspofungin, our first thought was that the altered 
ratios in chitin and β-glucan in the fungal cell wall could influence the immune system 
of the host. Both chitin and β-glucan are considered pathogen-associated molecular 
patterns (PAMPs) in the fungal cell wall, which act as signaling molecules on the outside 
of pathogens. PAMPs are recognized by pattern recognition receptors (PRRs), which are 
localized on immune cells of the host. Subsequent to attachment, an immune reaction is 
triggered through activation of a specific pathway, mounting a pro- or anti-inflammatory 
response. Each specific PAMP binds to a specific PRR and causes a certain response. The 
PAMP β-glucan is recognized by Dectin-1 and complement receptor 3 (CR3), which are 
supported by toll-like receptor (TLR)2 (26, 27). For the PAMP chitin no specific recep-
tor was identified, however chitin, or chitin particles, can cause co-stimulation of TLR2, 
which leads to activation of many inflammatory pathways (28-34). Not only TLR2, but 
also TLR4 was demonstrated to be important in the recognition of A. fumigatus (35).
In order to answer the question whether an altered composition of the fungal cell 
wall would result in an altered immune response in the host, we first had to determine 
the normal immune response towards IPA in our rat model. Many studies investigating 
cytokines in aspergillosis were published. Most studies focused on only a small panel 
of cytokines or used models of immunocompetent hosts. In Chapter 3 we describe the 
cytokine response in neutropenic rats with IPA. We determined levels of 24 pro- and anti-
inflammatory cytokines as well as chemokines and regulatory cytokines in 4 groups of 
rats. Cytokine responses in immunocompetent rats, inoculated with A. fumigatus conidia 
were compared to cytokine responses in immunocompromised rats with IPA. First, we 
observed that the dynamics in the levels of local cytokines and chemokines at the site 
of infection, i.e. in the lungs, differed from that of the cytokines circulating in the blood-
stream. In the lungs, IPA clearly induced pro-inflammatory interleukin (IL)-1α and IL-6. 
Furthermore, the chemokines interferon-gamma induced protein (IP)-10, keratinocyte 
chemoattractant (KC, the murine functional homologue of human CXCL-8), monocyte 
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chemoattractant protein (MCP)-1 and macrophage inflammatory protein (MIP)-1α were 
all significantly increased rats with IPA. However, the levels of anti-inflammatory cyto-
kines in the lungs did not change during IPA. In contrast, in serum we found increased 
levels of pro-inflammatory granulocyte macrophage-stimulating factor (GM-CSF) and 
IL-12p70 and of anti-inflammatory IL-5 and IL-10. Chemokines IP-10 and KC were also 
found significantly increased in serum of rats with IPA. Many investigators determined 
cytokine responses in mammals exposed to A. fumigatus, however none studied such 
a broad panel of cytokines and chemokines. Tomee et al (36) stimulated human airway 
epithelial cells with A.  fumigatus and found similar results for production of IL-6, IL-8 
and MCP-1, but found no increase in GM-CSF, which we found exclusively in the blood-
stream. Stimulation of dectin-1 was previously shown to induce IL-6 and IL-10 (37) and 
also in patients IL-10 was found increased after infection with A. fumigatus (28, 38). It is 
clear that some evidence is conflicting. Activation of dectin-1 is known to stimulate IL-17 
and TNF-α (31, 37) and likewise chitin is known to stimulate IL-17 and IL-12/23p40 but 
not IL-12p70 (39). Our results are not in line with these earlier observations by others. 
However, differences in route of infection, in vivo or ex vivo study design and the selec-
tion of host species may influence results and, therefore, the observed differences in 
cytokine responses may, in part, help explain the results.
CasPoFuNgIN: EFFECts oF ChaNgEd PamPs oN thE CytokINE rEsPoNsE
Changes in the fungal cell wall as a result of exposure to caspofungin, cause an alteration 
in the relative contribution of the PAMPs chitin and β-glucan. This change in cell wall 
composition is likely to lead to modifications in the activation of PAMP-TLR molecular 
pathways and thus in an altered immune response in the host.
In Chapter 3 we investigated the cytokine response in caspofungin-treated rats with 
IPA. Treatment with caspofungin resulted in 100% rat survival as opposed to 100% rat 
mortality among untreated rats. In general we observed that the cytokine responses in 
caspofungin-treated rats was very similar to that in untreated rats. Some subtle differ-
ences occurred, though no striking differences were found. However, these seemingly 
subtle differences might be responsible for the good clinical outcome after treatment 
with caspofungin.
We found that in the lungs, caspofungin caused an attenuation of the increase in 
pro-inflammatory IL-1α and IL-6 and the chemokines IP-10, KC, MCP-1 and MIP-1α. 
Furthermore the increase in systemic inflammatory GM-CSF and IL-12p70, as well as 
the anti-inflammatory IL-5 and IL-10 and chemokines IP-10 and KC was attenuated by 
treatment with caspofungin. In summary, caspofungin limited the increase in several 
locally and systemically produced cytokines and chemokines, which coincided with 
Discussion 137
9
100% survival of the rats. Apart from limiting the β-glucan synthesis, caspofungin also 
unmasks the deeper cell wall layers and thus increases the exposure of the β-glucan 
to the immune system of the host (8, 10, 24, 40-42). These immunomodulatory effects 
of caspofungin have been investigated previously. There is conflicting evidence on the 
effects of the increased exposure to β-glucan. An increased pro-inflammatory response 
in reaction to Aspergillus species and in Candida species was described (40-42), but also 
a decreased inflammatory response was reported after treatment with micafungin (43), 
which is more in line with our results (Chapter 3). Olson et al investigated the cytokine 
response in vivo in neutropenic mice with Aspergillus flavus infection (44) and cytokines 
in caspofungin-treated rats were compared to those in untreated rats. They found an 
increased mortality in mice treated with caspofungin due to increased levels of pro-in-
flammatory cytokines, including TNF-α. Increased levels of pro-inflammatory cytokines 
seem to coincide with decreased survival, whether or not as a result of treatment with 
antifungal agents.
Finally, Netea et al described that balance between TLR2 and TLR4 seems to be crucial 
for the outcome of fungal infections (31). As a result of treatment with caspofungin, 
PAMPs are changed and the TLR2/TLR4 balance could be shifted, resulting in favorable 
outcome.
In conclusion, our results are in line with the previously reported hypothesis that 
an excessive immune response is responsible for tissue injury and is associated with 
mortality (45).
ChItINasE ProduCtIoN IN rats wIth IPa
Based upon the cytokine response, we could not completely explain the clinical results 
after treatment with caspofungin. Therefore, we continued by investigating another 
component of the immune system: the chitinase response.
In Chapter 2 we showed that treatment with caspofungin led to upregulated chitin 
contents of the fungal cell wall. When a mammalian host encounters chitin polymers, 
it can produce chitinases, which are chitin-cleaving enzymes. Two types of chitinases 
have been discovered in humans so far: chitotriosidase and acidic mammalian chitinase 
(AMCase)(46). Since fungi contain chitin, it may be expected that mammals experienc-
ing invasive fungal infection such as IPA, produce increased levels of chitinases.
In Chapter 4 we investigated the role of chitinases in the host with IPA. In a rat model, 
chitotriosidase and AMCase production was investigated after infection with A. fumiga-
tus. We investigated both immunocompetent and immunocompromised hosts and mea-
sured serum and pulmonary chitinase activity. We showed that in immunocompromised 
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rats the production of both chitotriosidase and AMCase are significantly increased in IPA 
and that it is increasing with progressing infection, parallel with increasing fungal load. 
In immunocompetent rats however, both chitinases are only slightly and transiently 
increased after challenge with A. fumigatus conidia. After clearance of the conidia the 
chitinase production declines again to undetectable levels. Furthermore, we showed 
that serum chitinase and tissue chitinase kinetics do not parallel each other, and that 
chitotriosidase and AMCase are both found in the lung at the site of infection.
CasPoFuNgIN: EFFECts oN ChItINasE ProduCtIoN
Infection with fungal pathogens containing more chitin (for example as a result of treat-
ment with caspofungin) could lead to increased levels of chitinases produced by the 
infected host (47, 48). These chitinases lyse the fungal cell wall, which could assist in 
clearance of the fungus. These indirect effects of the antifungal agent may help explain 
the favorable clinical outcome of treatment with caspofungin whilst the in vitro effects 
of caspofungin on the fungus are poor.
We therefore hypothesized that chitinase levels in caspofungin-treated rats with IPA 
are higher than in untreated rats with IPA, as result of the chitin upregulation of the 
fungal cell wall. However, partly due to small numbers of rats in the experiments, a 
significant difference could not be detected between caspofungin-treated (surviving) 
rats and the untreated (non-surviving) rats (Chapter 4). Interestingly and in contrast to 
our expectation, there was a trend towards lower chitinase levels in caspofungin-treated 
rats. This was probably due to the overriding influence of the fungal load on the host’s 
chitinase response, fungal loads being much lower in caspofungin-treated surviving 
rats compared to the increasing fungal loads in rats left untreated and dying from IPA. 
When the overall fungal load remains lower, the overall amount of chitin is probably also 
lower, resulting in a lower production of chitinases by the infected host. However, we 
concluded that chitinases do play a significant role in the host’s response to IPA, though 
other factors are also involved.
The effects of increased levels of chitinase have not been established by others. In-
creased levels of chitotriosidase were reported to present in the lung fluid and in lung 
macrophages of patients suffering from chronic obstructive lung disease, especially 
among smokers (49). The same authors also showed that chitotriosidase was able to 
stimulate the production and release of IL-8 and MCP-1 from alveolar macrophages in 
humans, even more from macrophages from smokers and COPD patients compared to 
healthy controls (49) However, the role of these chitinases in IPA remains to be eluci-
dated. We showed that when A. fumigatus is treated with caspofungin, a combination 
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of chitotriosidase and AMCase can lyse the fungal cell wall, whereas untreated A.  fu-
migatus seems to be unaffected by the combination of the two chitinases. Caspofungin, 
therefore, somehow leads to enhanced fungal susceptibility to the combination of these 
chitinases.
Caspofungin is known to unmask the deeper cell wall layers (8, 10, 24, 40-42) contain-
ing the chitin-β-glucan matrix. When the deeper cell wall becomes more accessible to 
lysing enzymes such as chitinases, chitin-degrading effects would be expected to occur. 
When chitinase levels are high and when chitinases can better reach the chitin, large 
chitin polymers can be cleaved into smaller particles. Previously it was reported that the 
size of chitin particles determines the immune response of the host (32, 39, 50). Da Silva 
et al investigated the immune response mounted by different sizes of chitin particles 
(32). They found that large chitin particles (70-100 μm) and very small chitin particles (<2 
μm, created by cleaving of larger particles due to chitinase) are immunologically inert, 
while somewhat larger but still small chitin particles (<40 μm but mostly 2-10 μm) as 
well as intermediate chitin particles (40-70 μm) each mount a specific immune response. 
For example, small chitin particles induce the release of the anti-inflammatory IL-10 and 
the pro-inflammatory tumor necrosis factor (TNF), whereas intermediate chitin particles 
only induce TNF (32). Also, intermediate particles induced IL-17, whereas larger chitin 
particles did not (39). Furthermore Shibata et al showed that chitin particles of 1-10 μm 
induce IFN-γ via IL-12 and TNF-α production, whereas larger particles of 50-100 μm did 
not induce IL-12 or IFN-γ (50). The exact size of the chitin polymers or particles used in 
our challenge experiments described in Chapter 3 is not known. Since in our rat model 
A.  fumigatus conidia are used to induce the infection, which after inoculation subse-
quently develop into hyphae which do not present chitin particles of a well defined size 
range, the immune response reported in Chapter 3 was rather induced by the combina-
tion of chitin, β-glucan and mannan present in the cell walls of the conidia and hyphae. 
This could explain why our results, although directly observed in an infection model, do 
not completely match the hypothesized cytokine response for isolated chitin particles.
When large chitin polymers are cleaved into smaller particles to a significant degree, 
the immune response probably changes. Smaller chitin particles skew the immune 
response towards Th1 instead of the Th2 response that is mounted by large chitin poly-
mers (51).
Strong et al confirmed that application of chitin microparticles (mostly <1 μm) in-
creased levels of Th1 cytokines IL-12, IFN-γ and TNF-α, finally resulting in a decrease of 
lung inflammation (52). Again our results in Chapter 3 do not completely match this 
cytokine profile, probably due to the difference in immune response to chitin particles 
versus live A. fumigatus.
Application of small chitin particles (1-10 μm) in an allergic animal model down-regu-
lated Th2 cytokines as well as IgE production and lung eosinophilia (53). In a fulminant 
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infection, the inflammatory response could lead to increased inflammatory damage of 
tissue when the cytokine response is not down-regulated. Hence the host benefits from 
smaller chitin particles that induce anti-inflammatory cytokines. These cytokines limit 
the inflammatory reaction and terminate the immune reaction in order to prevent tissue 
damage (32). Degradation of chitin by chitinases thus ultimately results in a reduced 
immune response (54). In summary, increased levels of chitinases lead to smaller chitin 
particles, leading to a change in the specific immune response, eventually resulting in 
changed cytokine production. This change could lead to a shift in balance between Th1 
and Th2 response, reflecting pro- and anti-inflammatory states, with a Th1 response 
limiting tissue damage in the host and a Th2 response inducing tissue damage (30). This 
Th1/Th2 balance could make the difference between rat survival and rat mortality in IPA 
(55-57).
The most important Th1 cytokine is interferon-γ whereas most important Th2 cyto-
kines are IL-4, IL-5, IL-10 and IL-13 (58). Profiles for systemic IL-5 and IL-10 and, partly, 
pulmonary IFN-γ reported in this thesis on day 1 and 3 but not on day 6 in our IPA model, 
substantiate this hypothesis, whereas levels of systemic IL-4, IL-13 and IFN-γ and pulmo-
nary IL-4, IL-5, IL-10 and IL-13 did not change significantly during IPA (Chapter 3, Figure 
2). Thus the data we found are at least party supportive of this hypothesis. However, 
exact time frames in which cytokine and chemokine levels reach their maximum are 
unknown and the half-life time of cytokines in vivo can be brief. Thus further studies 
of cytokine profiles generated during IPA are needed to further unravel the role of the 
balance between Th1/Th2 cytokines in IPA.
ChItINasEs IN aNothEr FuNgal INFECtIoN: MAdurellA MyCeToMATis 
myCEtoma
In Chapter 4 we showed that chitinases are upregulated after exposure to Aspergillus 
fumigatus. Since it is one of the major cell wall components of A.  fumigatus, it is not 
surprising that exposure to chitin causes a rise in chitin-degrading enzymes. This finding 
raised the question whether chitinases are upregulated as result of exposure to other 
sources of chitin as well. Chitin is ubiquitous in nature and is found in many organisms, 
such as parasites, insects and nematodes (59). In Chapter 6, we investigated whether 
levels of chitinases are also found in individuals suffering from another fungal infec-
tion: mycetoma. Mycetoma is a chronic granulomatous infectious disease, resulting 
in tissue destruction. This invalidating disease is mainly found in tropical areas (60). It 
can be caused by different micro-organisms, but globally the most common causative 
agent is the fungus Madurella mycetomatis. The fungal agent penetrates the skin and 
causes granulomatous grains, consisting of fungal material, cement and inflammatory 
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cells (61, 62). We showed that the grain also contains chitin (Chapter 6), which had not 
been proven previously. In addition to demonstrating the presence of chitin, we also 
confirmed that both chitotriosidase and AMCase are present in the grain (Chapter 6), 
which had also not been reported previously.
gENEtIC PolymorPhIsms IN ChItINasE gENEs
As described above, levels of both mammalian chitinases are increased as a result of 
invasive fungal infection. The exact role of chitinases in clearance of the fungal material 
and in infectious diseases in general, is not completely clear. Chitinases are thought to 
be part of the antiparasitic immune response, since many parasites carry chitin (63, 64). 
Association between chitinase activity or expression and several diseases was studied 
previously. (48, 49, 64-98; Table 1). 
Chitotriosidase is produced by macrophages and polymorphonuclear neutrophils 
and can be found in the lungs of mammals as well as in their lacrimal glands, where 
it has antimicrobial activity (49, 64-67). Increased levels of chitotriosidase are found in 
Gaucher’s disease, a lysosomal storage disease (68) and in asthma (69), but infectious 
diseases such as candidiasis, malaria and even aspergillosis have also been associated 
with increased levels of chitotriosidase in serum or plasma (see Table 1)(70-73). Further-
more, expression of chitotriosidase in the stomach was correlated with Helicobacter 
pylori infection (74).
A genetic polymorphism in the chitotriosidase gene, resulting in a decrease in 
enzymatic activity, was described previously (48, 68, 75, 76). Homozygosity leads to 
complete inactivity of chitotriosidase whereas heterozygosity for the 24-bp insertion 
leads to a variable decrease in chitotriosidase activity (67, 77). This polymorphism is 
found relatively frequently in the healthy population all over the world (68, 78), however 
with major variation by geographic areas (48, 68, 79-83). Several studies investigated the 
association between this polymorphism and pulmonary diseases. Heterozygosity for 
the 24-bp insertion was in some studies, though not in all, associated with asthma (84, 
85) and correlation between the polymorphism and clinical outcome in sarcoidosis was 
not confirmed (86). The association between this polymorphism, resulting in enzymatic 
inactivity, and pulmonary infectious diseases was not investigated previously. 
The other chitinase, AMCase, was also studied previously (47, 51, 63, 65, 74, 87, 99-109; 
Table 2). AMCase is produced by macrophages and epithelial cells (99). It is found in the 
stomach (65, 74, 100), tears (101), sinus mucosa (102), saliva (103) and lungs (47, 65, 104) 
and it is thought to play a role in allergic diseases. Zhu et al showed that production 
of AMCase is upregulated in Th2 inflammatory responses in the lungs (47). However, 
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table 1. Polymorphisms in the gene for chitotriosidase and the associations studied.
Polymorphism in 
chitotriosidase
Ref Association described
Rs3831317 
(24bp insertion)
48 Associated with increased susceptibility to filarial infection with Wuchereria Bancrofti 
in South Indians
68 Prevalent in Dutch subjects and in Ashkenazi Jewish subjects, chitotriosidase 
deficiency is caused by homozygosity of a 24-bp duplication
77 Prevalent in Europeans, including in Gaucher disease
79 No chitotriosidase deficiency found in African subjects; high levels of chitotriosidase 
in acute malaria infection in African children. Suggestion that mutant allele increases 
the susceptibility to malaria.
83 Found very frequently in Peruvian Amerindians exposed to chitin-bearing food and 
enteroparasites
84 Association between heterozygosity and asthma
85 Not associated with asthma in children
86 Not associated with outcome in Sarcoidosis
87 Associated with decline in FEV1 in African Americans
88 Not associated with bronchial asthma in Caucasian children
89 Not associated with atopy in Korean children
90 Associated with Gram-negative bacteremia in children with AML
91 Not associated with sepsis or death caused by sepsis in patients with AML
92 Not associated with chronic disseminated candidiasis in acute leukemic adults
93 Not associated with filarial infection status, lymphedema of an extremity or 
hydrocele.
94 Not associated with coronary artery disease
95 Not associated with atherosclerosis, however in subjects with athersclerosis higher 
levels of chitotriosidase were found
96 Chitotriosidase activity does not correlate with lipid levels; mean levels of enzymatic 
activity did correlate with allelic dosage
97 Associated with development of non-alcoholic fatty liver disease
98 Associated with longevity in Mediterranean
G102S 76 Found in Asians, Africans and Europeans; normal chitotriosidase activity
77 Prevalent in Europeans, including in Gaucher diseases
Rs1065761 88 Not associated with bronchial asthma in Caucasian children
89 Associated with atopy in Korean children
Rs2297950 87 Strongly associated with decline in FEV1 in Caucasians
88 Not associated with bronchial asthma in Caucasian children
Rs2494303 76 Found in Asians, Africans and Europeans; normal chitotriosidase activity
A442G 89 Not associated with atopy in Korean children
G354R 76 Mainly found in Africans; associated with reduced
A442V chitotriosidase activity
Haplotypes 76 Chitotriosidase deficiency was associated with tuberculosis in European subjects, but 
not in Asians
Chitotriosidase deficiency was associated with less atopic conditions (allergic rhinitis, 
contact dermatitis, drug or food allergy, asthma) in Asians
Chitotriosidase deficiency was associated with less atopic conditions (allergic rhinitis, 
contact dermatitis, drug or food allergy, asthma) in Asians
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also a limitation of chitin-induced eosinophil and basophil influx was reported as a 
result of AMCase production (51, 105). Mainly associations with allergic diseases such 
as asthma have been described (47, 63, 106) and AMCase plays a role in the Th1/Th2 
responses in the lungs (107) although its exact function remains to be clarified. Several 
polymorphisms in the gene for AMCase were described and some were associated with 
asthmatic diseases (see Table 2)(87, 106, 108) Association between infectious pulmonary 
diseases and altered AMCase activity was not investigated previously. 
We hypothesized that the risk for IPA might be influenced by the (in)ability to produce 
chitinases. As we showed in chapter 3, a combination of chitotriosidase and AMCase 
is necessary to degrade the fungal cell wall. In Chapter 5 we investigated 4 polymor-
phisms resulting in altered chitinase activity in a group of patients at risk for IPA. Prob-
ably due to small numbers of patients with IPA we did not find a correlation between 
decreased chitinase activity and the occurrence of IPA. However, we did find a trend for 
an association between impaired chitotriosidase activity and an increased risk for IPA. 
No association was found between incidence of IPA and altered activity of AMCase. We 
concluded that other factors than chitinase activity seem to play a more important role 
in the development of IPA. Other polymorphisms that seem to play a role in the develop-
ment of IPA have been described previously. Polymorphisms in the genes for TLR1, TLR 6 
(111), TLR4 (112), mannose-binding lectin (113) and plasminogen (114) were associated 
with increased incidence of invasive aspergillosis or other invasive fungal infections. 
Also, polymorphisms in the genes for several cytokines or their receptors were associ-
ated with increased incidence of IPA, such as IL-10 (115, 116), IL-1α (117) and CXCL2 
(118) and TNF-receptor type 2 (119). For chitinases, the investigated polymorphisms 
were not associated with increased risk for IPA in our small cohort. Combination of these 
polymorphisms with other polymorphisms was not investigated, but could reveal a 
further increase of the risk for IPA. Genetic screening for polymorphisms could identify 
the population that is at increased risk for invasive fungal infections, but for now the 
relation between decreased chitinase activity and IPA risk remains to be proven. Van der 
Velden et al reviewed genetic polymorphisms that were associated with invasive mold 
disease (IMD) and concluded that many polymorphisms are associated with IMD but 
also concluded that many inconsistencies have been reported (120). They suggest that 
consistent polymorphisms need to be tested in much larger cohorts, before conclusions 
can be drawn for their value in risk assessment in infectious diseases (120).
In addition to IPA, we investigated the influence of polymorphisms in the genes for 
chitinase in patients with M. mycetomatis mycetoma (Chapter 6). We investigated the 
same 4 polymorphisms in the genes for chitinases as in Chapter 5, in order to assess 
these polymorphisms as a potential risk factor to develop mycetoma. We found that 
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mycetoma patients more often have impaired chitotriosidase activity than healthy 
controls. For AMCase activity, no difference was found between patients and controls.
Apparently, chitotriosidase activity is more crucial in the development of mycetoma 
than is AMCase. Bierbaum et al investigated the presence of polymorphisms in the 
genes for both chitotriosidase and AMCase in a population at risk for bronchial asthma 
(88, 106) and found a difference in the association between asthma and both chitinases. 
table 2. Polymorphisms in the gene for AMCase and the association studied.
Polymorphism AMCase Ref Association described
Rs3818822 87 Homozygosity associated with lower FEV1 in Caucasians
106 Associated with increased prevalence of asthma in children and adults
108 No association with asthma in African American subjects
110 No direct association with asthma#
K17R 106 Associated with increased prevalence of asthma in children and adults
110 No direct association with asthma#
Rs12033184 106 No association with asthma
109 Linkage disequilibrium; no association with asthma for the block of SNPs
110 No direct association with asthma#
Rs2275253 106 No association with asthma
108 No association with asthma in African American subjects
110 No direct association with asthma#
Rs2275254 106 No association with asthma
108 No association with asthma in African American subjects
110 No direct association with asthma#
Rs36011905 106 No association with asthma
110 No direct association with asthma#
Rs2256721 106 No association with asthma
108 No association with asthma in African American subjects
110 No direct association with asthma#
G339T 87 Associated with accelerated loss of FEV1 in African Americans
108 Associated with asthma in African Americans
A531G 108 No association with asthma in African American subjects
Rs4442363 109 All SNPs were in linkage disequilibrium; no association
Rs35042265 the with asthma for block of SNPs based on rs4442363
Rs4546919
Rs4554721
Rs11102235
Rs34698010
Rs11102234 109 No variation observed in the population investigated
Rs12023459 109 Same prevalence in healthy children and in asthmatic Turkish children
#haplotype-based association analyses with asthma genes (IL-4, IL-13, IL-8, IL-15 and TLR10) showed best 
evidence for a joint effect on asthma for AMCase and IL-4 and for AMCase and IL-13.
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Decreased activity of AMCase was associated with increased prevalence of bronchial 
asthma, whereas chitotriosidase inactivity was not associated with asthma (88, 106). 
These studies suggest a difference in function for the two chitinases, while both have 
the same substrate. Previously it was shown that chitotriosidase is found in a Th1 re-
sponse, whereas AMCase is part of a Th2 response (121-125). From our study, it seemed 
that chitotriosidase is essential to skew the immune response towards a Th1-response, 
resulting in the clearance of the fungal material and preventing a grain to be formed.
Based upon the results of Chapter 6 and previously published studies, we posit the 
hypothesis that the balance between a Th1 and Th2 response is crucial in the develop-
ment of mycetoma (122, 126-130). We showed that impaired activity of chitotriosidase 
is associated with increased risk for mycetoma. However, other factors also play a role. 
Several different polymorphisms were shown to influence risk for mycetoma (126, 127, 
131, 132). Screening for the chitotriosidase polymorphism could result in identification 
of a risk group for mycetoma. However, due to costs, screening for a genetic polymor-
phism is not yet feasible in tropical areas with limited financial supplies such as Sudan, 
where mycetoma is endemic. Other tests might help out. For example, screening for 
chitotriosidase activity bypasses the genetic test and could identify individuals with im-
paired chitotriosidase activity. However, in healthy individuals, levels of chitotriosidase 
activity are low as well (133). Furthermore, tests for chitotriosidase are not commercially 
available yet. These problems limit the usability of the genetic polymorphism as screen-
ing test in daily use endemic areas such as Sudan. Since the exact role of chitinases is 
not fully understood, further studies are needed to better understand the function of 
chitinases in the development of mycetoma.
NoVEl dIagNostIC tEChNIquEs For IdENtIFICatIoN oF Aspergillus 
sPECIEs
Diagnosing a fungal infection is usually not easy. Lack of specific symptoms, heteroge-
neous patient populations and low sensitivity of diagnostic tests challenge clinicians to 
diagnose IPA in the immunocompromised patient. However, for early start of adequate 
therapy, it is required to accurately identify the causative agent of the infection, for 
example for antifungal susceptibility testing.
Over the last years, a novel species of Aspergillus was discovered, called Aspergillus 
lentulus (134). With conventional techniques, it is very difficult to distinguish A. lentulus 
from A.  fumigatus. Studies showed that many isolates of A.  lentulus have previously 
been misidentified as A. fumigatus (135). The distinction between both fungal species is 
important, however, since susceptibility for several widely used antifungal agents differs 
between the two species (136-138). In Chapter 7 we compare two newer techniques to 
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identify A. fumigatus and A. lentulus. We investigated MALDITOF-MS, which was used be-
fore in identification of fungi (139-141) and Raman spectroscopy, which already showed 
its value in identification of bacterial species (142, 143). Both techniques were tested on 
their ability to correctly identify several isolates of both species. Buskirk et al showed 
that pigmentation of fungi hampers identification by MALDI-TOF MS (144). Conidia of 
A.  lentulus and A.  fumigatus are both darkly pigmented. However, despite pigmenta-
tion, MALDI-TOF MS correctly identified 100% of the isolates. Pigmentation did hamper 
identification of fungi in Raman spectroscopy. Performed on white conidia, Raman spec-
troscopy correctly identified 78% of fungal isolates. We concluded that MALDITOF-MS 
is an accurate technique to rapidly identify A. lentulus, but Raman spectroscopy is not 
suitable for daily use due to its lower specificity (Chapter 7).
MALDI-TOF MS was confirmed as identification method for fungi and yeasts in several 
other studies (139, 145-148), but also other novel techniques have been investigated. 
Most novel techniques are PCR-based. Staab et al used PCR-restriction fragment length 
polymorphism method to distinguish several variants of A.  fumigatus (149). Further-
more, ITS sequencing of the β-tubulin, calmodulin and rodlet A genes whether or not 
combined with antifungal susceptibility testing was also used to identify A.  lentulus 
(150-152). Finally, Tamiya et al identified Aspergillus species based on secondary me-
tabolite profiles (153). The disadvantage of most of these techniques is that they are also 
culture based and thus require time. In our study, time frame was an important variable 
in the diagnostic route for both techniques. A reduced diagnostic period enhances early 
treatment of the patient and improves clinical outcome. Both MALDI-TOF MS and Raman 
spectroscopy remain culture-based. Culture is time consuming and has a low sensitivity, 
which are disadvantages. However, based on conventional morphological properties it 
is still very difficult to distinguish both species. The ideal detection technique would be a 
rapid method with high specificity and high sensitivity, which can be performed directly 
on patient materials. Further technical improvement and development of the current 
techniques could increase the detection rate for fungi in patient material.
NoVEl thEraPEutIC stratEgIEs For INVasIVE asPErgIllosIs
Even though several classes of antifungal agents are in use to date, the mortality of 
IPA remains dramatically high (154, 155). Therefore it is important to not only improve 
diagnostics (see above), but to also improve the currently available therapeutic strate-
gies. In Chapter 2, 3 and 4 we discussed the mechanism of action of caspofungin and 
hypothesized how the clinical outcome of treatment with caspofungin could be im-
proved. Improvement of current antifungal strategies is very important, but the search 
for novel antifungal agents must also continue. In this context, we investigated a group 
Discussion 147
9
of peptides with antifungal properties. Branched histidin and lysin rich peptides (BHKPs) 
were originally developed as gene delivery agents but were shown in prior studies to 
have antifungal activity against Candida species (156-158). BHKPs are thought to act 
via a similar mechanism as histatin-5, which also is a histidine-rich peptide, that binds 
to Ssa1/2 receptor in Candida species (159). After binding this receptor, it causes dys-
function of the Trk-1p transporter, resulting in efflux of ATP and other small molecules, 
resulting in cell death (157).
In Chapter 8 we tested the in vitro antifungal activity of three different BHKPs on 
several species of fungi and molds, including Aspergillus species, Candida species, 
Cryptococcus species and Trichosporon species. We showed that BHKPs mainly have an-
tifungal activity against Cryptococcus species and Trichosporon species, but not against 
Aspergillus species and Candida species, in contrast to previously published data. Differ-
ences in methods (different culture media used) could be responsible for the observed 
differences in minimal inhibitory concentrations (MICs). These agents could be a new 
treatment option for infections with Cryptococcus species and with Trichosporon species 
but are less suitable for infections with Aspergillus species and Candida species. More in 
vivo studies are needed to investigate toxic side effects and adverse events of this new 
category of antifungal agents.
mEChaNIsm oF aCtIoN oF CasPoFuNgIN: hyPothEsIs BasEd uPoN thIs 
thEsIs
In this thesis we investigated the mechanism of action of caspofungin and its effects on 
the immune system of the host. It is evident that chitinases play a role in the immune 
response to chitin-containing fungi. Based on this thesis we developed a hypothesis of 
how caspofungin and the immune system act synergistically in the clearing of fungal 
pathogens (see Figure 1). Exposure of A. fumigatus to caspofungin causes a shift in cell 
wall components with increase of chitin and decrease of β-glucan. As a result of the 
exposure of the host to chitin, the host produces two chitinases, chitotriosidase and 
AMCase. Caspofungin also unmasks the deeper cell wall layers by releasing galactoman-
nan from its surface. When deeper layers are more exposed, the produced chitinases can 
better reach chitin polymers in the deeper cell wall layers. Chitotriosidase and AMCase 
cooperate in the degradation of chitin polymers, resulting in lysis of the fungal cell wall 
and in smaller chitin particles, which mostly are immunologically inert. The smaller chitin 
particles shift the immune response towards a Th1 response. The balance between Th1 
and Th2 responses is responsible for either clearance of the fungal infection resulting 
in reduced mortality, or increase of the inflammatory response, ultimately resulting in 
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Figure 1.
A. Schematic representation of the fungal cell wall in the untreated host with IPA. Host chitotriosidase and 
AMCase cannot easily reach chitin, which is found in deeper cell wall layers, and is covered by a superficial 
layer of mannoproteins.
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death. Treatment with caspofungin shifts the balance towards Th1 response, resulting in 
clearance of the infection and in survival of the host.
Based upon this hypothesis, it can be questioned whether additional treatment with 
recombinant chitinases in combination with to caspofungin would result in even better 
outcomes for the host. After all, addition of certain immune cells, such as monocytes, 
monocyte-derived macrophages and serum itself were shown to enhance the fungi-
static activity of caspofungin (160). Moreover, higher levels of chitinases were found to 
be protective in murine models of cryptococcosis (161). However, in our murine model 
of IPA we found a trend for lower chitinases among rats successfully treated with caspo-
fungin, a finding that is possibly due to a much lower fungal load presented to the host 
system in these caspofungin-treated rats compared to rats left untreated.
More studies are needed to further investigate the combined effects of caspofungin 
and recombinant chitinases. One suggestion would be to investigate the in vitro suscep-
tibility of A. fumigatus to combination of caspofungin and recombinant chitotriosidase 
and recombinant AMCase. When this combination has been proven successful, in vivo 
studies will have to be performed to investigate pharmacokinetics and pharmacody-
namics of recombinant chitinases, since these enzymes were not used previously for 
treatment of mammals. Furthermore, caspofungin treatment could be combined with 
cytokine therapy in order to influence the balance between Th1 and Th2 cytokines and 
shift it towards a Th1 response, hopefully resulting in better outcome in the patient.
In summary, chitinases and their role in infectious pulmonary diseases are a promising 
field of interest and offer possibilities for the improvement in management of fungal 
infections.
B. Schematic representation of the fungal cell wall in the caspofungin-treated host with IPA. After treatment 
with caspofungin, chitin in the fungal cell wall is upregulated and β-glucan synthesis is inhibited. Due to 
release of mannoproteins, deeper cell wall layers are unmasked. Chitotriosidase and AMCase can better 
reach chitin and cleave larger polymers into smaller particles.
C. Schematic representation of the changes in cytokine production in different compartments as mea-
sured in our animal model of invasive pulmonary aspergillosis. The PAMPs chitin, β-glucan and mannans 
are recognized by different PRRs, such as TLR2, TLR4 and dectin-1 on the host immune cell. A specific chitin 
receptor was not described yet, however since chitin was shown to act as a PAMP, the existence of such a 
receptor is assumed. Stimulation of the PRRs by the specific PAMPs leads to activation of the immune sys-
tem. Chitotriosidase and AMCase are produced and production of several cytokines is increased in several 
compartments. Treatment with caspofungin leads to an attenuation of the increase in most cytokines. Lev-
els of these cytokines determine the balance between Th1 and Th2 responses, which ultimately is thought 
to qualify the outcome in the patient. TLR2 toll-like receptor 2; TLR4 toll-like receptor 4; CR3 complement 
receptor 3.
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Aspergillus fuMigATus EN INVasIEVE PulmoNalE asPErgIllosE
Aspergillus fumigatus is een veelvoorkomende sporenvormende schimmel, die zowel 
buitenshuis als in gebouwen frequent wordt aangetroffen. Sporen worden dagelijks 
in- en uitgeademd. Mensen met een normaal functionerend immuunsysteem worden 
niet ziek van deze schimmel, maar bij een niet of minder goed functionerend, of juist 
overactief immuunsysteem kunnen overgevoeligheid of invasieve schimmelinfecties 
optreden. Helaas overlijden veel van de patiënten met invasieve pulmonale aspergillose 
(IPA) nog aan de ziekte.
Het diagnosticeren van een schimmelinfectie is in de kliniek vaak erg lastig. Er is een 
grote verscheidenheid aan patiënten die risico lopen, en verder zijn de symptomen 
niet specifiek. Ook de laboratoriumdiagnostiek zou kunnen worden verbeterd. Het kan 
namelijk lastig zijn om verschil te maken tussen kolonisatie met schimmelsporen (de 
schimmel rust toevallig even in de longen) en een infectie (de schimmel veroorzaakt 
lokaal weefselschade). Het vaststellen om welke schimmel het gaat is erg belangrijk, 
omdat de behandeling afhankelijk is van de schimmelsoort. Daarom is het van belang 
om zo snel mogelijk het type en subtype van de ziekmakende schimmel te detecteren.
Als de schimmel eenmaal gedetecteerd is, is behandeling ervan de volgende uitdaging. 
Er is een beperkt arsenaal aan anti-schimmelmedicatie op de markt. Bij IPA is voriconazol 
de 1e keus. Als de patiënt niet opknapt met voriconazol, kan caspofungin worden gege-
ven. Caspofungin werkt op de schimmelcelwand en verandert deze van samenstelling. 
Bij testen met caspofungin in het laboratorium remt dit middel de schimmelgroei pas bij 
hoge concentraties. Echter, als patiënten worden behandeld met caspofungin in lagere 
doseringen, knappen ze wel daadwerkelijk op. Het is niet duidelijk waardoor dit verschil 
tussen in vitro en in vivo effect wordt verklaard. In dit proefschrift wordt onderzocht hoe 
verschillende onderdelen van het immuunsysteem van de gastheer betrokken zijn bij 
het klaren van de schimmelinfectie onder behandeling van caspofungin.
ChItINasEs BIj sChImmElINFECtIEs
In hoofdstuk 2 is onderzocht hoe de celwandsamenstelling van A. fumigatus verandert 
door behandeling met caspofungin. Twee belangrijke celwandcomponenten zijn de 
suikers chitine en β-glucan. Caspofungin remt de aanmaak van β-glucan, waarop de 
schimmel reageert met extra chitine aanmaak. Deze veranderde celwandsamenstel-
ling geeft een veranderde groei, die ook zonder microscoop goed zichtbaar is. Pas bij 
heel hoge concentraties caspofungin gaat de schimmel dood. In hoofdstuk 2 wordt 
beschreven dat als een β-glucan remmer zoals caspofungin wordt gecombineerd met 
een chitine remmer zoals nikkomycine Z, synergie optreedt. Beide middelen versterken 
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elkaar dusdanig dat bij lage concentraties van beide middelen de schimmelgroei wordt 
geremd. De cellen zien er groter en opgeblazen uit, waardoor ze uiteindelijk kapot gaan. 
Helaas is nikkomycine Z niet vrij verkrijgbaar dus klinisch onderzoek met deze combina-
tie middelen is niet mogelijk.
De buitenkant van schimmelcellen bevat structuren (pathogen associated molecular 
patterns; PAMPs) die kunnen worden herkend door het immuunsysteem van zoogdie-
ren. Chitine en β-glucan zijn voorbeelden van PAMPs. De receptoren om deze PAMPs 
te herkennen heten pattern recognition receptors (PRRs) en hiervan zijn dectin-1 en 
TLR-2 en TLR-4 voorbeelden. Elke stimulatie van PRRs door PAMPs leidt bij de gastheer 
tot een bepaalde reactie met enzymen en signaalstofjes zoals cytokines en chemokines. 
Als de stimulus verandert doordat de celwandsamenstelling is veranderd, is dus ook 
te verwachten dat daardoor ook de signaalstofjes veranderen. In hoofdstuk 3 wordt 
onderzocht welke cytokines en chemokines veranderen als een rat geïnfecteerd wordt 
met A. fumigatus. In totaal zijn 24 cytokines en chemokines onderzocht, waarbij van een 
groot aantal gedurende de infectie verhoogd raken. Ook is gekeken naar de verschillen 
in cytokinerespons tussen onbehandelde ratten, die de infectie niet overleven, en ratten 
die behandeld zijn met caspofungin, die de infectie allemaal overleven. In grote lijnen 
bleek de cytokinerespons overeen te komen, met enkele subtiele verschillen. Vanwege 
kleine aantal dieren die onderzocht zijn, werden geen evidente significante verschillen 
gevonden.
Hoewel zoogdieren zelf geen chitine kunnen aanmaken, zijn ze wel in staat om chitinases 
te produceren. Chitinases zijn enzymen die chitine afbreken en die worden aangemaakt 
na blootstelling aan chitine in bijvoorbeeld schimmels. Er zijn bij mensen 2 chitinases 
bekend, chitotriosidase en acicid mammalian chitinase (AMCase), met elk hun eigen 
aangrijpingspunt op het chitine molecuul.
Aangezien caspofungin bij A. fumigatus een verhoging geeft van chitine, was het de 
verwachting dat de chitinase activiteit ook zou toenemen in de gastheer met IPA. In 
hoofdstuk 4 is de chitinase respons onderzocht in ratten die blootgesteld waren aan 
A.  fumigatus. Een deel van de ratten had een normaalwerkend immuunsysteem en 
werd niet ziek van de schimmel, maar een ander deel van de ratten was immuun ge-
compromitteerd en ontwikkelde IPA. Van de laatste groep werd een deel van de dieren 
behandeld met caspofungin. De activiteit van zowel chitotriosidase als AMCase steeg 
na blootstelling aan de schimmel in alle ratten. Na enkele dagen daalde de activiteit in 
de ratten met normaal werkend immuunsysteem. Bij de onbehandelde immuun gecom-
promitteerde ratten stegen de activiteit van beide chitinases verder tijdens de infectie. 
Behandeling met caspofungin gaf, in tegenstelling tot de verwachting, juist minder stij-
ging van de activiteit van beide chitinases. Door behandeling met caspofungin is er in 
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totaal minder hoeveelheid schimmel aanwezig. Uit onze resultaten concludeerden we 
dat de hoeveelheid schimmel uiteindelijk meer bepalend lijkt voor de chitinase respons 
dan de celwandsamenstelling.
Bij laboratoriumtesten bleek de combinatie van caspofungin met chitotriosidase of 
met AMCase de schimmel niet te doden. Wel bleken beide chitinases gelokaliseerd te 
zijn op de schimmeldraden. Bij aanvullende testen bleek dat de schimmelcelwand kapot 
ging wanneer de schimmel werd behandeld met caspofungin en de beide chitinases.
Uit bovenstaande paragrafen komt naar voren dat chitinases een belangrijke rol lijken te 
spelen in de afbraak van chitine van schimmeldraden. Uit eerdere publicaties is geble-
ken dat bepaalde genetische afwijkingen (polymorfismen) resulteren in een niet-actief 
chitinase. Dit is bekend voor zowel chitotriosidase als voor AMCase. Voor AMCase zijn 
ook polymorfismen beschreven die resulteren in een overactiviteit van het enzym. In 
hoofdstuk 5 is onderzocht welke invloed deze polymorfismen hebben op de kans om 
IPA op te lopen. Bij een grote groep mensen met een verzwakt immuunsysteem, en 
dientengevolge risico op IPA, is gekeken naar de chitinase genen. Bij de mensen die 
IPA kregen kwamen alle vier de onderzochte polymorfismen even vaak voor als bij de 
mensen die geen IPA kregen. Hieruit concludeerden we dat verminderde chitinase 
activiteit het risico op IPA niet verhoogt en dat overactiviteit van AMCase niet tegen IPA 
beschermt.
Het is niet duidelijk of andere chitine-bevattende schimmels dezelfde reactie geven als 
A. fumigatus in de gastheer wat betreft chitinase productie. In hoofdstuk 6 is een andere 
schimmel onderzocht, Madurella mycetomatis. Madurella mycetomatis is een schimmel 
die mycetoma veroorzaakt, wat granulomateuze ontstekingen met ‘grains’ geeft in met 
name de extremiteiten. De ziekte komt voor in tropische gebieden en geeft pussende 
ontstekingen die het bot kunnen aantasten. Uiteindelijk leidt dit frequent tot invalide-
rende amputaties. Een groot deel van de bevolking in bijv. Sudan wordt blootgesteld 
aan deze schimmel, omdat deze op de grond voorkomt. Echter niet iedereen die eraan 
wordt blootgesteld, ontwikkelt deze infectie. Daarom is in hoofdstuk 6 ook gekeken 
naar de invloed van chitinases. Allereerst is aangetoond dat de M. mycetomatis grain 
chitine bevat. Daarnaast kleurden zowel chitotriosidase als AMCase ook op de schimmel 
zelf aan, net als bij A.  fumigatus. Vervolgens is gekeken naar de rol van de hierboven 
beschreven polymorfismen in de genen voor chitinases. Het vóórkomen van het chito-
triosidase polymorfisme kwam significant vaker voor bij patiënten met mycetoma dan 
bij de gematchte controlepopulatie. Afwezige chitotriosidase activiteit vergroot dus 
het risico op mycetoma, maar verhoogde of verlaagde AMCase activiteit was niet van 
invloed. Mogelijk stuurt chitotriosidase de immuunrespons richting het klaren van de 
166 Nederlandse samenvatting
schimmel, wat mede bepalend is voor het niet-ontwikkelen van een chronische infectie 
met een grain.
NIEuwE dIagNostIEk EN BEhaNdElINg Voor IPa
De laatste jaren is een nieuwe species schimmel ontdekt, die qua uiterlijk identiek is aan 
A. fumigatus: A. lentulus. Met conventionele diagnostiek zijn deze twee soorten niet van 
elkaar te onderscheiden. A. lentulus is aanzienlijk minder gevoelig voor antifungale mid-
delen dan A. fumigatus. Zoals eerder beschreven, is het belangrijk om zo snel mogelijk 
de veroorzaker van een schimmelinfectie te identificeren. Zo kan de behandeling in een 
vroeg stadium gericht worden op deze specifieke ziekteverwekker, waarmee de overle-
ving van patiënten verbetert. In hoofdstuk 7 zijn twee nieuwe technieken vergeleken 
om A. fumigatus en A. lentulus te identificeren. Matrix-assisted laser desorption/ionisation 
time of flight – mass spectrometry (MALDITOF-MS) identificeert micro-organismen op 
basis van het gewicht van bepaalde celcomponenten. Door met een laser op het micro-
organisme te schieten, valt het uiteen in componenten. Deze componenten geven een 
piekenpatroon van massa’s, waarmee het micro-organisme geïdentificeerd kan worden. 
Deze techniek is eerder bruikbaar gebleken voor identificatie van schimmels. Raman 
spectroscopie is een optische techniek, die micro-organismen identificeert op basis 
van lichtverstrooiing. Elke celcomponent in een micro-organismen geeft een bepaalde 
verstrooiing van licht. Het spectrum dat hiermee wordt gegenereerd is specifiek genoeg 
gebleken om bacteriën te identificeren. Schimmels zijn echter nooit getest.
In hoofdstuk 7 zijn 16 A.  lentulus isolaten en 16 A.  fumigatus isolaten geblindeerd 
getest met beide technieken. Voor Raman werden alleen betrouwbare piekenpatronen 
gemeten als de schimmels op een ander kweekmedium groeide, waarmee sporen 
ontkleurd waren. Raman spectroscopie identificeerde 78% van de isolaten correct in ca. 
100 uur, terwijl MALDITOF-MS 100% correct kon identificeren in ca. 50 uur. Hieruit con-
cluderen we dat MALDITOF-MS een geschikte techniek is om in de dagelijkse praktijk 
A. lentulus van A. fumigatus te onderscheiden. Raman spectroscopie is minder geschikt 
vanwege de lagere nauwkeurigheid en de langere tijdsduur tot identificatie.
Tot slot is een nieuwe groep medicijnen getest, die mogelijk tegen IPA zou kunnen 
werken. Branched histidine- en lysine rich peptides (BHKPs) zijn peptides die oorspron-
kelijk zijn ontwikkeld voor gentherapie. Ze blijken ook antimicrobiële eigenschappen te 
hebben, waarbij groei bijv. van de gist Candida geremd wordt. In hoofdstuk 8 is de anti-
fungale werking van drie van deze peptides getest. Verschillende groepen schimmels en 
gisten zijn in het laboratorium getest op gevoeligheid voor verschillende concentraties 
van de drie peptides. Het bleek dat de vier geteste Aspergillus species en de twee Can-
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dida species niet gevoelig zijn voor de BHKPs. In tegenstelling tot Aspergillus en Candida 
bleek de groei van de gisten Cryptococcus en Trichosporon wel geremd te worden door 
de BHKPs. Van de drie geteste peptides bleek H2K4b de sterkste anti-microbiële werking 
te hebben. Voor de behandeling van IPA zijn deze middelen niet geschikt, maar bij 
gistinfecties zouden ze mogelijk wel effectief kunnen zijn. Gegevens over toxiciteit en 
over afbraak in het menselijk lichaam zijn niet bekend dus dit zou onderzocht moeten 
worden voordat deze groep medicijnen op de markt kan komen.
Samenvattend beschrijft dit proefschrift een aantal factoren van het immuunsysteem 
die bijdragen aan het klaren van de schimmelinfectie IPA. Met deze informatie hopen we 
IPA beter te begrijpen en met name de reactie van de gastheer die behandeld wordt met 
caspofungin. Door beter begrip van hoe caspofungin werkt, hopen we de effectiviteit 
van de behandeling te vergroten, om zo tot een betere klinische uitkomst bij patiënten 
te leiden.
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En dan is het zover, je proefschrift is af. Het was een flinke klus, met hier en daar meer 
vertraging dan gewenst, maar toch is het uiteindelijk af gekomen. Dit geheel was niet 
mogelijk geweest zonder ontzettend veel steun van de mensen om mij heen.
Prof. dr. Verbrugh, beste Henri. Het zit erop! Geen meetings meer waarin ik uit de doeken 
doe hoe ver ik ben gekomen, tussen de opleidingsmomenten door. Fijn dat je als promo-
tor, na het vertrek van Alex, meer verdieping richting de schimmels hebt willen zoeken. 
Ik zal ons fietstochtje op de tandem bij de Veluwe niet gauw vergeten… Bedankt voor 
het kritisch doorlezen van mijn stukken en voor de opbouwende kritiek. Het product is 
prachtig geworden.
Dr. van de Sande, beste Wendy. Wat heb ik geboft met jou als copromotor! Super dat je 
mijn stukken altijd zo snel had nagekeken. Dank voor de vrijheid die je me gaf tijdens 
mijn promotie, maar ook voor de ruimte die ik kreeg tijdens het starten van mijn oplei-
ding. Dit boekje is ook jouw boekje!
Prof. dr. dr. van Belkum, beste Alex. Zonder jou was ik nooit begonnen aan dit project. 
Bedankt voor het vertrouwen dat je in mij had, om een arts een lab-promotie te laten 
starten. Ondanks dat ik er wat langer over heb gedaan dan gemiddeld heb ik je hopelijk 
niet teleurgesteld. Veel dank ook voor de gastvrijheid in la Balme-les Grottes en voor de 
mooie publicatie die daaruit is voortgekomen. 
Prof. dr. Mouton en prof. dr Netea, veel dank voor het plaatsnemen in de kleine commis-
sie en voor het beoordelen van mijn proefschrift. Prof. dr. Hoogsteden, veel dank voor 
het uitvoeren van de secretariële taken in de kleine commissie.
Dr. Bakker-Woudenberg, beste Irma. Wat ben ik blij dat ik jouw expertise van dichtbij 
heb mogen meemaken. De besprekingen werden van serieus in de beginjaren uitein-
delijk een steeds gezelliger weerzien nadat mijn labtijd erop zat. Je was altijd kritisch en 
toch opbouwend. Jouw tekstuele handigheid zal me nog lang bijblijven. Bedankt voor 
je toewijding maar vergeet af en toe niet aan jezelf te denken!
Jasper! Jasper… Wat moet ik hier nu schrijven. Woorden schieten tekort… Het was voor 
mij direct duidelijk dat jij mijn paranimf zou zijn. Bedankt voor je mentale ondersteuning 
en morele support tijdens mijn promotie, zowel op als buiten het werk. En tsja, die eeu-
wige gewilligheid om de slachtofferrol aan te nemen waardeer ik ook! Respect ook voor 
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jouw volharding; net als met de marathon: het duurt wat langer, maar je komt er écht. 
Succes met jouw laatste stukkie!
Char, chica! Top dat jij het vandaag van zo dichtbij kon meemaken. Na onze gezellige 
start op unit 28 was jij de aangewezen 2e paranimf. Fijn dat je altijd zo enthousiast bent. 
Nijmegen is wel ver, maar het wereldje is klein. Bedankt voor de vele gezellige borrel-
momentjes, je steun tijdens de opleiding en de gezellige dates op en na het werk. Veel 
succes met je eigen onderzoek, dank dat ik jouw promotor even mocht lenen vandaag.
Prof. Falcone, dear Franco. Thanks for your contribution to Chapter 4 of this thesis. Even 
though we never met, the enthousiasm in your emails worked contagious and inspired 
me to continue writing and submitting. Thank you for the cooperation.
Alle overige co-auteurs van de publicaties in dit proefschrift: veel dank voor jullie bij-
drage en kritische blik op de manuscripten.
To all other co-authours: thank you for your contribution to the publications in this 
thesis.
Beste collega’s van MMIZ, ik kwam, ik ging en uiteindelijk promoveerde ik. Hadden jullie 
het nog verwacht? ☺ Het waren gezellige jaren en ook na 3,5 jaar was het een warm 
weerzien. Bedankt hiervoor! Speciale dank gaat uit naar de onderstaande mensen:
Marian, wat een werk heb je verzet voor mijn dierexperimenten. Dank voor je begelei-
ding en voor je begrip voor mijn klinische, niet-altijd-lab-blik.
Gerjo, had ik met iemand beter een labtafel kunnen delen dan met jou? Jouw stickers 
boven mijn bench maakten het leven draaglijker. Dank en succes met de laatste efforts 
voor jouw boekje.
Jeannine, mede-schimmel-promovendus. Dank voor de gedeelde smart! Veel succes 
met de laatste loodjes van je eigen promotie. Je komt er heus!
Kimberly, veel dank voor het draaien van ongeveer 382.479 PCRs.
Alle andere postdocs die mij voorgingen, maar ooit tegelijk met mij promovendus 
waren.. (Rogier, Astrid, Suzanne, Sanne, Wendy Ka, Saskia en vele anderen) Het is toch 
nog af gekomen! Dank voor jullie gedeelde-smart-is-halve-smart-mentaliteit door de 
jaren heen, de gezelligheid tijdens het werk en natuurlijk de R&D borrels.
Michiel, dank voor je technische blik op mijn (ICT-)problemen gedurende mijn promo-
tietraject. Fijn dat je als altijd voor me klaar stond. Succes met jouw laatste stuk.
René, alweer een tijdje weg, maar de koffiemomenten zitten nog vers in mijn geheu-
gen! Te gek dat je met mij als eerste wilde investeren in een nieuwe koffiemachine.
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Willem vL, top om met jou samengewerkt te hebben. Het hoekje met de scheur ach-
terin de L-vleugel was toch wel een erg gezellig hoekje. Dank voor het mogelijk maken 
van hoofdstuk 7 en voor je ondersteuning met Raman.
Loes en Hans, dank voor jullie hulp bij het maken en bewerken van de vele foto’s voor 
mijn artikelen. Jullie hulp was onmisbaar.
Carla, jouw keuken-inspanningen waren voor mij als schimmel-promovendus de 
hemel op aarde. Ik hoefde het maar te zeggen of er stond alweer een nieuwe batch met 
SAB-platen klaar. Superveel dank voor jouw ondersteuning in de afgelopen jaren.
Alle analisten en andere medewerkers van MMIZ: bedankt voor de gezellige periodes 
die ik op de afdeling heb gehad.
RopaRun team 27, wat tof dat ik mee mocht doen, al was het geblesseerd het 1e jaar. 
Fijn dat ik een herkansing kreeg. Nog nooit heeft de tocht van Hamburg naar Rotterdam 
zo lang geduurd, maar het was het zeker waard. Gouden herinnering! Gerard en Ad, aan 
jullie een extra bedankje voor het begeleiden van de zwaarste 10 kms uit mijn leven! 
Toppers!
Minke en Christa, thanks voor de afleiding die jullie met enige regelmaat boden. We 
houden de etentjes, koffiemomenten en de wijntjes er toch wel in? Mink, succes met 
jouw laatste loodjes. Ook jij zal er zeker komen!
Meiden van 24, dank voor het delen van alle promotieleed in de afgelopen jaren! Zonder 
jullie was het heel anders geweest. Fijn dat ik altijd bij jullie mocht klagen. Dank voor de 
gezellige momentjes om de promotie-stress even te kunnen vergeten. Het klagen wordt 
zeker minder!
Amphia meiden, Eefje, Sophie, Eri-Jo en Charlotte, wat een top-collega’s in Breda! Jullie 
zorgden voor voldoende ontspanning tussen werk en proefschrift door. Gelukkig zien 
we elkaar ook buiten Breda regelmatig nu en hebben we nog flink wat mooie feestjes 
voor de boeg met elkaar. Ik heb er zin in! PS bij wie staat de beker nu?
Juul, Jacq en Chris (+4 natuurlijk). Vanaf nu wordt alles beter… Het was altijd maar weer 
die promotie en chagrijnig gedoe van mijn kant. Nu is het klaar. Dit jaar is een feestjaar 
en dit is deel 1. In Lissabon wordt het super! Fijn dat jullie er zijn en dat ik er voor jullie 
kan zijn wanneer dat nodig is.
Dirk en Margot, de laatste vier jaar ben ik natuurlijk veel met jullie zoon bezig geweest 
maar ook met dit lange project. Het is uiteindelijk iets moois geworden; nu het af is, 
wordt het tijd voor een nieuwe hobby denk ik. Superveel dank voor jullie begrip en in-
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teresse voor mijn bezigheden van afgelopen periode. En natuurlijk voor de open armen 
waarmee ik sinds jaar en dag word ontvangen!
Oudersch, daar is het dan... Een beetje voor papa maar ook voor mijzelf. Het was een 
drukke tijd, waarin ik regelmatig gefrustreerd moest uitleggen dat ‘het bij geneeskunde 
promoties echt heel anders gaat tegenwoordig dan bij rechten in de jaren ‘70’. Sorry 
voor alle kortaf-antwoorden, frustraties en het regelmatige zuchten, en dank voor het 
begrip en de ondersteuning, in alle vormen. Mama, het enthousiasme mag af en toe iets 
worden beteugeld maar wordt desondanks erg gewaardeerd. Deel 1 vandaag, deel 2 in 
september!
Bob, lieve Bob. Wat is mijn leven veranderd sinds ik in naar het Amphia kwam. Het 
gelukkige toeval kon niet beter uitpakken voor ons allebei. Fijn dat je steeds kritisch 
wilde meekijken, meelezen en aanpassen in mijn teksten. Jij hebt wel het meeste begrip 
getoond van allemaal. Gelukkig kan ik soms iets terugdoen in jouw presentaties, al is het 
wat gezever (soms dan!). Nu een klein feestje, in september een groots feest. Daarna wil 
ik die wijncursus wel overwegen… You’re the best!
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Health Management (Beleid & Management van de gezondheidszorg, first-year exami-
nation passed) at Erasmus University, Rotterdam, after not being selected for medical 
school due to the lottery system. In 2002, she was nevertheless selected for medical 
school by ‘decentrale selectie’ at Erasmus MC, Rotterdam. During studies she partici-
pated in several education-oriented committees. She completed the internships at St. 
Elisabeth Ziekenhuis te Tilburg. In 2007 Patricia went to Perth, Australia, for a Master’s 
thesis concerning Staphylococcus aureus colonization in healthcare workers, under 
supervision of Tom Riley and Geoff Coombs. This work was presented on International 
Symposium on Staphylococci and Staphylococcal Infections (ISSSI 2008) in Cairns, Aus-
tralia. In 2008 she graduated from medical school and started working as resident at 
St. Elisabeth Ziekenhuis. Patricia was invited by prof. van Belkum for a PhD study at the 
department of Medical Microbiology & Infectious Diseases at Erasmus MC. In 2009 she 
started her PhD on Aspergillus fumigatus infections, under direct supervision of Wendy 
van de Sande. During her PhD Patricia participated in several courses organized by the 
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(Utrecht)
2010 0,5 ECTS
NVVM Wetenschappelijke voorjaarsvergadering: poster presentation 
(Papendal)
2011 1 ECTS
NVvMy Wetenschappelijke najaarsvergadering 2011: oral presentation 
(Utrecht)
2011 0,5 ECTS
Wetenschapsmiddag Amphia ziekenhuis Breda 2012, 2013 8h
Internistendagen 2013, 2014, 2015, 
2016
3 ECTS
Afscheidssymposium prof. Verbrugh: Golden Oldies - staphylococcen 2015 5h
180  
6th European Congress of Clinical Microbiology and Infectious DIseases 
(Amsterdam)
2016 1 ECTS 
seminars and workshops
Workshop Finding literature I & II, workshop Endnote (Medical Library) 2009 4,5h
Workshop Negotiation (VVAA) 2010 2,5h
3rd Annual symposium on Host Defence Peptides: oral presentation 2010 0,5 ECTS
Workshop Allemaal beestjes; infectieziekten in de huisartsenpraktijk 2011 5h
MolMed & NVMM: Microbial pathogenesis 2011 0,25 ECTS
Bijscholingen afdeling MMIZ HIV, parasieten, antibiotica, SOA, 
darminfecties
2009, 2010, 2011 9h
Klinische avond Interne Geneeskunde (NaI) 2012, 2013 (2×), 
2015
12h
DOO Gezondheidsrecht Amphia ziekenhuis 2013 4h
DOO Samenwerking Desiderius school 2013 8h
DOO Kwetsbare ouderen Amphia ziekenhuis 2013 8h
DOO Financiering van de zorg en de arts van straks 2014 8h
didactic skills
DOO Teach the Teacher II 2015 1 ECTS
other
PhD Day Erasmus MC 2009, 2010, 2011 15 h
Journal Club / Research besprekingen MMIZ 2009, 2010, 2011 2 ECTS
2. Teaching activities Year Workload 
(hours/ ECTS)
lecturing
Master Infection & Immunity: Summercourrse II 2010, 2011 8h
supervising practicals and classes
Curriculum Erasmus Arts; 2e-jaars onderwijs geneeskunde  2010, 2011 3 ECTS
Klinisch redeneren Bachelor I (3 sessies) 2015, 2016 9h
Supervising HLO trainee
C.C. Notenboom; sept 2011 – jan 2012 2011 5 ECTS
Total 114h
30,3 ECTS
Chitinases in Invasive Fungal Infections 
Patricia Verw
er
